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ABSTRACT
INVESTIGATION OF THE MECHANISMS GOVERNING CARRIER DOMAIN
TRANSLOCATION IN S. AUREUS PYRUVATE CARBOXYLASE
Joshua H. Hakala, B.S., B.A.
Marquette University, 2019
A central debate in protein biochemistry focuses on the mechanism by which
ligands contribute to conformational changes in proteins. Two primary hypotheses
describe this process: the induced-fit hypothesis and the conformational ensembles
hypothesis. In contrast to the induced-fit hypothesis, the conformational ensembles
hypothesis states that the protein pre-exists in multiple conformational states, with ligand
binding shifting the equilibrium towards a preferred conformation. The contribution of
ligand binding to large-scale conformational changes is particularly relevant to multidomain “swinging-arm” enzymes, for which pyruvate carboxylase (PC) serves as a well
characterized paradigm system. PC catalyzes the ATP-dependent carboxylation of
pyruvate to oxaloacetate. The biotin cofactor on the biotin carboxyl carrier protein
(BCCP) domain is carboxylated via a MgATP-dependent reaction in the biotin
carboxylase (BC) domain. The BCCP domain then travels to the carboxyltransferase
(CT) domain where the carboxyl group is transferred from the biotin cofactor to pyruvate,
generating oxaloacetate. There have been conflicting proposals for how ligand binding
governs carrier domain translocation in PC but, to date, there have been no attempts to
directly observe the positioning of the carrier domain independent of catalytic turnover.
To directly observe the equilibrium positioning of the BCCP carrier domain, site-specific
cross-linking was used to trap the BCCP domain in two separate orientations during
translocation. This approach enabled a detailed analysis of how BCCP domain
positioning responds to substrates and allosteric effectors. These studies show that carrier
domain positioning is governed by conformational selection, with the carrier domain
accessing intermolecular positions irrespective of the presence or identity of the ligand(s).
Further, interactions between biotin and several conserved active site residues in both the
BC and CT domains serve to shift the carrier domain positioning equilibrium. These
studies offer the first compelling evidence that carrier domain positional equilibrium in
PC is governed by conformational selection and offer new insights into the molecular
level interactions contributing to these conformational changes.
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I. INTRODUCTION
Chemical and physical interactions are necessary for the maintenance of life. The
regulation of these interactions is critical to cellular maintenance, proper development,
the prevention of disease, and successful reproduction. For example, the TCA cycle that
is central to cellular metabolism must maintain a proper equilibrium of intermediates to
ensure an appropriate metabolic flux into the numerous biosynthetic pathways that
branch out from the main cycle. When the concentration of TCA cycle intermediates are
low, they must be replenished to maintain metabolic flux and prevent deleterious
outcomes. Pyruvate carboxylase (PC; E.C. 6.4.1.1), which converts pyruvate to
oxaloacetate, is present in nearly all life forms, where it plays a critical role in
maintaining proper flux through the TCA cycle. Aberrant PC activity is a hallmark of
diseases such as Type-II diabetes and cancer (Han and Liu, 2010; Phannisil, et al., 2015).
PC has been intensely studied since its initial discovery and purification in
the 1960s. Subsequent kinetic studies determined that the pyruvate carboxylation reaction
occurs in two separate steps catalyzed by the same enzyme (Utter and Keech, 1960; Utter
and Keech, 1963; Keech and Utter, 1963; Scrutton, Keech, and Utter, 1965). By 1981, it
had been established that PC consisted of two separate active sites, like other biotindependent carboxylases, with a biotin cofactor tethered to a carrier domain responsible
for transferring CO2 from the first subsite to the second (Goodall, et al., 1981). Many
early kinetic studies were interpreted to suggest that carrier domain translocation was
induced by the binding of substrate to the second active-site (Easterbrook-Smith, et al.,
1976; Goodall, et al., 1981; Attwood and Wallace, 1986). These early studies revealed
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that acyl-CoA derivatives activated pyruvation carboxylation, specifically acetyl-CoA
(Scrutton, Keech, and Utter, 1965). The first X-ray crystal structure of PC, from
Rhizobium etli, clearly showed the existance of two spatially distinct active sites (St.
Maurice, et al., 2007). The carrier domain with tethered biotin was also captured in a
conformation between the intramolecular first active site and intermolecular second
active site, suggesting an intermolecular translocation pathway for catalysis. When
describing interactions between the carrier domain and another domain throughout this
dissertation, the term “intramolecular” will be used when the carrier domain is interacting
with a domain on its own polypeptide chain. The term “intermolecular” will be used
when the carrier domain is interacting with a domain across the face of the PC tetramer
on a separate polypeptide chain.
Studies over the past decade have continued to interpret results in light of an
induced conformational change mechanism for carrier domain translocation, despite the
lack of any direct experimental observations of carrier domain positioning. In this model,
the carrier domain is proposed to remain in the vicinity of the first active site until a
substrate binds in the second active site. Binding of a substrate in the second active site
induces a conformational change that causes carrier domain translocation to the second
active site.
This dissertation describes a series of biophysical studies designed to elucidate the
effect of ligands on carrier domain positioning and to understand the mechanism that
governs carrier domain positioning in PC. This enables the proposal of a new model for
carrier domain translocation in PC and offers a detailed description of how ligands and
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active site residues alter carrier domain positioning in this complex, multi-domain
enzyme.

1.

Fundamental Principles and Mechanisms of Ligand Binding to Proteins

At the core of many biological processes is a binding interaction between two or
more units. Whether the target is a receptor, a strand of DNA, or an enzyme, at least two
units must bind together in order for a signal to be transmitted, transcription to begin, or a
reaction to be catalyzed. When considering this phenomenon in enzymes, a fundamental
challenge has been to understand the mechanism that couples ligand binding with the
conformational changes that result in catalysis. In 1894, Emil Fischer was the first to
attempt a description of this phenomenon using the “lock-and-key” model, which views
the protein as a rigid structure that must precisely fit the shape of the ligand. A second
model, published by Daniel Koshland in 1958, became a lasting, canonical description of
ligand binding in proteins. This model, commonly called the “induced conformational
change” model, considers that the protein exists in a single conformation, similar to the
“lock-and-key” model, but allows that a conformational change can occur as a result of
ligand binding. Finally, in the last few decades, a model has been evolving that takes into
account observed conformational heterogeneity in protein populations as well as the
energy landscape theory of proteins. This model, called “conformational selection”,
views proteins as conformationally flexible entities and takes into account
thermodynamic laws when considering conformational behavior. This section will trace
the evolution of models that have been developed to explain the relationship between
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ligand binding and conformational change in proteins and will apply these models to
enzyme systems.

1.1

Evolution of the Ligand Binding Models

Emil Fischer’s “lock and key” model was the first attempt to explain ligand
binding to proteins (Fischer, 1894). In this model, the enzyme is viewed as a rigid
construct that contains a binding pocket of a specific size and shape. To accommodate
ligand binding, this binding pocket, the “lock”, must precisely match the shape of the
ligand, “the key”. While this model was successful in explaining why an enzyme has
specificity for a certain substrate, a failing of this model is that it does not consider
conformational changes that occur throughout the enzyme and that give rise to regulatory
properties. This model also does not explain how the unstable transition state is stabilized
by the enzyme during catalysis.
In 1958, Daniel Koshland proposed his theory of ligand binding, commonly
referred to as the “induced conformational change” model. In this model, the protein is
considered to be flexible, in contrast to the rigidity that is assigned by Fischer’s model.
Binding of the ligand to the enzyme is allowed, even if the binding site does not perfectly
fit the shape of the ligand. Upon binding, the ligand interacts with nearby residues,
resulting in conformational changes that further strengthen the binding interaction. Some
years later, this initial model was further expanded in a classic paper by Koshland,
Némethy, and Filmer to describe cooperativity in hemoglobin, and became known as the
KNF model (Koshland, et al., 1966). Hemoglobin consists of two heterodimers (ab) that
together form a homodimer (a2b2), with one binding site for molecular oxygen in each
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subunit, as observed in the first crystal structure of hemoglobin obtained by Perutz
(Perutz, et al. 1960). Molecular oxygen binding to hemoglobin obeys a sigmoidal
binding behavior. The shape of the curve indicates positive cooperativity within
hemoglobin, such that when one oxygen molecule binds to one subunit of hemoglobin, a
conformational change occurs, facilitating the subsequent binding of molecular oxygen to
the remaining, non-oxygen-bound subunits.
Hemoglobin subunits exist in two dominant conformations, the “T” state, which
has low oxygen affinity, and the “R” state, which has high oxygen affinity. When oxygen
binds to the T state, a conformational change occurs that shifts the hemoglobin
conformation from the T state to the R state. This relationship led to the concept of
oxygen-binding cooperativity, with the affinity for oxygen of hemoglobin increasing as
oxygen binds. The KNF model predicts that in the absence of oxygen, all subunits exist
in the T state. Upon oxygen binding, the oxygen-bound subunit adopts the R state and
induces adjacent subunits to also adopt the higher affinity R-state. Ultimately, all
subunits of hemoglobin will adopt the R state in the presence of oxygen, proceeding via a
sequential transition of the individual subunits (Figure I-1).
A competing model was proposed to explain cooperativity in hemoglobin by
Monod, Wyman, and Changeux, referred to as the “MWC” model (Monod, Wyman,
Changeux, 1965). This model relies on three assumptions that set it apart from the KNF
model: (1) Hemoglobin can exist in one of only two states, T or R; (2) the state of the
protein (T or R) is governed by the overall quaternary structure of the protein; (3) all of
the subunits switch between states simultaneously, such that the tetramer exists either
entirely in the T state or entirely in the R state. Regardless of the presence/absence of
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ligands, the hemoglobin population would exist in an equilibrium with some percentage
existing in the T state and some percentage existing in the R state (Figure I-1).
A major difference between these two models becomes clear when considering
the conformational flexibility of the protein. According to the KNF model, the protein
subunits uniformly exist in the T state in the absence of ligands. According to this model,
hemoglobin cannot access the R state in the absence of oxygen. In the KNF model,
conformational changes take place only as a consequence of ligand binding. Conversely,
in the MWC model, the protein always exists in an equilibrium between the T and R
states, so that each state is populated to some degree. In the MWC model, conformational
changes precede ligand binding, shifting the population equilibrium between T and R
states (Figure I-1).
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Figure I-1. Comparison between KNF model and MWC model
The low-oxygen affinity T state is represented by squares while the high-oxygen affinity R state is
represented by triangles. Red fill represents the oxygen-bound state. The MWC model is contained in the
blue rectangle with all subunits of hemoglobin changing conformation together and existing as a population
in an equilibrium between the T and R states. The KNF model displays the sequential conformational
change steps as oxygen binding induces a conformational change to the R state.
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As the mechanisms underlying the thermodynamics of protein folding were
coming into focus, the energy landscape theory of protein folding began to take shape.
The energy landscape theory is often represented by a “protein folding funnel”.
According to this model, each conformation that a protein adopts has an associated free
energy, with a lower free energy being more stable than a conformation with a higher free
energy. As a protein folds, its free energy generally flows down the energy funnel,
ultimately reaching a free energy minimum that represents the final, stable conformation
of the protein. Along the path from the high-energy unfolded state to the low-energy
folded state, there can be many local energy wells that stabilize the protein for a period of
time. These wells can reside at energy levels far above the energetic minimum and may
be deep enough to become “kinetic traps”, where time and/or energy input is required for
the protein to emerge and continue down the folding pathway. This protein folding
landscape has also been applied to the conformational changes that take place during
enzyme catalyzed turnover.
Recent models of protein conformational change have combined principles of the
MWC model and the energy landscape theory into what is known as the “conformational
selection” model. According to this model, a population of enzymes will exist in an
ensemble of conformations, including (but not limited to) the “free” state and the “ligandbound” state, according to a thermodynamic distribution that is driven by thermal
fluctuations; those conformations with a lower free energy will be more populated
(Kumar, et al., 2000, Boehr, et al., 2009). In this model, a ligand preferentially binds to a
pre-existing conformation of an enzyme that has the highest affinity for the ligand, much
like the lock and key model. However, ligand-binding generally results in a lowering of
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the free energy for the ligand-bound state, leading to a shift in the enzyme population
towards this conformation.
Since the initial studies on hemoglobin, the KNF / induced conformational change
model has been applied to a range of systems, including enzymes (Michel, 2016; Corbett,
P.T., et al., 2005). This model starkly contrasts with the conformational selection model
in not considering flexible oscillations in enzymatic conformation prior to the ligandbinding event. More recently, many enzyme systems have been described using the
conformational selection model. For example, the MWC/conformational selection model
better accounts for conformational changes in aspartate transcarbamylase (Changeaux, et
al., 1968; Changeaux and Rubin, 1968; Velyvis, et al., 2007), nicotinic acetylcholine
receptors (Colquhoun and Sakmann, 1985; Jackson, 1984; Bertrand, et al., 1992), and Gprotein coupled receptors (Lefkowitz, et al., 1993; Choe, et al., 2011; Xu, et al., 2011),
while the induced conformational change model best explains conformational change in
hexokinase (Bennett and Steitz, 1978) and kinesin (Kull and Endow, 2013).

1.2

Applying Ligand-Binding Models in Enzymes

The role of an enzyme in living systems is to accelerate the rate of a chemical
reaction. This rate enhancement is primarily achieved through the stabilization of the
high-energy transition state for the chemical reaction. In addition, an enzyme active site
must bind the substrate(s) such that the substrate is optimally oriented for catalysis.
Active site residues often play a dual-role: they must bind the substrate in the ground
state, but they must also preferentially stabilize the high energy transition state as the
substrate is converted into product. There are three major steps in any enzyme-catalyzed
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reaction: the binding of substrate(s), the chemical conversion of substrate(s) into
product(s), and the release of product(s). The binding affinity of an enzyme (E) with a
substrate is represented by the dissociation constant, Kd but this is often difficult to
measure kinetically. In most treatments, all of the microscopic rate constants that
represent the formation and breakdown of the enzyme-substrate complex (ES) are
collected into what is called the Michaelis constant, Km. Finally, the maximum turnover
rate, which is calculated by dividing the maximum velocity by the total enzyme
concentration, is represented by kcat.
The lock and key model can be described by the simple expression E + L ⇌ EL,
in which the conformation of the enzyme (E) does not change throughout the binding
process. In the induced conformational change model, a conformational change occurs as
a result of interactions between the ligand and active site, such that the expression can be
written E + L ⇌ EL ⇌ E*L, in which E* represents a different conformation of the
enzyme that has a high affinity for the ligand. Finally, in the conformational selection
model, a population of an enzyme would contain an ensemble of conformations with the
ligand preferentially binding to the conformation with highest affinity for the ligand. This
can be written E + L ⇌ E* + L ⇌ E*L (Vogt, et al., 2014). Therefore, the conformational
state E* exists in the absence of ligands in the conformational selection model, while
existing only in the presence of ligands in the induced conformational change model. An
observation of multiple enzyme conformational states in the absence of ligands serves to
experimentally support the conformational selection model in an enzymatic system.
When considering the thermodynamics of enzyme catalyzed reactions, the
energetic difference between the enzyme-substrate (ES) complex at the ground-state
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energy level and the high-energy transition state ([ES]‡) is represented by Gibbs free
energy of activation (DG‡) (Figure I-2A). Catalysis is generally accompanied by an
overall reduction in DG‡ for a reaction. These concepts can be applied to protein folding
as well, with a distribution of conformations existing in solution, each with an associated
Gibbs free energy. Generally, the lower-energy conformations will be more heavily
populated than a higher-energy conformation. The free energy of a conformation can
shift upon ligand binding, generally to a lower energy state which leads to an increase in
the population of that state (Figure I-2B) (Boehr, et al., 2009).
This section has presented the development of ligand-binding theories and their
relationship to conformational changes in proteins and enzymes. The conformational
selection model embraces the thermodynamic principles and concepts of protein
conformational fluidity introduced here. Rather than considering substrates and products,
the free energies of interacting domains can be considered, with kinetic barriers
separating the transition from one interaction to another. The thermodynamic and kinetic
barriers associated with conformational changes accompanying ligand binding events can
reveal fundamental information regarding the free energy landscape of an enzyme.
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Figure I-2 Thermodynamic representation of enzymatic reactions and conformational changes.
Gibbs free energy is plotted on the y-axis while reaction progress is plotted on the x-axis. A. The free enzyme
in the presence of substrates state (E+S), high-energy transition state (ES‡), and free enzyme in the presence
of product state (E+P) are shown. The dashed lines indicate the changes in Gibbs free energy between the
states with the blue line representing the enzyme catalyzed reaction and the black line the uncatalyzed
reaction. B. The Gibbs free energy associated with two empty active sites is shown by solid horizontal black
lines. Ligand binding results in a change in free energy (red). The dashed lines represent the kinetic barrier
for the conformational change from Conformation 1 to Conformation 2. The thermodynamic change depicted
by the decreased Gibbs free energy of the ligand bound state of Conformation 1 results in a shift in the
conformational equilibrium, represented by the large red arrow.
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2.

PYRUVATE CARBOXYLASE

Carrier domain enzymes present a unique system in which to study the effect of
ligand binding on enzyme conformation. In many enzymes, the carrier domain must
translocate a relatively large distance during catalysis. However, the mechanism
governing this translocation to ensure efficient transfer of intermediates between active
sites is an area of active study (Perham, 2000; Lowry, et al., 2016; Khosla, et al., 2014;
Zeczycki, et al., Menefee and Zeczycki, 2014). PC is a multi-domain enzyme that can
serve as a model to study the relationship between ligand binding and conformational
changes. It is an enzyme with a relatively simple construction, containing just two active
sites and a carrier domain that bridges the individual half reactions. PC forms a tetramer
of ~500 kDa, which is smaller and more easily studied than many other carrier domain
systems that are often composed of larger oligomeric structures that can be more than 1
MDa in mass. PC has also been well characterized kinetically and structurally, making it
an ideal system for these studies.
PC catalyzes the carboxylation of pyruvate to oxaloacetate, which serves as an
anaplerotic input to the TCA cycle. The first half-reaction, which occurs in the biotin
carboxylase (BC) domain, carboxylates the biotin cofactor that is tethered to the carrier
domain, using bicarbonate as the carboxyl donor concomitant with the cleavage of ATP.
The carrier domain translocates to the second active site in the carboxyltransferase (CT)
domain, where the second half-reaction occurs. In this domain, the carboxyl group is
transferred from biotin to pyruvate, forming oxaloacetate. The translocation of biotin,
which covers ~70 Å, is responsible for coupling these reactions. The substrate and
product of this reaction, pyruvate and oxaloacetate, are both important molecules in
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metabolism. Pyruvate is the final product of glycolysis and can be funneled into several
different metabolic pathways while oxaloacetate serves as one of the major inputs into
the TCA cycle, which is a central pathway for oxidative metabolism. The metabolic role
of PC will be briefly introduced, along with the structure and function of the individual
domains of PC.

2.1

The Role of Pyruvate Carboxylase in Metabolism and Disease

Pyruvate serves as a central metabolite in what may be the most crucial
crossroads in all of metabolism. It is best known as the final product of glycolysis, but it
is derived from many catabolic pathways including amino acid catabolism, and lactic
acid oxidation. Pyruvate can have several fates, including being shuttled into the
mitochondria (in organisms containing this organelle) for entry into the TCA cycle as
acetyl-CoA under aerobic conditions, fermentation into lactate or ethanol under anaerobic
conditions, or transamination to the amino acid alanine (Gray, et al., 2014). When one or
more biosynthetic pathways are upregulated to draw intermediates away from the TCA
cycle, levels of TCA cycle intermediates decrease, which deleteriously impacts the flux
in and out of the cycle. The primary role of pyruvate carboxylase is to replenish the TCA
cycle intermediate oxaloacetate through the biotin-dependent carboxylation of pyruvate,
thereby balancing the withdrawal of intermediates from the TCA cycle.
TCA cycle intermediates are drawn out through several biosynthetic pathways
including lipogenesis, amino acid generation, nucleotide synthesis, and porphyrin
biosynthesis. Citrate can be transported out of the mitochondria for conversion back to
acetyl-CoA which can be used for fatty acid synthesis or the formation of the lipid
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cholesterol. Succinyl-CoA is a key component in the synthesis of porphyrins, which
themselves are used for the construction of hemes and other metal-binding structures.
Several amino acids, including glutamate and glutamine, are derived from the TCA cycle
intermediate a-ketoglutarate. Not only is glutamine incorporated into proteins, it also
serves as a key precursor for the synthesis of both purine and pyrimidine nucleotides and
acts as the major nitrogen carrier in vertebrates. While pyruvate is the major metabolite
used in gluconeogenesis, glutamine, alanine, lactate, and glycerol can also be converted
for use in gluconeogenesis (Gerich, et al., 2001). PC catalyzes the first step of
gluconeogenesis with the conversion of pyruvate to oxaloacetate, which is then shuttled
out of the mitochondria as malate.
Given the crucial role of PC in central metabolism, a disruption in PC expression
and/or activity has been linked to a number of disease states. Pyruvate carboxylase
deficiency, for example, is an autosomal, recessive disorder that ranges from benign to
severe (Marin-Valencia, et al., 2010). In mice, a correlation between PC activity,
pancreatic islet cell size and mass, as well as the presence of hyperglycemia has been
observed, highlighting the role of PC in metabolic health (Han and Liu, 2010). PC
expression is upregulated in human breast cancer tissue, where an increase in PC
expression has been associated with tumor size and proliferation (Phannisil, et al., 2015).
The higher metabolic demand on PC in many cancers is explained by the need for
increased anaplerotic input to compensate for a higher flux through the biosynthetic
pathways needed to support cellular growth and division in cancer cells (Phannisil, et al.,
2015).
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PC is broadly distributed among bacteria, plants, invertebrates and vertebrates
(Wallace, et al., 1998). At least one microbial species, Listeria monocytogenes is
particularly dependent on the anaplerotic role of pyruvate carboxylase. L. monocytogenes
does not encode 2-oxoglutarate dehydrogenase, leaving L. monocytogenes with an
incomplete, branched TCA cycle. Consequently, L. monocytogenes is highly dependent
upon PC (encoded by pycA in L. monocytogenes) to replenish oxaloacetate, which is the
only route to malate and fumarate in this incomplete TCA cycle. It has been observed that
in pycA mutants, L. monocytogenes has decreased virulence in mice and cannot replicate
in mammalian hosts (Schär, et al., 2010).

2.2

Structure of Pyruvate Carboxylase

In most PC enzymes, all functional domains are encoded on a single polypeptide
chain (Figure I-3). The biotin carboxylase (BC) domain, site of the first half-reaction, is
located at the N-terminus of the polypeptide and is linked to the carboxyltransferase (CT)
domain by a helical region that forms the core of the allosteric domain. The CT domain
threads back into a half beta barrel that completes the allosteric domain, which then
terminates in the biotin carboxyl carrier protein (BCCP) domain.

2.2.1

Tetrameric Structure

PC forms tetramers at high concentrations, which dissociate to dimers and
monomers at concentrations below 4 EU/mL (~0.13 mg/mL) (Khew-Goodall, et al.,
1991; Attwood and Geeves, 2002). This process of dilution inactivation can be rescued,
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to varying degrees, by the addition of the allosteric activator, acetyl-CoA, as well as by
ATP and/or Mg2+, both of which bind in the BC domain (Attwood, et al., 1993; Attwood
and Geeves, 2002). The PC homotetramer is stabilized by contacts at each corner of the
tetramer, where homodimerization interfaces stabilize identical domains to form two
perpendicular faces of the tetramer, as observed in the first X-ray crystal structures of PC
from Rhizobium etli (RePC) and Staphylococcus aureus (SaPC) (Figure I-4) (St. Maurice,
et al., 2007; Xiang and Tong, 2008). These first structures revealed that the distance
between active sites is ~70 Å, too far apart for biotin to reach both active sites without
involving significant carrier domain translocation. A pathway of carrier domain
translocation was hinted at in the RePC structure with the carrier domain positioned
between the intramolecular BC domain and intermolecular CT domain. After the
structure was obtained, it was then experimentally confirmed that the carrier domain
travels across the face of the tetramer to the CT domain on a separate polypeptide chain
(St. Maurice, et al., 2007). This was further supported by the first SaPC structure in
which the carrier domains were observed to be interacting with the CT domain of the
opposing polypeptide chain on the same face of the tetramer (Xiang and Tong, 2008).
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Figure I-3 Rhizobium etli pyruvate carboxylase monomeric structure.
Shown is the monomeric structure of Rhizobium etli PC. The biotin carboxylase (BC) domain is blue, the
allosteric domain is green, the carboxyltransferase domain (CT) is yellow, and the biotin carboxyl carrier
protein (BCCP) domain is green. The resolved nucleotide portion of ethyl-CoA is shown bound in the
allosteric domain and a non-hydrolyzable ATP analog is shown bound in the BC domain.
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Figure I-4 Pyruvate carboxylase tetrameric structures from R. etli and S. aureus.
Shown is the tetrameric structures of Rhizobium etli PC (PDB ID: 2QF7) A difference between the
asymmetric (RePC) and symmetric (SaPC) conformations are visible with the interaction of allosteric
domains between faces in the symmetric conformation. (A) and Staphylococcus aureus (PDB ID: 3BG5)
(B). The top face is colored green while the bottom face is blue.
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2.2.2

Biotin Carboxylase (BC) Domain Structure

The biotin carboxylase (BC) domain is common across all biotin-dependent
carboxylase enzymes. The active site in the BC domain binds Mg-ATP, with the aid of an
additional magnesium ion, and bicarbonate, which donates the CO2 for carboxylation of
biotin. The structure of the BC domain is comprised of three subdomains: A, B, and C
(Waldrop, et al., 1994; Broussard, et al., 2015; Tong, 2017). The A and C subdomains
contribute the bulk of the BC domain, while the B-subdomain acts as a highly flexible lid
that closes down on the active site in the presence of substrates (Thoden, et al., 2000).
The B subdomain interacts with substrates through a glycine-rich P-loop that positions
itself over the phosphate groups of ADP/ATP. In the presence of the nucleotide and
Mg2+, the B-subdomain combines with the C-subdomain to form the complete binding
interface for the carrier domain (Thoden et al., 2000; Lietzan et al., 2011; Kondo, et al.,
2004; Chou, et al., 2009; Chou, et al., 2011; Menefee and Zeczycki, 2014). Interestingly,
only two specific interactions between non-conserved residues have been identified
between the BC and BCCP domains (Lietzan, et al., 2011), suggesting that the interface
itself between the B-subdomain lid and C-subdomain makes the most important
contribution to carrier domain docking.

2.2.3

Carboxyltransferase (CT) Domain Structure

The carboxyltransferase (CT) domain of PC is less broadly distributed among the
biotin-dependent enzymes, where different domains have evolved to accommodate the
carboxylation of different substrates. The CT domain is composed of two subdomains: an
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a8b8 TIM-barrel core capped by a C-terminal funnel-like subdomain composed of nine
a-helices that leads to the CT domain active site located at mouth of the TIM-barrel. At
the near-edge of the TIM barrel, a dicationic metal ion, Zn2+ or Mn2+, is bound that aids
in the coordination and binding of pyruvate (St. Maurice, et al., 2007; Xiang and Tong,
2008; Yu, et al., 2009). The TIM barrel is a conserved structure present in members of
the DRE-TIM superfamily which contains a wide range of enzymes that require the
breaking or formation of C-C bonds (Frantom, et al., 2014).
The presence of pyruvate has a dramatic impact on the conformation of a flexible
loop (Arg621-Asn630) within the CT domain active site (PDB ID: 4JX5) (Lietzan, et al.,
2013A) (Figure I-5). In the presence of pyruvate, Arg621 (RePC numbering) forms a salt
bridge with the carboxyl moiety of pyruvate (Figure I-5B). Whereas, in the absence of
pyruvate, Arg621 is disordered (Figure I-5A). This Arg621-pyruvate interaction
corresponds with movement of the loop into a closed conformation, which rotates Tyr628
from an outward facing conformation to one where it is oriented into the active site and
within hydrogen-bonding distance of Asp590 (Figure I-5B) (PDB ID: 4JX4) (Lietzan, et
al., 2013A). The positioning of Asp590 is further stabilized by an interaction with the
side chain of nearby Arg594. This chain of interactions directly contributes to active site
conformational rearrangements upon pyruvate binding.
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Figure I-5 RePC CT domain active site structure rearrangement in the presence of pyruvate.
A. RePC X-ray crystal structure in the absence (A) (PDB ID: 4JX4) and presence (B) (PDB ID: 4JX5) of
pyruvate. Y628 rotates into the active site in the presence of pyruvate, providing a binding platform for biotin.
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The repositioning of Tyr628 upon pyruvate binding stabilizes biotin binding in
the CT domain active site through a sulfur-pi interaction between the thiophene ring of
biotin and the aromatic ring of Tyr628 (Lietzan, et al., 2013A). Such interactions are
predicted to contribute 1-2 kcal/mol of stabilization energy (Reid, et al., 1985;
Maveyraud, et al., 1996; Zauhar, et al; 2000). The importance of these residues (Tyr628,
Arg594, Asp590) to catalysis were confirmed by the near-complete loss of catalytic
activity in Y628A and D590A RePC mutants (Lietzan, et al., 2013A). The structure of the
pyruvate binding pocket also supports the observation that a-keto acid analogues can
induce carboxybiotin decarboxylation (Attwood and Wallace, 1986). Several small aketo acids analogs bind in an identical manner to pyruvate in the active site (Lietzan and
St. Maurice, 2013), stabilizing the Tyr628 biotin-binding platform and favoring the
placement of carboxybiotin in the active site. Conversely, analogs lacking either the aketo group or carboxyl group do not induce carboxybiotin decarboxylation (Attwood and
Wallace, 1986).

2.2.4

Carrier Domain Structure

The crystal structure for the carrier domain from E. coli acetyl-CoA carboxylase,
which is homologous to the PC carrier domain, was first determined in 1995 (Athappily
and Hendrickson, 1995). The BCCP domain is composed of two stacked b-sheets which
are each composed of four antiparallel b-strands. Located roughly midway through this
domain, and projecting out from a b-hairpin turn, is the conserved biotinylated lysine.
This lysine is one of four conserved residues (MKME) that make up a common
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biotinylation motif across all biotin-dependent enzymes (Samols, et al., 1998; Duval, et
al., 1994). The carrier domain is positioned at the C-terminus of PC and is connected to
the allosteric domain by a relatively long, flexible arm.

2.2.5

Allosteric Domain Structure and Function

The first X-ray crystal structure of RePC, co-crystallized with ethyl-CoA,
revealed the existence of the allosteric domain, which is positioned between the BC and
CT domains and at the base of the carrier domain (PDB ID: 2QF7) (Figure I-3) (St.
Maurice, et al., 2007). The allosteric domain has a simple composition in PC, consisting
of a central a-helix covered by four antiparallel b-strands partially wrapping around it.
The a-helix and b-strands are non-contiguous, with the helix originating from the Cterminal end of the BC domain and the four antiparallel b-strands located C-terminal to
the CT domain. In the symmetric tetrameric conformation captured in the SaPC structure,
the allosteric domains of the top face of the tetramer formed a dimerization interface with
the allosteric domains on the bottom face of the tetramer. Thus, this domain has also been
named the PC tetramerization domain (Xiang and Tong, 2008). This domain has no
strong sequence conservation in other biotin-dependent enzymes, though a very similar
structural motif has been observed in several other biotin-dependent enzymes. The BT
domain of acyl-CoA carboxylases is one example of a similarly structured domain that
resembles the PC allosteric domain. However, rather than containing four b-strands like
the PC allosteric domain, the BT domain has eight b-strands that wrap around the central
a-helix (Tong, 2017)

25
Since the discovery and initial characterizations of PC, it was known that acylCoA derivatives activated PC (Scrutton, et al., 1965). Acetyl-CoA is commonly the most
effective activator of PC and has been the most extensively studied, along with allosteric
inhibitors such as L-aspartate. The first crystal structure of RePC showed ethyl-CoA (a
nonhydrolyzable analogue of acetyl-CoA) bound in the allosteric domain (Figure I-3).
Acetyl-CoA is stabilized in the binding site by hydrogen bonding with two conserved
arginine residues, Arg427 and Arg472 in RePC (St. Maurice, et al., 2007). Mutations to
these residues have an impact beyond simply affecting acetyl-CoA binding. For example,
the Km for ATP is increased by mutations to these residues. (Adina-Zada, et al., 2012).
Many site-specific mutations have been made in this domain to elucidate the mechanism
of allosteric activation by acetyl-CoA.
Activation by Acetyl-CoA. Soon after PC was initially purified, it was discovered
that acetyl-CoA acted as an activator (Scrutton, et al., 1965). Acetyl-CoA is generated
cellularly by the pyruvate dehydrogenase complex for entry into the TCA cycle or by
fatty acid oxidation. As acetyl-CoA enters into the TCA cycle, it condenses with
oxaloacetate, forming citrate. This is a logical feedback mechanism, in which a higher
concentration of acetyl-CoA, perhaps derived from an increased flux through glycolysis,
requires an increased concentration of oxaloacetate with which to condense.
Several kinetic studies have determined that the BC domain is the locus of action
for acetyl-CoA. Acetyl-CoA was observed to increase the magnitude of the dissociation
rate constant for fluorescent analogues of both ATP and ADP (Geeves, et al., 1995). One
initial study suggested that acetyl-CoA accelerates the formation of the carboxyphosphate
intermediate and ATP cleavage. ATP cleavage was also better coupled to carboxybiotin
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formation in the presence of acetyl-CoA, as well (Legge, Branson, Attwood, 1996). This
was supported by a more recent study in which chimeric PC enzymes constructed from
two isoforms of yeast PC (PYC1 and PYC2) were investigated for their regulatory
properties. Despite having different degrees and characteristics of activation by acetylCoA, it was determined that the BC domain was the locus of acetyl-CoA activation
(Jitrapakdee, et al., 2007).
Several recent studies have suggested that the role of acetyl-CoA is not simply
confined to the BC domain. A 2011 study by Zeczycki, et al. showed that, under ideal
conditions, acetyl-CoA enhanced the coupling between the BC domain and CT domain
reactions, reducing non-productive ATP cleavage (Zecycki, et al., 2011). Succeeding this
study was a thermodynamic and kinetic study conducted in SaPC to investigate the
activation of acetyl-CoA. Acetyl-CoA was proposed to not only constrain the movements
of the carrier domain, but also to kinetically and thermodynamically couple MgATP and
pyruvate. The authors suggested that acetyl-CoA may even regulate the quaternary
conformation and domain motions of PC (Westerhold, et al., 2018). This is consistent
with suggestions by Sirithanakorn, et al. that acetyl-CoA may stabilize the symmetric
conformation in PC, which involves a conformational change in the quaternary structure
and corresponds to a repositioning of the carrier domain (Sirithanakorn, et al., 2016).
However, direct observations of the effects of acetyl-CoA on carrier domain positioning
or conformational dynamics of PC in response to acetyl-CoA are currently lacking.
Inhibition by L-aspartate. As a product of the TCA cycle, L-aspartate displays
classic feedback inhibition of PC. Studies of L-aspartate inhibition have generally been
performed in conjunction with acetyl-CoA in which L-aspartate has been observed to
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reduce the degree of activation by acetyl-CoA. However, studies of PC cloned from three
different species revealed that acetyl-CoA and L-aspartate binding are mutually
exclusive, suggesting that they share a common binding site (Cazzulo and Stoppani,
1968; Osmani, et al., 1981; Sirithanakorn, et al., 2014). Supporting this, Osmani, et al.
suggested the binding site to be outside of the BC active site, as its inhibition with respect
to MgATP is non-competitive in Aspergillus nidulans PC whereas an observation of
competitive inhibition would have suggested a shared binding site between MgATP and
L-aspartate

(Osmani, et al., 1981). Despite being mutually exclusive, the two effectors

appear to have distinct binding sites: mutation of the acetyl-CoA binding site does not
affect L-aspartate inhibition in RePC (Adina-Zada, et al., 2012). No crystal structure has
yet revealed the L-aspartate binding site, preventing a complete understanding of how Laspartate competes with acetyl-CoA and inhibits BC domain activity.
The locus of action of L-aspartate is the BC domain and not the CT domain
(Sirithanakorn, et al., 2014). L-aspartate does not affect the coupling between BC and CT
domain reactions whereas acetyl-CoA greatly affects half-reaction coupling
(Sirithanakorn, et al., 2014; Zeczycki, et al., 2011B). Finally, L-aspartate was observed to
similarly affect all carrier domain translocation pathways in RePC while acetyl-CoA
preferentially activated the translocation pathway between the intramolecular BC domain
and intermolecular CT domain (Liu, et al., 2018). The mechanism by which L-aspartate
inhibits PC catalytic activity remains unresolved and direct observations of the effect of
L-aspartate

on carrier domain translocation have not been made.
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2.3

Catalysis in Pyruvate Carboxylase

The carboxylation of pyruvate requires two active sites working in concert. The
cleavage of ATP in the presence of bicarbonate leads to the carboxylation of the carrier
domain-tethered biotin. The carrier domain must then translocate to the CT domain
where it transfers the carboxyl group from biotin to pyruvate, forming oxaloacetate
(Figure I-6). Each domain must stabilize biotin in the active site while preventing the
abortive decarboxylation of carboxybiotin. Abortive decarboxylation can occur if
pyruvate isn’t present to accept the carboxyl group in the CT domain or if carboxybiotin
returns to the BC domain active site and decarboxylates in the reverse reaction. The
catalytic reactions and the BC domain mechanism for controlling biotin access will be
introduced here. The mechanism of stabilizing biotin in the CT domain active site was
discussed above.
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Figure I-6 Illustration of SaPC carrier domain translocation.
The SaPC tetramer is shown with BC domains in blue, CT domains in yellow, and a BCCP domain in pink.
Biotin is represented as a grey sphere tethered by a flexible black linker. The CT domain active site Mn2+ is
represented by a light grey sphere. Carrier domain translocation is shown from the BC domain of its own
polypeptide chain to the CT domain of the opposing polypeptide chain. Other carrier domains have been
omitted for clarity. Illustration by Anya Lei Koza with creative and scientific input by Joshua H. Hakala.
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2.3.1

BC Domain Function
The first step in the RePC BC domain reaction occurs when Mg2+ and MgATP

bind in the BC domain active site, which may occur in either an ordered binding process
or through a rapid random equilibrium (Attwood and Graneri, 1992). To aid in proper
orientation of the nucleotide, Lys245 interacts with the 𝛾-phosphate of ATP with the
positively charge Lys stabilizing the negatively charge phosphate group of ATP
(Zeczycki, et al., 2011A). In turn, the positioning of Lys245 is stabilized by the formation
of a hydrogen bond between the side chain of Glu218 and the amino group of Lys245
(Zeczycki, et al., 2011A). After bicarbonate binds, the first chemical step is the
deprotonation of bicarbonate. Glu305 acts as a general base in the deprotonation of
bicarbonate, which is promoted by hydrogen-bonding to Glu218 (Zeczycki, et al.
2011A). This highlights the dual-purpose of Glu218, which was further supported when
the E218A mutation in RePC resulted in a complete loss of catalytic activity (Zeczycki, et
al., 2011A). The 𝛾-phosphate of ATP undergoes a nucleophilic attack by the “activated”
bicarbonate. This is proposed to form a carboxyphosphate intermediate, along with ADP
(Ogita and Knowles, 1988). This highly unstable carboxyphosphate intermediate breaks
down to CO2 and inorganic phosphate (PO43-). However, at this stage, the N1 position of
biotin would still be protonated and unable to react with CO2. The phosphate liberated
from ATP cleavage has been proposed to deprotonate the N1 position of biotin, priming it
for the final electrophilic attack by CO2 (Menefee and Zeczycki, 2014). The proposed
mechanism for the BC domain reaction is summarized in Figure I-7.
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Figure I-7 BC Domain Mechanism
Shown is the proposed mechanism of the BC domain. Adapted from Zeczycki, et al., 2011A.
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To aid in the positioning of the inorganic phosphate in close proximity to biotin,
Arg301 has been proposed to behave as a general base catalyst in promoting the proton
transfer from the N1 position of biotin to the phosphate. The deprotonation of the N1 of
biotin results in the formation of a biotin enolate, which is stabilized by Arg353
(Zeczycki, et al., 2011A). This mechanism was further supported by the dramatically
reduced ability of the R353M RePC mutant to catalyze the formation of carboxybiotin
(Zeczycki, et al., 2011A). When the biotin enolate breaks down, a nucleophilic attack is
initiated on the electrophilic carbon of CO2, resulting in the final carboxybiotin product.
A mechanism to control carboxybiotin access to the BC domain active site has
also been proposed. A T882A RePC X-ray crystal structure co-crystallized with ADP and
phosphonoacetate shows the carrier domain docked with the BC domain (PDB ID:
3TW6) (Lietzan, et al., 2011). In this structure, biotin does not project into the active site.
Instead, biotin is removed and pointing away from the active site. In this structure,
Glu248 and Arg353 interact through a salt bridge, forming a “gate” that appears to block
the entry of biotin to the active site. This Glu248-Arg353 interaction has been proposed
to prevent the abortive decarboxylation of biotin. This proposal was supported by the
observation that, when these residues were mutated, it led to increased rates of ADP
phosphorylation, increased rates for the reverse BC domain reaction, and decreased
coupling efficiency between the BC and CT domain reactions (Lietzan, et al., 2011;
Lietzan et al., 2013B; Zeczycki, et al., 2013).
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2.3.2

CT Domain Function

The CT domain is responsible for properly orienting and binding carboxybiotin in
the active site, stabilizing the formation of the biotin enolate during the decarboxylation
of biotin, binding pyruvate, and stabilizing the formation of the enol-pyruvate
intermediate as pyruvate carboxylation is underway. To accomplish this, there are two
separate regions in the vicinity of the active site. The N-terminal subdomain provides all
residues necessary for pyruvate binding and enolization while the C-terminal subdomain
provides the residues that bind carboxybiotin and stabilize the biotin enolate.
In RePC, after carboxybiotin is bound in the active site, biotin decarboxylates,
leading to the formation of a biotin enolate intermediate (Figure I-8). The developing
negative charge on the ureido oxygen is stabilized by Gln844, Ser885, and the
polypeptide backbone amide of Lys866 (Zeczycki, et al., 2009). In the next step, Thr882
donates a proton to the N1 position of biotin which then, in a concerted manner, abstracts
a proton from the methyl group of pyruvate (Sheng and Liu, 2014). This action leads to
the generation of the pyruvate-enol intermediate, which is stabilized by the positivelycharged active site Zn2+. Finally, the enol-pyruvate breaks down to promote a
nucleophilic attack on the carbon of CO2, completing the carboxylation of pyruvate
(Zeczycki, et al., 2009).
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Figure I-8 CT Domain Mechanism
Shown is the proposed CT domain mechanism. Adapted from Zeczycki, et al., 2009.
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2.4

Conformational Changes in PC Associated with Catalysis

Many kinetic studies on PC have attempted to provide insights into how carrier
domain positioning contributes to catalytic turnover. Based on increased rates of
carboxybiotin decarboxylation in the presence of CT domain ligands, it was suggested
that CT domain ligands induce the translocation of the carrier domain from the BC
domain to the CT domain (Easterbrook-Smith, et al. 1976; Goodall, et al., 1981; Attwood
and Wallace, 1986). This led to a model in which the carrier domain was proposed to
occupy two different positional states in or near the BC domain in the absence of CT
domain ligands, with a third state representing carboxybiotin translocation to the CT
domain for rapid decarboxylation (Easterbrook-Smith, et al., 1976; Goodall, et al., 1981;
Attwood and Wallace, 1986). These initial models assumed that the carrier domain did
not translocate to the CT domain or occupy any other conformations near the CT domain
in the absence of a CT domain ligand. More recent structural and kinetic studies have
revealed a high inherent flexibility to the carrier domain (Adina-Zada, et al., 2019, Liu, et
al., 2018), suggesting that this assumption may not hold to be true.
In 2011, Zeczycki, et al. observed that, in the presence of saturating pyruvate and
acetyl-CoA, the ratio of phosphate release to oxaloacetate formation was 1:1 in RePC.
Recall that in the BC domain, ATP cleavage occurs concomitantly with biotin
carboxylation, which produces ADP and inorganic phosphate, which is released after the
reaction is complete. Oxaloacetate is the product of the CT domain reaction. Therefore,
the observation that the ratio of phosphate release to oxaloacetate formation was near
unity indicates an efficient coupling of these two reactions. In the absence of acetyl-CoA,
the half-reactions become highly uncoupled, with much more Pi released than
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oxaloacetate formed (Zeczycki, et al., 2011B). Thus, acetyl-CoA plays a crucial role in
establishing catalytic efficiency in PC, but the mechanism for this enhancement was still
unknown. Recently, a kinetic study using a system of hybrid tetramers of SaPC with
inactivated BC or CT domains was used to suggest that pyruvate and acetyl-CoA
facilitate long-range communication throughout the tetramer and induce carrier domain
translocation (Westerhold, et al., 2016). Westerhold, et al. also discovered that acetylCoA thermodynamically couples MgATP and pyruvate, while this coupling is abolished
in the absence of acetyl-CoA, further suggesting a role for acetyl-CoA in long-range
communication between active sites. In addition, acetyl-CoA decreased the activation
entropy in SaPC, suggesting that acetyl-CoA constrained the motions of the carrier
domain (Westerhold, et al., 2017). Finally, a study of carrier domain translocation
pathways demonstrated that, in RePC, acetyl-CoA activates the catalytic pathway for
carrier domain translocation from the intramolecular BC domain to the intermolecular CT
domain whereas the allosteric inhibitor, L-aspartate, did not influence any one
translocation pathway over any other (Liu, et al., 2018).
Several structural studies have been performed which have helped to understand
the role of acetyl-CoA on PC structure. Initial electron microscopy studies revealed that
the tetrahedral shape of PC adopts a tighter conformation in the presence of acetyl-CoA
or pyruvate (Attwood, et al., 1986). RePC was captured in an asymmetric conformation
with the BC and CT domains on opposing polypeptide chains on one face of the tetramer
65 Å apart and 80 Å apart on the opposite face. The carrier domain in this conformation
of PC was located in the vicinity of the BC domain in the presence and absence of acetylCoA (St. Maurice, et al., 2007). Conversely, the symmetric conformation was captured in
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SaPC with the opposing active sites approximately 75 Å apart. In the symmetric PC
conformation, the carrier domain was positioned in the vicinity of the CT domain in the
absence and presence of acetyl-CoA (Xiang and Tong, 2008; Yu, et al., 2009). When
combined, these structures highlight the difficulty in assigning any specific conformation
to the presence of acetyl-CoA. In 2010, a cryo-EM study of SaPC observed several
different conformational states of PC in the absence of active turnover. These
conformational states supported suggestions that the carrier domain interacts with the BC
domain on the same polypeptide chain (intramolecular) and the CT domain of the
opposing polypeptide chain (intermolecular) (Lasso, et al., 2010). Finally, a cryo-EM
study was performed in which SaPC samples undergoing catalysis were frozen and
analyzed for conformational variability (Lasso, et al. 2014). It was discovered that there
were populations of SaPC that adopted the symmetric conformation and populations that
adopted the asymmetric conformation, demonstrating that PC can adopt both
conformations during catalysis. These two conformations appeared to capture PC in the
process of catalyzing the two separate half-reactions, with PC oscillating between these
two states during the catalytic cycle. Each state, symmetric or asymmetric, correlated
with specific carrier domain positions. Interestingly, asymmetric PC displays only two
acetyl-CoA binding sites whereas symmetric PC contains four binding sites, suggesting
that acetyl-CoA may regulate the adoption of these conformational states (Lasso, et al.,
2014).
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3.
CARRIER DOMAIN ENZYMES AND CONFORMATIONAL CHANGE
STUDIES

Pyruvate carboxylase belongs to a large class of multi-domain enzymes that
utilize a prosthetic group aboard a carrier domain to transport an intermediate between
active sites. Multifunctional enzymes and multi-enzyme complexes of this class are
similar in that they catalyze multi-step reactions in spatially distinct active sites and
require a carrier domain to physically couple their activities. While the prosthetic group
carrying the intermediates may differ, the core function of efficiently transporting
intermediates from one active site to another is conserved. The prosthetic groups
participating in these reactions provide two benefits. First, the intermediate is prevented
from diffusing away into solvent or being captured by a different system due to the
covalent bond with the prosthetic group. Second, the flexible nature and length of these
groups and the carrier domains allow the prosthetic group to reach and access distant
active sites while maintaining high local concentrations for the reactive intermediates
(Perham, 2000). The prosthetic groups of the enzymes discussed here and shown in
Figure I-9 include biotin (biotin-dependent enzymes), phosphopantetheine (polyketide
synthases), lipoic acid (pyruvate dehydrogenase complex), and the amino acid cysteine
(which acts as a prosthetic group for the carrier protein in the bacterial sulfur oxidation
pathway).

39

Figure I-9 Prosthetic Group Structures
Several prosthetic groups utilized by carrier domain enzymes are shown. A. Biotin B. Lipoic Acid C.
Phosphopantetheine D. Cysteine

3.1

Biotin-Dependent Enzymes

Biotin was first discovered as an agent that reduced the toxicity of raw egg whites
to humans in 1936. The “toxin” responsible for this toxicity was the protein avidin, which
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irreversibly binds biotin. This strong interaction has proven useful, as avidin has been
used in studies of biotin-dependent enzymes for decades as well as in a variety of
biotechnological applications. (Waldrop, et al., 2012; Diamandis and Christopoulos,
1991). As exemplified above, the biotin cofactor is utilized by carrier domain enzymes
for the transport of carbon dioxide in transcarboxylation reactions. Biotin is composed of
a ureido ring fused to a tetrahydrothiophene ring with a valerate side chain. The cofactor
is covalently tethered through a pseudo-peptide linkage to a specific lysine side-chain in
biotin-dependent enzymes. Biotin participates in three types of enzyme-catalyzed
reactions. The first reaction, exemplified by PC, is ATP-dependent carboxylation. The
second reaction type occurs in a class of enzymes that couple sodium transport in
anaerobes to the decarboxylation of b-keto acids (Dimroth and Hilbi, 1997). The third
reaction type is catalyzed by a large assembly of polypeptides called transcarboxylase. In
this unusual reaction, transcarboxylase transfers a carboxyl group to pyruvate from
methylmalonyl-CoA, forming oxaloacetate and propionyl-CoA (Wood, et al., 1963).
Pyruvate carboxylase was extensively described in section 1.2. This section will focus on
a related, well-characterized biotin-dependent carboxylase that catalyzes the ATPdependent carboxylation of acetyl-CoA.
Acetyl-CoA carboxylase (ACC) catalyzes the ATP-dependent carboxylation of
acetyl-CoA to malonyl-CoA. The product of this reaction is a key precursor in fatty acid
biosynthesis, as well as in the biosynthesis of some polyketides. Like PC, ACC is
composed of at least three major domains: the BC domain, CT domain, and BCCP
domain.

41
Prokaryotic ACCs function as assemblies of individual subunits while eukaryotic
ACCs include all functional domains on a single polypeptide chain (Cronan Jr., et al.,
2002). Eukaryotic ACCs also contain two additional domains: a large central domain
(CD) and a BC-CT (BT) interaction domain (Wei and Tong, 2015). The BC domain of
ACC catalyzes the ATP-dependent carboxylation of the biotin-cofactor and is structurally
and functionally similar to the BC domain in PC and all other biotin-dependent
carboxylases. More uniquely, the BC domain of ACC is also subject to regulation and
conformational dynamics. In eukaryotic ACC, the BC domain is only catalytically active
as a dimer. Large conformational changes have been observed in the BC domain dimer
interface in crystal structures comparing the BC domain dimer and monomer (Wei and
Tong, 2015; Shen, et al., 2004). During catalysis, the BC domains from two different
polypeptide chains come together to form an active dimer. In the monomeric form, a
flexible loop occupies part of the BC-BCCP binding interface while, in the dimer, this
loop is not in a position to obstruct this binding interaction (Wei and Tong, 2015). This
illustrates one mechanism of controlling biotin access to an active site. However, in either
the open conformation or the dimerized BC domain conformation, the distance between
BC and CT domains is greater than 110 Å. This is much larger than the observed
separation of active sites in other biotin-dependent enzymes and is too large to be bridged
by carrier domain translocation alone (Hunkeler, et al., 2016).
The central domain of single-chain ACCs has only recently been structurally
characterized and have been found to be quite dynamic and an important point of
regulation (Hunkeler, et al., 2016). This domain does not directly bind substrates or
catalyze any reactions, but instead plays a large regulatory role in the dynamics of ACC.
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The CD domain is positioned between the BC and CT domains and serves as the
attachment point for the BCCP domain. The central domain is regulated by
phosphorylation of a regulatory loop at the interface between two smaller subdomains.
Phosphorylation stabilizes the loop and restricts conformational flexibility. While the
regulatory role of the CD domain has been related to BC domain dimerization, its
proximity and physical connection to the carrier domain may be important. However,
there have been no direct attempts to relate the conformational dynamics of the BC, CD,
and BCCP domains in ACC. Especially absent to date are studies of how carrier domain
dynamics relate to catalysis in ACC, making this recent study on the effects of
phosphorylation on conformational dynamics our best understanding of conformational
dynamics in ACC.

3.2

Crosslinking Studies of Polyketide Synthase

Polyketide synthases (PKSs) are massive, multi-modular enzyme complexes that
catalyze the production of a diverse range of natural products. PKSs operate like an
assembly line, passing an intermediate product between multi-domain modules to
catalyze very specific, ordered reactions to generate elaborately decorated natural
products. Due to the complex nature of the final product, these reactions must maintain
exquisite directionality. There are many open questions regarding the structure and
organization of the modules, the mechanism ensuring proper reaction directionality, and
the mechanism behind conformational changes in these enzymes. Given the size of these
complexes, many of the standard biochemical and biophysical approaches are
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inaccessible in these systems. Currently, no X-ray crystal structure of a complete PKS
module has been determined.
6-deoxyerythronolide B synthase (DEBS) is a PKS that operates as an a2b2g2
homodimer and has been extensively studied in recent years. X-ray crystal structures of
individual domains and lower-resolution techniques such as cryo-EM and small angle Xray scattering (SAXS) has contributed to a better understanding of this system in recent
years (Robbins, et al., 2016). A DEBS module, which is a homodimer, is composed of at
least a ketosynthase domain (KS), an acyltransferase (AT) domain, and an acyl-carrier
protein (ACP). Some modules also contain a ketoreductase domain (KR) and/or a TE
domain, which cyclizes the 14-membered product. An ACP domain can interact with
either AT domain in the homodimer. Interestingly, the ACP domain only participates in
chain elongation with the intermolecular KS domain but prefers the intramolecular KS
domain during chain translocation (Robbins, et al., 2016). Previous work has
demonstrated that protein-protein interactions play an important role in transporting
intermediates between modules, but there is no direct evidence to explain the reason for
the preferred ACP domain associations during catalysis.
While no studies have reported directly on ACP domain positioning, one recent
study has shed light on a mechanism related to ACP domain translocation. This study
was designed to reveal how the assembly line-style process of catalysis is synchronized
to keep the directionality of reactions proceeding in the proper direction. Protein
interactions between various DEBS domains were captured by crosslinking in the
presence/absence of substrates. This study ultimately revealed a mechanism that prevents
more than one polyketide chain from being bound to an active site of the same module.
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This mechanism, dubbed the “turnstile mechanism”, prevents KS domain acylation of the
next polyketide chain until the previous chain elongation product has moved downstream
by virtue of the ACP domain transferring it to a downstream module. To summarize, the
KS domain active site is closed until the growing polyketide chain that has just finished
interacting with the KS domain is transported to the next module, ensuring proper
directionality of the multi-step reaction and correct product formation. However, the
molecular underpinnings of this mechanism have not been established and the role of
conformational changes in this system is not yet known (Lowry, et al., 2016).

3.3

Sulfur Oxidation Enzyme Interactions Explored by Disulfide Bond Formation

The microbial oxidation of sulfide to sulfate for energy generation in bacteria can
follow two pathways: the sulfide:quinone oxidoreductase pathway or the Sox pathway.
The Sox pathway utilizes a heterodimeric carrier protein SoxYZ that uses a Cys residue
to carry various sulfur-containing species for catalysis by multiple enzyme partners.
Since SoxYZ does not co-purify with any Sox enzymes, it has been suggested that these
interactions between SoxYZ and the active-site containing partners are weak and
transient (Rother, et al., 2001). Prior to a 2015 study by Grabarczyk, et al., there have
been no specific interactions between the carrier protein and other Sox enzymes
discussed in the literature. However, a highly conserved loop on the surface of SoxYZ,
termed the “Z-loop”, was proposed to play a role in interactions between SoxYZ and its
partners (Sauvé, et al., 2007).
The 2015 study by Grabarczyk, et al. investigated the interactions between
SoxYZ and SoxB, a Sox pathway enzyme, using crystallography, biophysical techniques,
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and molecular modelling (Grabarczyk, et al, 2015). One of these techniques involved
mutating an active site residue to a cysteine that would form a disulfide bond with the
carrier protein cysteine, trapping the interacting pair together for further analysis. SoxYZ
interacts with SoxB at several places on the surfaces of each protein. When the SoxY
carrier arm is inserted into the tunnel leading to the active-site of the SoxB enzyme,
hydrogen-bonding interactions occur in the active-site tunnel and at the base of the carrier
arm. In this scenario, a surface loop on SoxB is positioned to rest in a pocket on the SoxZ
surface through stabilizing hydrophobic and electrostatic interactions. While a description
of these interactions contributed to a greater understanding of the molecular interface
between SoxB and SoxZ, they did not provide an explanation for how the dissociation of
the carrier arm facilitates interactions with other Sox enzymes. Structural and kinetic data
suggest that Arg416 in the SoxB active site undergoes an induced conformational change
in the presence of the sulfonate-containing substrate. In the absence of substrate, Arg416
forms an ion pair with a mobile loop near the active site. This mobile loop sterically
clashes with SoxY insertion into the active site, disfavoring binding in the absence of
substrate. When SoxY-substrate binds, the mobile loop is displaced, freeing Arg416 to
interact with the sulfonate-group on the carrier domain, further disfavoring interaction
with the mobile loop. After catalysis, the sulfonate-group is lost, favoring the return of
the Arg416-mobile loop interaction. This disfavors SoxY binding, freeing the carrier
domain to dissociate and interact with other Sox enzymes. This protein-protein
interaction resembles the Tyr621-biotin interaction proposed in the CT domain of PC as a
way to stabilize the carrier domain in a catalytically-relevant conformation.
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3.4

A FRET Investigation of a Nonribosomal Peptide Synthetase

Nonribosomal peptide synthetases (NRPSs) produce peptide-based natural
products such as the antibiotic vancomycin or the immunosuppressant cyclosporin A.
The genes for these enzymes are typically arranged in an operon in bacteria and as a gene
cluster in eukaryotes. NRPSs operate as a series of modules, much like polyketide
synthases, with each module containing multiple domains to catalyze various chemical
steps and the addition of amino acids to the growing peptide. The aminoacyl or peptidyl
intermediate is transferred between domains or modules using a central peptidyl-carrierprotein (PCP) domain. The PCP domain has a 4’-phosphopanthetheine with a terminal
sulfhydryl group which covalently binds the aminoacyl or intermediate for transport.
Crystal structures have shown that only one catalytic site is within range of the prosthetic
group, indicating that the PCP domain must translocate. However, prior to 2017, no
observations of PCP domain translocation had been made, nor was it clear how carrier
domain positioning is governed.
In 2017, conformational changes within gramicidin synthetase I from
Aneurinibacillus migulanus were investigated using FRET (Alfermann, et al., 2017). The
construct of gramicidin synthetase I investigated was composed of two domains, the
catalytic A domain and the PCP carrier domain. The A domain is a member of the acylCoA synthetase, NRPS adenylation domain, luciferase enzyme (ANL) superfamily
(Marahiel, et al., 1997; Gulick, A.M., 2009). This domain catalyzes the activation of an
amino acid with ATP, forming aminoacyl adenylate (amino acid-AMP) and
pyrophosphate (PPi), and covalently attaches it to the terminal cysteine of the PCP
domain. In a full gramicidin synthetase I enzyme, the PCP domain would then interact
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with an upstream or downstream module for peptide bond formation or chemical
alterations of the intermediate peptide. The A domain is composed of two subdomains:
the N-terminal AN and C-terminal AC, connected by a short linker (Conti, et al., 1997). In
the absence of substrate, these domains do not strongly interact and adopt an open
conformation. In the presence of substrate, a closed conformation is adopted with active
sites forming at the interface between the domains.
In the FRET study, EGFP was fused to the C-terminal portion of the PCP domain
while a cysteine was introduced in the A domain which was labeled with an appropriate
fluorophore to generate a FRET signal when interacting with EGFP. It was observed that
gramicidin synthetase I adopts multiple conformations in solution with the
conformational equilibrium shifted by ligand binding. Large concentrations of PPi, one of
the products of the reaction catalyzed by the A domain, inhibited forward progress in
catalysis by favoring the adoption of a specific conformation, disfavoring conformations
required for further catalytic steps. Separately, the PCP-bound thioester intermediate was
proposed to have high affinity for a downstream catalytic domain, ensuring proper
direction of peptide synthesis (Linne and Marahiel, 2000; Mootz and Marahiel, 1997;
Belshaw, et al., 1999). Taken together, these mechanisms offer insight into how these
complex enzymatic systems may control carrier domain translocation and reaction
progress.

3.5

Trapping the Acyl Carrier Protein of a Fatty Acid Synthase

Fatty acid synthesis generally refers to the production of long-chain fatty acids
using acetyl-CoA and NADPH. This process is catalyzed by a series of enzymes that
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perform chain elongation and chemical modifications to achieve specific end products.
An acyl carrier protein is used to transport the growing fatty acid between enzyme active
sites throughout the reaction cycle. This carrier protein utilizes phosphopantetheine as the
prosthetic group that covalently bonds to the fatty acid chain. These enzymes are of
interest for their potential to be used in biofuel synthesis, as well as antibiotic
development (Finzel, et al., 2015). As in other carrier domain enzyme systems, there are
many open questions regarding the mechanism that controls fatty acid length and how the
acyl carrier protein (ACP) selectively binds to the “correct” downstream enzyme (Finzel,
et al., 2015).
A recent study re-engineered ACPs with covalently bound substrate analogues of
different lengths, for investigation with FabA, an enzyme in the microbial fatty acid
synthesis pathway that performs a dehydratase reaction with a specific preference for
fatty acid chains 8-12 carbons long. To investigate how this enzyme selects for a
substrate of a specific length and interacts with the carrier protein, a crosslinking system
was developed to trap ACP-substrate complexes bound to FabA (Finzel, et al., 2015).
This study revealed three relevant regions. A positively charged area on the surface of
FabA, which was proposed to form the ACP binding interface, was confirmed to play a
crucial role in binding ACP. Two phenylalanines at the opening of a tunnel leading to the
active site contributed favorable hydrophobic interactions with fatty acid chains of longer
lengths. Finally, the morphology of the active site pocket was determined to impact the
length of the fatty acid chain that selected for catalysis. Constriction of the pocket
through mutagenesis of residues lining the pocket led to less interaction with longer fatty
acid chains (Finzel, et al., 2015). Taken as a whole, these findings are similar to PC in
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that protein-protein interactions are proposed to stabilize the carrier domain-active site
complex (BC and CT domain of PC) while active site residues may restrict access of the
prosthetic group to the active site (BC domain arginine and glutamate of PC).

3.6
Pyruvate Dehydrogenase Complex Lipoyl Domain Interactions Investigated by
Crosslinking

The pyruvate dehydrogenase complex (PDC) catalyzes the production of acetylCoA and NADH from the decarboxylation of pyruvate. This is a central enzyme in
metabolism, controlling the carbon flux from glycolysis into the TCA cycle and
maintaining glucose homeostasis. The PDC is a massive, unwieldy complex that is
composed of duplicates of three catalytic enzymes, referred to as E1, E2, and E3. There
are generally multiple E1 and E3 units bound to each E2 unit. The E2 enzyme,
dihydrolipoyl transacetylase, utilizes lipoic acid as the prosthetic group of the carrier
domain that transfers an acetyl group to CoA, forming acetyl-CoA (Patel, et al., 2014).
A study in 2006 in which the bovine dodecahedral E2 core domain was
crystallized in the absence/presence of acyl-CoA revealed a gating mechanism to control
substrate access to the active site. These structures revealed that CoA binding favors a
conformational change that opens up the opposite side of the active site channel, allowing
a second substrate to bind (Kato, et al., 2006). Recently, the first high-resolution structure
of the E2 core (H. sapiens E2) was obtained using cryoEM (Jiang, 2018). This structure
revealed a similar gating structure to that observed in bovine E2, suggesting that these
two E2 cores behave similarly.
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A recent study combined crosslinking of the carrier domain to catalytic domains
with mass spectrometry to analyze the interaction frequency in the absence/presence of
CoA (Prajapati, et al., 2019). This study revealed that the presence of CoA increased
carrier domain interaction with the E2 domain and the downstream E3 active site. The
authors interpreted this to suggest that substrate binding affected the sampling of catalytic
conformations. However, given the lack of high-resolution structures of the lipoyl carrier
domain interacting with the E1, E2, and E3 catalytic domains, much remains to be
discovered about how its translocation is controlled, such as exactly how the
conformational change promoted by CoA binding affects interactions with the carrier
domain, how the organization of interactions between the carrier domain and many
surrounding active sites is controlled, and how substrate binding in the E1 and E3
domains might affect lipoyl domain binding (Yu, et al., 2008) (Prajapati, et al., 2019).

4.

OVERVIEW

PC is an important enzyme of central metabolism, providing a critical anaplerotic
input for a variety of biosynthetic reactions. PC also serves as an important paradigm in
which to study mechanisms of allosteric regulation and the relationship between ligandbinding and large-scale domain movements. There have been numerous studies over the
past ~50 years focused on kinetically characterizing the enzyme function, understanding
the effect of acetyl-CoA on the enzyme structure and function, and describing the overall
PC catalytic cycle in great detail. The results of all of these studies, at some level, are
dependent on carrier domain translocation. The carrier domain bridges the individual
reactions in each of the two active sites during catalysis, translocating a relatively large
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distance in the process. While many studies have interpreted carrier domain behavior
indirectly from kinetic or structural data, the mechanism governing the translocation of
the carrier domain is perhaps the least understood phenomenon in PC. In this section, I
will highlight the major questions related to carrier domain translocation in PC and
outline how this dissertation will contribute to clarifying the relationship between ligand
binding and carrier domain positioning in PC.
In early kinetics studies of pyruvate carboxylase, CT domain ligands were shown
to enhance the decarboxylation of carboxybiotin, presumably in the CT domain
(Easterbrook-Smith, et al., 1976; Goodall, et al., 1981; Attwood and Wallace, 1986).
These results were, understandably, interpreted to suggest that CT domain ligands
induced carrier domain translocation to the CT domain and that, in the absence of these
ligands, the carrier domain remained in the vicinity of the BC domain. Under ideal
conditions, acetyl-CoA was observed to efficiently couple the BC domain half-reaction
with the CT domain half-reaction, suggesting that acetyl-CoA plays a key role in
mediating carrier domain translocation (Zeczycki, et al., 2011B). More recently, a
kinetics-based study in SaPC has suggested that pyruvate and acetyl-CoA facilitate longrange communication that serve to induce carrier domain translocation (Westerhold, et
al., 2016). Acetyl-CoA has also been shown to reduce the activation entropy in SaPC,
suggesting that the conformational flexibility of the carrier domain is constrained by
acetyl-CoA (Westerhold, et al., 2017) However, none of these studies have directly
demonstrated that carrier domain translocation is induced by ligand binding, nor have
they offered a mechanism for the role that acetyl-CoA plays in affecting carrier domain
translocation. Meanwhile, various structural studies have proposed an alternative to the
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induced conformational change mechanism in PC, where local conformational changes
are sufficient to alter the domain positioning (Lietzan, et al., 2011; Lietzan, et al.,
2013A).
This dissertation describes a detailed effort to investigate the mechanism
governing carrier domain translocation. I have focused on directly observing the
positioning of the carrier domain through the use of crosslinking traps, in order to capture
the carrier domain in two distinct intermolecular conformations. The effects of substrates
and effectors on carrier domain positioning are also investigated to more thoroughly
investigate the mechanism governing carrier domain positioning and to better understand
the molecular interactions responsible for shifting the positional equilibrium. Decades of
prior studies have interpreted carrier domain translocation using the induced
conformational change model, which was developed prior to the modern description of
thermodynamics in protein folding and conformational change. Prior to the studies
outlined in this dissertation, there had been no attempts to directly observe carrier domain
positioning in PC. Crystal structures suggest an alternative to the induced conformational
change model for controlling carrier domain positioning by revealing potential
interactions between active site residues and biotin which may favor/disfavor biotin
access to these active sites (Lietzan, et al., 2011; Lietzan, et al., 2013A). However, these
static structures do not capture the dynamic interplay between ligand binding and shifts in
the carrier domain positional equilibrium. While there is clear evidence to support that
CT domain ligands stimulate carboxybiotin decarboxylation, the induced conformational
change model is not required to explain these observations. Similarly, while acetyl-CoA
has been observed to accelerate the rate of reactions catalyzed in the BC domain, the
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relationship between this allosteric activator and carrier domain positioning has not been
explored. This dissertation will outline research that is focused on directly determining
the mechanism behind carrier domain translocation and the role of ligands in shifting
carrier domain positioning.
This study was performed entirely with PC cloned from Staphylococcus aureus
PC (SaPC). This was considered an ideal choice since several X-ray crystal structures
exist with the carrier domain positioned in two different intermolecular interactions: one
with biotin positioned in the CT domain active site and the other structure with biotin
positioned in the exo-binding site (Xiang and Tong, 2008). SaPC is also responsive to
acetyl-CoA activation (Yu, et al., 2009) has been studied kinetically (Yu, et al., 2009) and
has recently been used to study the kinetic and thermodynamic effects of acetyl-CoA on
SaPC activation (Westerhold, et al., 2016; Westerhold, et al., 2017).
Based on the studies described in this dissertation, I propose that carrier domain
positioning in PC is governed by the conformational selection model. Regardless of the
presence or absence of ligand(s), the carrier domain repositions itself into various
intermolecular conformations. This is in direct opposition to the induced conformational
change model. Ligands shift the equilibrium positioning of the carrier domain, with
biotin playing the primary role in the sensitivity of the carrier domain to these ligands.
Residues that have been proposed to interact with biotin and which serve to
favor/disfavor positioning of biotin in either the CT or BC domain active sites are
observed to shift carrier domain positioning and alter the kinetic barriers to carrier
domain translocation. Acetyl-CoA favors carrier domain positioning away from the BC
domain by reducing a kinetic barrier to translocation in the presence of substrates and by
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thermodynamically favoring this intermolecular repositioning. BC domain substrates
have a kinetic and thermodynamic effect on carrier domain translocation, shifting carrier
domain positioning towards the BC domain, while pyruvate has the opposite effect,
thermodynamically and kinetically favoring translocation of the carrier domain to adopt
an intermolecular position. These combined studies revolutionize our understanding of
carrier domain translocation in PC by offering the first direct observations of carrier
domain translocation and positioning, offering alternative explanations to several
previous interpretations of carrier domain behavior. This work highlights the great
potential for PC to serve as a paradigm system in which to study the relationship between
ligand binding, catalytic turnover and large-scale domain rearrangements in complex
enzyme systems.
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II. MATERIALS AND METHODS
Acetyl-CoA was purchased from Crystal Chem, Inc. (Elk Grove Village, IL) and
CoALA Biosciences (Austin, TX). Sodium phosphate (mono- and di-basic), potassium
phosphate (mono- and di-basic), ammonium chloride, Tris buffer, L-arabinose, Dglucose, glycine, bis-tris propane, DL-dithiothreitol (DTT), sodium dodecyl sulfate
(SDS), ethylene glycol-bis(β-aminoethyl ether)-N,N,N′,N′-tetraacetic acid (EGTA),
chloramphenicol, glycerol, and granulated Luria broth were purchased from Research
Products International Corp. (Mount Prospect, IL). Kanamycin sulfate was purchased
from VWR (Dublin, Ireland) and Gold Biotechnologies (Olivette, MO). D-biotin was
purchased from VWR (Dublin, Ireland). Epoxysuccinyl-L-leucylamido(4-guanido)
butane (E-64) was purchased from Research Products International Corp. (Mount
Prospect, IL) or Gold Biotechnologies (Olivette, MO). Pepstatin A and dimethyl
sulfoxide was purchased from Fisher Scientific (Waltham, MA). Sodium chloride, malic
dehydrogenase, and lactate dehydrogenase were purchased from Sigma Aldrich (St.
Louis, MO). 30% acrylamide/bis solution, tetramethylethylenediamine (TEMED),
Coomassie Brilliant Blue G-250 and R-250 were purchased from Bio-Rad (Hercules,
CA). 4´ Laemmli SDS loading buffer and triethanolamine hydrochloride were purchased
from Alfa Aesar (Haverhill, MA). Glacial acetic acid was purchased from
MilliporeSigma (Burlington, MA). Methanol was purchased from Avantor (Radnor, PA).
Staphylococcus aureus (SaPC) PC was previously cloned into a modified pET-27b vector
and was generously supplied by Dr. Liang Tong, Columbia University (12). The masses
of reagents used were measured by Mettler Toledo XS2002S or Mettler Toledo XS105
balances (Columbus, OH).
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SaPC Mutagenesis, Expression, and Purification. All SaPC genes were expressed
and purified in an identical manner. Mutations in SaPC were generated according to the
Agilent Quikchange II Site-Directed Mutagenesis protocol. Primers were obtained from
Integrated DNA Technologies. All constructs used in this study were confirmed by DNA
sequencing of the gene in its entirety by Functional Biosciences, Inc. (Madison, WI). The
primers used for mutagenesis are shown in Appendix A, Figure VIII-1 and were
synthesized by Integrated DNA Technologies (Coralville, IA). Each PCR reaction tube
for mutagenesis had a total reaction volume of 28 μL with consisted of 2.5 μL of 10´
ammonium buffer, 0.5 μL each of a 10 μM stock of the forward and reverse primer, 5 μL
DNA template (50-100 ng/μL plasmid DNA), 0.5 μL dNTP (from 10 mM stock), 0.5 μL
Premium Bullseye PR DNA polymerase obtained from Midwest Scientific (Valley Park,
MO), and 19 μL of sterile, distilled and deionized water. The PCR reaction for
mutagenesis was performed in several steps. Step 1: 95 °C for 3 minutes, Step 2: 95 °C
for 50 sec., Step 3: 3-5 °C below lowest TM of primers for 50 sec., Step 4: 72 °C for 14
min., and Step 5: 72 °C for 7 min. Steps 2-4 were repeated 18 times before Step 5 was
initiated. After mutagenesis, 1 μL of Dpn1, obtained from New England Biolabs
(Ipswich, MA), was reacted with the PCR reaction product for 3 hours at 37 °C to digest
the original DNA template before transformation. Electro-competent E. coli Top10 cells
were used for transformation by electroporation. 50-100 ng of plasmid was added to the
50 μL of Top10 cells on ice. This mixture was transferred to a frozen electroporation
cuvette with a 1 mm electroporation gap and electroporated at 1600V in an Eppendorf
Electroporator 2510. 1 mL of Luria broth was added immediately after transformation,
transferred to a sterile tube, and the cells were allowed to recover at 37 °C for 45 mins. –
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1 hour before plating on a Luria Broth agar plate with 25 µg/mL kanamycin. DNA was
purified from the Top10 cells using the Promega Wizard Plus SV Miniprep Kit following
the included spin purification protocol obtained from Promega (Fitchburg, WI).
Glycerol stocks were created by mixing 700 mL of overnight culture, incubated at
37 °C, with 300 µL of 50 % (v/v) sterile glycerol and stored at -80°C.
All PC clones were co-transformed and co-expressed with the pCY216 vector
encoding Escherichia coli biotin protein ligase A (BirA) to ensure complete biotinylation
of PC. Transformed E. coli BL21 (DE3) cells were cultured in M9 minimal media with
25 µg/mL kanamycin and 30 µg/mL chloramphenicol at 37 °C to an optical density
(OD600) of 0.8 - 1.0, after which protein expression was induced by the addition of
isopropyl 1-thio-β-D-galactopyranoside (IPTG) and L-arabinose to a final concentration
of 0.5 mM and 25 mM, respectively. The culture was also supplemented with D-(+)biotin at a final concentration of 3 mg/L. Induced cells were incubated at 16 °C for 16 24 hours before harvesting by centrifugation at 6000 rpm for 15 min. at 4 °C.
All SaPC enzymes were purified using sequential Ni2+-affinity and anion
exchange chromatography. Harvested cell paste (20 – 30 g) was re-suspended in 200 mL
lysis buffer (20 mM Tris-HCl pH 7.8; 200 mM NaCl; 0.5 mM EGTA; 5 mM imidazole; 6
mM β-mercaptoethanol; 1 mM PMSF; 1 μM pepstatin A; and 5 μM E-64). Cells were
lysed by sonication for 10 minutes at a temperature, monitored by a thermoprobe in the
lysate, between 4-10 °C and pelleted by centrifugation at 20,000 rpm for 30 mins at 4 °C.
A Branson Model 450 Digital Sonifier with a model 102-c converter and a ½” diameter
Tapped Bio Horn was used for the sonication. The supernatant was loaded on a 5 mL
Ni2+-nitrilotriacetic acid profinity resin column (Bio-Rad, Hercules, CA). The column
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was washed with 12´ column volume of wash buffer (20 mM Tris-HCl pH 7.8; 200 mM
NaCl; 0.5 mM EGTA; 20 mM imidazole; 6 mM β-mercaptoethanol) and the protein was
eluted with a gradient from 20 mM to 250 mM imidazole using wash buffer and elution
buffer (20 mM Tris-HCl pH 7.8; 200 mM NaCl; 0.5 mM EGTA; 250 mM imidazole; 6
mM β-mercaptoethanol). Purified protein was pooled and dialyzed against a buffer
compatible with anion-exchange chromatography (20 mM triethanolamine, pH 8.0; 50
mM NaCl; 1 mM EGTA; and 2 mM dithiothreitol (DTT)) at 4 °C overnight. The
dialyzed protein was loaded onto a 10 mL Q-Sepharose Fast Flow resin column (GE
Healthcare), washed with 10x column volumes of dialysis buffer and eluted from the
column in dialysis buffer with a gradient from 50 mM to 1 M NaCl. SaPC typically elutes
between 400 - 800 mM NaCl. The purified protein was pooled and dialyzed against
storage buffer (20 mM Bis-Tris Propane, pH 7.2; 15 mM NaCl; 10 mM MgCl2, and 1
mM TCEP) for three successive changes of 4 hours or more. The protein was
concentrated to a final concentration of 4 mg/mL − 10 mg/mL and was drop frozen in
liquid nitrogen prior to storage at -80 °C. Concentration was achieved by using Amicon
Ultra-15 100K centrifugal filters from MilliporeSigma. Centrifugation was conducted at
4,000 rpm and All protein concentrations were determined using the predicted extinction
coefficient corresponding to absorbance at 280 nm.
Mutagenesis Rationale. The Q891/N1102 and D907/Q1118 pairs were chosen for
mutagenesis to cysteines for crosslinking due to their proximity (< 8 Å) for crosslinking
based on the 3BG5 SaPC crystal structure, as well as their general lack of conservation
(Xiang and Tong, 2008). Y621, E243, and T876 were mutated all mutated to alanine to
ensure consistency with previous studies of these mutations in literature (Lietzan, et al.,
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2013A, Lietzan, et al., 2011, Zeczycki, et al., 2009). V1062 was determined from the
3BG5 crystal structure of SaPC to represent an amino acid near the base of the carrier
domain suitable for truncation of the carrier domain. TAG was chosen for the stop codon
introduced as it required the least number of nucleotides to be mutagenized of the three
available stop codons (TAG, TAA, TGA). W808 was mutated to a phenylalanine as this
amino acid represented the most structurally and biochemically conservative choice.
K1112 was mutated to a glutamine as this is also a structurally conservative choice and
this mutation had been successfully performed in the lab in PC from other species.
Enzymatic Activity Assay. A Shimadzu UV-1800 UV Spectrophotometer with an
attached Shimadzu CPS Controller was used for all enzyme activity assays. The UV
Probe ver. 2.62 (Shimadzu Corp., Kyoto, Japan) software was used to monitor all activity
assays and calculate rates of absorbance change. The ranges for the rate measurements
were selected to cover linear portions of absorbance change during the reactions with the
same ranges applied to all replicates. Readings were taken for the times as described
below with a cycle time of 22 sec. with a Windows XP-based computer or 30 sec. after a
new Windows 10-based computer was installed.
Pyruvate carboxylation activity was measured spectrophotometrically at 340 nm
by following the conversion of oxaloacetate to malate using the coupled enzyme, malate
dehydrogenase (MDH). Reactions were performed in a buffer containing 0.1 M Tris-HCl
(pH 7.8), and 7 mM MgCl2. All substrates and coupling reagents were prepared as a 10x
stock solution in this buffer that provided final reaction concentrations of 25 mM
NaHCO3, 2.5 mM ATP, 0.25 mM acetyl-CoA, 12 mM sodium pyruvate, 0.12 mM
NADH, and 10 U/mL MDH. All measurements were performed in triplicate and the
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errors are reported as the standard deviation. The final PC concentration in the assay
ranged from 2.5 - 10 μg/mL per reaction. Reactions were followed until completion or 10
mins. had elapsed. Data from crosslinking inactivation assays were fit to Equation 1
using a least-squares regression in GraphPad Prism (version 8.1.1 for Windows,
GraphPad Software, San Diego, California, USA). The value for kobs was determined by
fitting the data to Equation 1, where a represents the initial value at t = 0, b describes the
limiting residual value, t is the time in seconds, and kobs is the observed rate constant.

y = (a − b) ∗ e-./01 ∙3 + b

(Equation 1)

The PC-catalyzed rate of oxamate-induced oxaloacetate decarboxylation activity
was measured spectrophotometrically at 340 nm by following the conversion of pyruvate
to lactate using the coupled enzyme, lactate dehydrogenase (LDH)5, 6, 12, 13. Reactions
were performed at 25 °C in a buffer containing 0.1 M Tris-HCl (pH 7.8), and 7 mM
MgCl2. All substrates and coupling reagents were prepared as a 10´ stock solution that
provided final concentrations of 0.12 mM NADH, 0.5 mM oxamate, 0.2 mM
oxaloacetate, 0.25 mM acetyl-CoA, and lactate dehydrogenase (10 units). Reactions were
initiated by the addition of SaPC (60-200 μg/mL). Reactions were followed until
completion or 20 mins. had elapsed.
ADP phosphorylation by carbamoyl phosphate activity was measured by
following the production of ATP photometrically at 340nm using a hexokinase/glucose6-phosphate dehydrogenase coupled assay5, 6, 12, 14. Specific activities were measured at
25 °C in 1-mL reaction volume containing 0.1 mM Tris, 7 mM MgCl2, 3.5 mM ADP,
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0.25 mM acetyl-CoA, 20 mM carbamoyl phosphate, 0.4 mM glucose, 0.36 mM NADP,
glucose-6-phosphate dehydrogenase (5 units) and hexokinase (1 unit). Reactions were
initiated by the addition of SaPC (150-200 μg/mL). Reactions were followed until
completion or 20 mins. had elapsed.
SaPC Crosslinking. BMOE was prepared in 100% DMSO at 20´ the desired
reaction concentration. SaPC was reacted at a final concentration of 1 mg/mL (premixed
with substrates for a minimum of 10 minutes when applicable) in a buffer containing 0.1
M Tris-HCl (pH 7.8), 7 mM MgCl2 with the desired concentration of BMOE (and
identical concentration of substrate when applicable) at room temperature. After a
defined incubation period, dithiothreitol was used to quench the reaction at a final
concentration of 13 mM for 15 minutes at room temperature. Samples were then either
assessed for activity using the MDH assay described above or mixed with 4´ Laemmli
Buffer in reducing conditions and heated to 100 °C for 3 minutes for SDS-PAGE analysis
using an 8% polyacrylamide gel. Protein molecular weights were estimated using the
Spectra Multicolor High Range Protein Ladder (Thermo Scientific, Waltham, MA). SDSPAGE gels were run at 100V until the dye-front ran off the bottom of the gel. Coloration
was achieved with Coomassie Brilliant Blue G-250 (Bio-Rad, Hercules, CA).
SDS-PAGE Gel Preparation. 150 mL of resolving buffer contained 27.23g Tris
base dissolved in distilled, deionized water and adjusted to pH 8.8 with 6N HCl. 100mL
stacking buffer contained 6g Tris base dissolved in distilled, deionized water and adjusted
to pH 6.8 with 6N HCl. 1 L of 10x electrode running buffer for SDS-PAGE contained
30.3 g Tris base, 144 g glycine, and 10 g SDS dissolved in distilled, deionized water. The
8% acrylamide resolving gel was composed of 13.8 mL distilled, deionized water, 8 mL

62
30% acrylamide, 7.2 mL resolving buffer, and 293 μL of 10% SDS. These components
were stirred together before the simultaneous addition of 154 μL of 10% ammonium
persulfate and 16 μL TEMED. The mixture was stirred briefly before pouring for gel
formation. This was allowed a minimum of 45 minutes for polymerization to occur. 5%
stacking gel was poured on top of this to form the stacking portion of the final SDSPAGE gel. This stacking gel was composed of 2.9 mL distilled, deionized water, 850 μL
30% acrylamide, 1.25 mL stacking buffer, 50 μL of 10% SDS. These components were
mixed before the simultaneous addition of 25 μL of 10% ammonium persulfate and 5 μL
TEMED. This mixture was stirred before it was poured on top of the resolving portion
and the appropriate comb was inserted for well formation. This was allowed to remain
undisturbed for 45 minutes for polymerization to occur. To achieve reducing conditions
in the loading buffer, β-mercaptoethanol was added to the 4´ Laemmli buffer to achieve
a 5% β-mercaptoethanol / 95% 4´ Laemmli buffer (v/v) final mixture.
Coomassie protein stain was composed of 225 mL distilled, deionized water, 225
mL methanol, 50 mL glacial acetic acid, and 0.25 g Coomassie Brilliant Blue G-250.
This was stirred until the Coomassie stain was completely dissolved. Protein gel destain
solution was composed of 700 mL distilled, deionized water, 200 mL methanol, and 100
mL glacial acetic acid. Staining was performed with an overnight incubation of the gel
with protein stain while destaining was performed for at least 1 hour to achieve minimal
background staining.
Densitometric Analysis. Densitometric analyses were performed using the
LabWorks software developed by UVP, Inc. (Upland, CA). The coloration intensity of
each band was determined from images of the SDS-PAGE gels. The “Area Density
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Analysis Tool” function in Labworks was utilized for determination of the density of
each band. A rectangle was drawn around each band with a size to include the full band
but exclude nearby bands or excess background. The software includes background
subtraction to minimize the effect of varying sizes of these rectangular areas. This was
verified by drawing varying sizes of rectangles around a band and ensuring that the areal
density remained unchanged. The normalized density of the monomer band was
determined by dividing the monomer band density by the total of the band density for
both the monomer and dimer bands. This software does not have any automatic feature to
detect overloads in the bands when determining areal density other than to color the
saturated portions of a band in red when obtaining the image. All images where obtained
using exposure times to prevent this kind of saturation.
Stopped-Flow Spectroscopy. Stopped-flow spectroscopy was performed using an
Applied Photophysics SX20 instrument at room temperature obtained from Applied
Photophysics, Ltd. (Leatherhead, England). Intrinsic tryptophan fluorescence was
observed at an excitation wavelength of 295 nm using a 350 nm emission filter. SaPC
(0.35 mg/mL) was premixed with substrates for a minimum of 10 minutes when
applicable and loaded in one drive syringe and mixed 1:1 with the substrate/BMOE
mixture in the second drive syringe. The final concentration of substrates or ligands used
was 2.5 mM ATP, 5 mM ADP, 5 mM phosphonoacetate (PPA), 0.25 mM acetyl-CoA, 12
mM pyruvate, and 10 mM L-aspartate. All solutions were prepared in a buffer containing
0.1 M Tris-HCl (pH 7.8), 7 mM MgCl2. Applied Photophysics Pro-Data SX software was
used to operate the instrument, interpret, and average the data. All data are the average of
4-5 replicates. Reported rates are the average value of three independent acquisitions of
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these replicates. The data from each sample was normalized to start at a value of 1 to
account for variability in initial fluorescence intensity. Normalization was performed to
plot the fractional change in intensity: the measured intensity at every time point was
divided by the initial measured intensity at t = 0. Data were fit to Equation 2, where a
represents the amplitude, kobs represents the observed rate, t represents time in seconds, c
represents the slope of the linear second phase, and d represents the initial value at t = 0.

y = a ∗ (1 − e./01 ∙3 ) + ct + d

(Equation 2)
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III.
CONFORMATIONAL SELECTION GOVERNS CARRIER DOMAIN
POSITIONING IN STAPHYLOCOCCUS AUREUS PYRUVATE CARBOXYLASE

1. Introduction

Two classical models are typically used to describe conformational changes
accompanying ligand binding in biological macromolecules: the induced-fit hypothesis
states that ligand binding induces a conformational change in the protein (Koshland,
1959; Koshland, et al., 1966), while the conformational selection hypothesis states that
the protein pre-exists in multiple conformational states, with ligand binding shifting the
population towards the ligand-bound conformation (Monod, et al., 1965; Boehr, et al.,
2009). While these models have been tested and elaborated upon in many systems, the
large-scale carrier domain motions associated with swinging domain enzymes provide a
particularly intriguing and challenging system in which to study the influence of ligands
on protein conformational change (Perham, 2000).
The mechanism by which reaction intermediates are transferred in a coordinated,
unidirectional manner remains largely undefined in swinging domain enzymes. For
example, assembly line polyketide synthases are built on an array of multiple modules
and domains, requiring exquisite coordination as intermediates are transferred between
active sites on distinct modules and domains. It has been proposed that vectorial synthesis
in multimodular enzymes is dependent on conformational changes among the catalytic
and carrier domains (Khosla, et al., 2014), but it remains unclear whether these
conformations interchange freely at equilibrium or whether conformational changes are
induced by ligand binding and catalytic turnover events. This is a particularly difficult
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question to investigate in large and unwieldy systems such as polyketide synthases and
their multi-domain counterparts, for which conventional structural and functional
approaches do not easily apply. Instead, smaller and more tractable swinging domain
enzyme systems can serve as structurally and biophysically accessible paradigms to study
the relationship between ligand binding and large-scale protein conformational changes.
One such enzyme, pyruvate carboxylase (PC), is a homotetrameric, swinging domain
enzyme that has been well characterized structurally and kinetically (Lietzan, et al., 2014;
Tong, 2013; Jitrapakdee, et al., 2008; Menefee and Zeczycki, 2014). During catalysis, the
carrier domain of PC undergoes a conformational change spanning more than 70 Å,
providing an ideal system to study the influence of ligand binding on large-scale
conformational changes in swinging domain enzymes.
PC catalyzes the ATP-dependent carboxylation of pyruvate to oxaloacetate, with
bicarbonate serving as the carboxyl group donor. The reaction proceeds through two
connected half-reactions catalyzed in distinct and remote active sites (Figure II-1A). In
the first half-reaction, the biotin cofactor on the biotin carboxyl carrier protein (BCCP)
domain is carboxylated with the concomitant cleavage of MgATP in the biotin
carboxylase (BC) domain. The second half-reaction occurs in the carboxyltransferase
(CT) domain, where the carboxyl group is transferred from the biotin cofactor on the
BCCP domain to pyruvate, generating oxaloacetate. These two half-reactions are coupled
through the intermolecular translocation of the biotinylated carrier domain, which must
translocate over 70 Å to transfer the carboxyl group between active sites on the BC
domain and the CT domain (Figure III-1A) (St. Maurice, et al., 2007; Xiang and Tong,
2008; Lasso, et al., 2014).
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Figure III-1 SaPC carrier domain motions and conformations.
A. A schematic of the PC tetrameric structure and intermolecular carrier domain translocation. BC
domains are colored in blue, CT domains in yellow, and the BCCP carrier domain in red. A hypothetical
intermolecular translocation pathway is traced for a single carrier domain from the BC domain of its own
subunit to the exo binding site on the CT domain of a neighboring subunit. B. The SaPC X-ray crystal
structure (PDB ID: 3BG5) showing the BCCP domain of one subunit (red) interacting at the exo binding
site of the CT domain on the opposing subunit (yellow). The Mn2+ ion, colored as a grey sphere, and
pyruvate are shown in the CT domain active site. Gln891 on the CT domain and Asn1102 on the BCCP
domain were both mutated to cysteine to enable maleimide-based crosslinking to trap the BCCP domain in
an intermolecular conformation.

Prior efforts to study the influence of ligand binding on carrier domain
translocation in PC have largely relied on interpretations of kinetic data. For example,
detailed studies of carboxybiotin decarboxylation in sheep liver PC (Easterbrook-Smith,
et al., 1976; Goodall, et al., 1981) and chicken liver PC (Attwood and Wallace, 1986)
were performed in the presence of various CT domain ligands and were interpreted based
on a ligand-induced conformational change model, where CT domain substrates were
considered to induce carrier domain translocation to the CT domain. Based on rate
enhancements observed in the presence of CT domain substrates or free biotin, it was
concluded that substrates and cofactors mediate communication between subunits by
inducing conformational changes through the enzyme (Zeczycki, et al, 2009). More
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recent kinetic analyses were also interpreted in light of an induced conformational change
model to propose that both pyruvate and the allosteric activator, acetyl-CoA, facilitate
long-range communications that induce carrier domain translocation (Westerhold, et al.,
2016; Westerhold, et al., 2017). While these interpretations are reasonable, kinetic studies
cannot directly observe carrier domain positioning and are limited to observations that
conflate ligand binding, catalytic turnover and carrier domain translocation. In short,
while many studies on PC have been interpreted using an induced conformational change
model, they do not attempt to directly assess the conformational change model itself.
In contrast to the interpretations described above, snapshots of PC from X-ray
crystallography and cryo-electron microscopy have revealed multiple conformational
states and carrier domain positions that are independent of the identity or bound state of
the ligand (St. Maurice, et al., 2007; Lasso, et al., 2014; Yu, et al., 2009). These structural
studies suggest that the carrier domain may sample multiple positions in a ligandindependent dynamic equilibrium (Lietzan, et al., 2011; Lietzan, et al., 2013A).
Ultimately, neither kinetic measurements nor structural studies are suitable to determine
whether carrier domain positioning exists in a dynamic equilibrium or, instead, is
governed by ligand-induced conformational changes. To address this question, alternative
approaches are required that directly follow the positioning of the carrier domain,
independent of catalytic turnover.
Here we directly observe positioning of the carrier domain to clarify the
mechanism of ligand associated conformational changes on the carrier domain in
Staphylococcus aureus PC (SaPC). Using an intermolecular crosslinking trap, combined
with a variety of analytical approaches, the positioning of the BCCP carrier domain is
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directly observed as a function of substrates and allosteric effectors. These data clearly
demonstrate that carrier domain positioning in PC is governed by conformational
selection and also suggest that the allosteric activator, acetyl-CoA, favors the carrier
domain to engage in an intermolecular interaction with the CT domain. This work
clarifies the mechanism of carrier domain positioning in PC and can be extended to other
carrier domain enzyme systems that function in vectorial biosynthesis.

2. Results

2.1

Crosslinkers trap the intermolecular SaPC carrier domain conformation.

To directly observe SaPC carrier domain positioning, a system was designed to
trap the BCCP carrier domain using maleimide-based homobifunctional crosslinkers.
Specifically, the system was designed to capture the BCCP domain as it accesses an
intermolecular interaction with the CT domain of an opposing subunit (Figure III-1A).
The carrier domain has been observed in two intermolecular conformations in the SaPC
crystal structure. In one conformation, biotin is docked in the CT domain active site
while, in the second conformation, biotin is docked in the so-called “exo-binding site”
which is located immediately adjacent to the CT domain active site. The exo-binding site
conformation of SaPC was chosen as the basis for the crosslinking mutations to minimize
detrimental effects on catalytic turnover. Two specific residues were targeted for
mutation to cysteines, based on the X-ray crystal structure of SaPC with BCCP in the
exo-binding site conformation (Xiang and Tong, 2008) (PDB ID: 3BG5): Gln 891 on the
CT domain and Asn 1102 on the BCCP domain were both mutated to cysteine to
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generate the double mutant, Q891C/N1102C SaPC (Figure III-1B). The Q891C/N1102C
double mutant and the corresponding single mutants retained 30 – 50% of the wild-type
pyruvate carboxylation activity, indicating that these mutations have only a modest
impact on catalytic turnover (Table -1).
Table III-1 Pyruvate carboxylation activity for SaPC and mutated constructs of SaPC.
SaPC
WT
Q891C
N1102C
Q891C/N1102C

kcat (min-1)
1430 ± 100
510 ± 50
690 ± 20
390 ± 30

% Compared to WT
36
48
27

(n = 3; errors represent standard deviations)

To initially characterize this system, Q891C SaPC, N1102C SaPC, and
Q891C/N1102C SaPC were incubated with bismaleimidoethane (BMOE) for 15 minutes
and analyzed by SDS-PAGE (Figure III-2A). BMOE was selected as the crosslinker for
its relatively short spacer arm, but longer crosslinkers were also evaluated and no
discernable difference was observed compared to BMOE (Figure III-3). Crosslinked
samples are predicted to run at twice the subunit molecular weight (SaPC monomer = 131
kDa), resulting in a ~260 kDa crosslinked dimer. No crosslinked dimers were observed in
the Q891C single mutant across a wide range of BMOE concentrations, while a very
small degree of crosslinked dimers developed in the N1102C mutant at low
concentrations of BMOE (10 μM). A high degree of crosslinked dimers were observed in
the Q891C/N1102C double mutant at 300 μM and 1 mM. Some higher molecular weight
species were observed at all BMOE concentrations in both the single mutants and the
Q891C/N1102C double mutant. Analytical ultracentrifugation of crosslinked wild-type
SaPC and Q891C/N1102C SaPC confirmed that these high molecular weight species
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were composed of large, aggregated protein. These species presumably arose from
nonspecific crosslinking between individual protomers. A small percentage of these high
molecular weight species were present across all samples incubated with BMOE and,
therefore, were not considered further in this analysis.

Figure III-2 Q891C, N1102C, and Q891C/N1102C SaPC crosslinked with BMOE.
A. 8% acrylamide SDS-PAGE gel of SaPC mutants at 1 mg/mL reacted with either 0 μM, 10 μM, 300 μM,
or 1 mM BMOE for 15 min. Q891C SaPC and N1102C SaPC did not form crosslinked dimers at BMOE
concentrations greater than 300 μM. Q891C/N1102C SaPC was primarily crosslinked into dimers at
BMOE concentrations of 300 and 1000 μM. 5 μg of SaPC was loaded in each lane. B. 8% acrylamide SDSPAGE gel showing time-dependent crosslinking Q891C/N1102C SaPC with BMOE ± 5 mM
ADP/phosphonoacetate for various reaction times. Q891C/N1102C SaPC at 1 mg/mL was incubated with 0
or 300 μM BMOE for the indicated times in the absence/presence of 5 mM ADP and 5 mM
phosphonoacetate and then quenched with 13 mM DTT for 15 minutes. Lane 1: Q891C/N1102C SaPC
reacted with 0 μM BMOE. Lane 2-7: Q891C/N1102C SaPC reacted with 300 μM BMOE for 30 s, 1 min, 2
min, 4 min, 8 min, or 15 min. Lane 8: Molecular Weight Ladder. Lanes 9-14: Q891C/N1102C SaPC
preincubated with 5 mM ADP and 5 mM phosphonoacetate for 15 minutes, then reacted with 300 μM
BMOE for 30 s, 1 min, 2 min, 4 min, 8 min, 15 min. Lane 15: wild-type SaPC reacted with 300 μM
BMOE. 5 μg of SaPC was loaded in each lane. C. Densitometric analysis of monomer bands in Figure 2B
as a function of time. Either no substrates were added (p) or 5 mM ADP and 5 mM phosphonoacetate (¢)
were present during crosslinking. The y-axis represents the normalized monomer density, determined as
described in the methods section.
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Figure III-3 Q891C/N1102C SaPC incubated with bismaleimidoethane (BMOE), 1,4(bis)maleimidobutane (BMB), and 1,6-(bis)maleimidohexane (BMH).
Each SaPC mutant was preincubated at 1 mg/mL with the indicated concentration of crosslinker for 120
seconds. Samples were quenched with 13 mM DTT for 15 minutes. 7 μg of SaPC was loaded in each lane.
1: 0 μM BMOE; 2: 10 μM BMOE; 3: 300 μM BMOE; 4: 0 μM BMB; 5: 100 μM BMB; 6: 300 μM BMB;
7: 0 μM BMH; 8: 100 μM BMH; 9: 300 μM BMH.

In the absence of ligands, the percentage of crosslinked dimers, as measured by
SDS-PAGE, rapidly approached equilibrium (Figure III-2B). The rate of approach to
equilibrium was greatly reduced, however, in the presence of ADP and
phosphonoacetate, an analogue of the carboxyphosphate intermediate. These ligands
substantially reduced the rate of crosslinked dimer formation relative to that observed in
the absence of ligands (Figure III-2B). A quantitative densitometric analysis was
performed to determine the change in monomer density as a function of time (Figure III2C). These data are described by a single exponential decay and revealed that ADP and
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phosphonoacetate dramatically reduce the observed rate constant for crosslinked dimer
formation (Table III-2). While this generally illustrates that BC domain ligands can
perturb the carrier domain equilibrium, the rapid re-equilibration observed in the absence
of substrates precluded a more detailed kinetic analysis using this approach. Although
this data is promising, the bands of the gels in Figure III-2 and others throughout the
following studies may be overloaded. Further, the Coomassie G-250 dye was used
throughout for protein coloration while R-250 may be more optimal for use in
densitometry.
Table III-2 Summary of observed first-order rate constants determined using densitometry,
inactivation kinetics and intrinsic tryptophan fluorescence.

*

**
#

Substrate

Densitometric
kobs (s-1)*

Inactivation
kobs (s-1)*

ITF
kobs (s-1)**

None

0.051 ± 0.003

0.057 ± 0.014

0.073 ± 0.002

ADP +
phosphonoacetate

0.009 ± 0.001

0.005 ± 0.001

0.026 ± 0.001

A. CoA

N/A

0.083 ± 0.17#

0.082 ± 0.001

Pyruvate

N/A

0.091 ± 0.24#

0.081 ± 0.001

Reported errors represent the standard errors calculated from iterative non-linear curve fitting. The data
were fit to Equation 1, where each data point was plotted as the average ± standard deviation of 3
independent determinations.
Reported errors represent standard deviations from n=3 independent measurements of kobs.
Very high errors result from manual sample handling. These values are provided as estimates only.

To complement and confirm the densitometric analysis by SDS-PAGE,
inactivation kinetics were also assessed as a reporter of carrier domain crosslinking.
Crosslinks between the BCCP and CT domains will immobilize the carrier domain,
thereby inactivating the enzyme by preventing subsequent rounds of carboxyl group
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transfer between active sites. To confirm that enzyme inactivation was specific to carrier
domain crosslinking, initial velocities were evaluated for the Q891C SaPC, N1102C
SaPC, Q891C/N1102C SaPC, and wild-type SaPC as a function of crosslinker incubation
time (Figure III-4). The native pyruvate carboxylation activities of these mutants are
shown in Table III-1. Wild-type SaPC retained its full enzymatic activity over 15 minutes
of incubation with 300 μM BMOE. The activity of the Q891C mutant increased slightly
upon incubating with BMOE, perhaps as a consequence of masking the cysteine mutation
at that position. The N1102C mutation exhibited a slight loss of activity (~8% over 15
minutes), which coincides with the small amount of dimers observed by SDS-PAGE
(Figure III-2A). Compared with the wild-type and individual mutants, the
Q891C/N1102C mutant exhibited a rapid and significant loss of activity upon incubation
with BMOE, consistent with specific crosslinking between the carrier domain and the CT
domain. The observed rate constant for inactivation was very similar to the rate of
crosslinked dimer formation observed by SDS-PAGE (Table III-2).
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Figure III-4 Inactivation kinetics for wild-type SaPC and 3 mutated constructs of SaPC.
Wild-type (p), Q891C (q), N1102C (¿), or Q891C/N1102C (¢) SaPC were reacted with 300 μM
BMOE in 5% DMSO for 30 s, 2 min, 8 min, or 15 min. All reactions were then quenched with 13 mM
DTT for 15 min. The initial velocity (vi) was determined and divided by the initial velocity determined
after incubating the same enzyme with 5% DMSO for 15 min (vo). Each sample was measured in triplicate
using the malate dehydrogenase coupled enzyme assay. The error bars represent the standard deviation
from three independent measurements. Error bars for Q891C/N1102C are included but are obscured by the
data markers.

2.2

Intrinsic tryptophan fluorescence reports on carrier domain conformational states.

Both densitometry and inactivation kinetics are constrained by their reliance on
manual sample handling, limiting these measurements to slower re-equilibration events
such as those slowed by the presence of ADP and PPA. To gain greater time-resolution
and accuracy, we explored whether changes in intrinsic tryptophan fluorescence (ITF)
intensity could serve as a reporter on carrier domain positioning. Fortuitously, in SaPC,
all 5 tryptophan residues are located in the CT domain (Figure III-5). As such, we
predicted that the Trp fluorescence intensity would increase when the carrier domain is
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positioned near the CT domain, resulting from the altered local environment of the five
CT domain tryptophan residues. Consistent with this prediction, wild-type SaPC yielded
distinct ITF signals in the presence of different ligands (Figure III-6A). When SaPC was
mixed with ATP, a BC domain substrate, a rapid decrease in the ITF signal intensity was
observed. Conversely, when SaPC was mixed with acetyl-CoA, an increase in the ITF
signal intensity was observed.

Figure III-5 Structure of SaPC (PDB ID: 3BG5) showing the location of the five tryptophan residues.
A: The BC domains (blue), CT domains (yellow), allosteric / PC tetramerization domains (green), and
BCCP domain (red) are shown. All five Trp residues (dark yellow) are located in the CT domain. B: A
close-up view of the CT domain (yellow) with the BCCP domain (red) docked in the exo-binding site.
Tryptophans (dark blue; Homo sapiens PC numbering) are highlighted, illustrating the proximity of Trp838
to biotin.
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Figure III-6 The role of substrates and the biotinylated carrier domain in generating the tryptophan
fluorescence signal.
A. Wild-type SaPC intrinsic tryptophan fluorescence (ITF) in the presence of substrate/effector. Wild-type
SaPC (0.35 mg/mL) was mixed with 2.5 mM ATP (blue), 0.25 mM acetyl-CoA (red), or buffer (black) at 0
s in a stopped-flow instrument with tryptophan excitation at 295 nm and ITF emission measured at 350 nm.
B. Q891C/V1062X (ΔBCCP) SaPC ITF in the presence of substrate/effector. Q891C/V1062X SaPC (final
concentration of 0.175 mg/mL) was mixed with buffer (black) or final concentrations of 2.5 mM ATP
(blue) or 0.25mM acetyl-CoA (red) at 0 s in a stopped-flow instrument with tryptophan excitation at 295
nm and ITF emission measured at 350 nm. C. Q891C/N1102C/K1112Q SaPC ITF in the presence of
substrate/effector. Q891C/N1102C/K1112Q SaPC (final concentration of 0.175 mg/mL) was mixed with
buffer (black) or final concentrations of 2.5 mM ATP (blue) or 0.25 mM acetyl-CoA (red) at 0 s in a
stopped-flow instrument with tryptophan excitation at 295 nm and ITF emission measured at 350 nm.
Dashed lines represent the fit of the data to Equation 2.

We reasoned that the presence of ATP favors one conformational state for the
BCCP carrier domain that reports as a decrease in ITF signal intensity, while the presence
of acetyl-CoA favors a different state for the carrier domain that reports as an increase in
ITF signal intensity. To confirm that carrier domain positioning mediates the ITF signal,
we produced a SaPC construct with a C-terminal truncation by introducing a STOP
codon (TAG) at Valine 1062, eliminating the BCCP domain (Q891C/V1062X; ΔBCCP
SaPC). This construct was assessed for changes in the ITF signal intensity in the presence
of ligands. When this ΔBCCP SaPC mutant was mixed with either substrate or allosteric
effector, no change in ITF intensity was observed (Figure III-6B), confirming that
changes in the ITF intensity are a consequence of interactions with the BCCP domain and
are not simply a result of conformational changes upon ligand binding. The specific
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contribution of biotin to the ITF signal was also investigated by mutating the biotinylated
Lys 1112 to glutamine (Q891C/N1102C/K1112Q), to produce an unbiotinylated SaPC.
Again, the fluorescence intensity did not change in the presence of substrates (Figure III6C), indicating that the biotin cofactor is necessary for generating the ITF signal.
Having established that the ITF signal intensity is both BCCP and biotin
dependent, the behavior of the system was evaluated in the presence of BMOE
crosslinker (Figure III-7). While wild-type SaPC and the single mutants displayed only
very small changes in signal intensity when mixed with BMOE (Figure III-7A), the
crosslinking competent Q891C/N1102C SaPC displayed a large increase in fluorescence
intensity in the presence of BMOE, as predicted from locking the BCCP domain in
proximity to the CT domain. To distinguish whether biotin contributes to the ITF signal
intensity or, rather, to positioning of the BCCP domain itself, crosslinking of the
unbiotinylated SaPC was evaluated by SDS-PAGE in the presence of BMOE (Figure III8). Crosslinking was observed both in the presence and absence of substrates and, while
the response to substrates dramatically diminished in unbiotinylated SaPC, the
unbiotinylated carrier domain did not lose the ability to position itself for crosslinking.
Furthermore, when Q891C/N1102C/K1112Q was reacted with 200 μM BMOE in the
presence of exogenously added biotin or biocytin, the ITF signal intensity did not
replicate what was observed with the biotinylated Q891C/N1102C (Figure III-7B),
indicating that biotin must be properly tethered to the BCCP domain to produce large
increases in the ITF intensity in the presence of BMOE. Thus, we conclude that the
intrinsic fluorescence signal changes observed in SaPC directly report on changes in the
positioning of the carrier domain and its tethered biotin cofactor.
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Figure III-7 SaPC ITF changes observed in the presence of crosslinker.
A. Q891C/N1102C mixed with buffer (black), Q891C SaPC reacted with 200 μM BMOE (blue), N1102C
SaPC reacted with 200 μM BMOE (green), Q891C/N1102C SaPC reacted with 200 μM BMOE (maroon),
and wild-type SaPC reacted with 200 μM BMOE (orange). All mixing occurred at 0 seconds in a stoppedflow instrument with excitation at 295 nm and ITF emission measured at 350 nm. B.
Q891C/N1102C/K1112Q SaPC ITF changes observed when crosslinked in the presence of biotin or
biocytin. Q891C/N1102C/K1112Q SaPC (0.175 mg/mL final concentration) was incubated with buffer
(black), 5 mM final concentration of biotin (blue), or 5 mM final concentration of biocytin (green) for 15
minutes before being mixed with an equal concentration of biotin or biocytin and 200 μM final
concentration of BMOE at 0 seconds in a stopped-flow instrument with excitation at 295 nm and ITF
emission measured at 350 nm. Q891C/N1102C/K1112Q SaPC mixed with buffer (black) is also shown for
reference. Dashed lines represent the fit of the data to Equation 2.
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Figure III-8 Q891C/N1102C (biotinylated) SaPC and Q891C/N1102C/K1112Q (unbiotinylated)
crosslinked in the presence and absence of ADP and phosphonoacetate (PPA).
Each SaPC mutant at 1mg/mL was preincubated with no ligands present or 5 mM ADP and 5 mM
phosphonoacetate for 10 minutes and then reacted with 300 μM BMOE for 10 s, 30 s, 60 s, and 120 s.
Samples were quenched with 13mM DTT for 15 minutes. 5 μg of SaPC was loaded in each lane. A.
Q891C/N1102C; B. Q891C/N1102C/K1112Q; C. Densitometry analysis of relative monomer density as a
function of time for Q891C/N1102C without ligands (p), Q891C/N1102C with 5 mM ADP and 5 mM
phosphonoacetate (¢), Q891C/N1102C/K1112Q without ligands (¿), and Q891C/N1102C/K1112Q with
5 mM ADP and 5 mM phosphonoacetate (q). The experiment was performed in triplicate, with the error
bars representing the error propagated standard deviation of the measured band densities.

Given that biotin is necessary for mediating changes in the ITF signal intensity,
we sought to determine which Trp residue(s) in the CT domain interact with biotin and
contribute to the ITF signal change. The crystal structure of SaPC (PDB ID: 3BG5)
reveals that biotin is positioned near Trp808 in the exo-binding site of SaPC (Figure III5B). This residue was mutated to a phenylalanine (W808F) to assess the sensitivity of
this mutated SaPC to changes in ITF intensity. Unfortunately, the W808F mutation
rendered the protein aggregation-prone and it could not be purified, precluding a clear
confirmation of this prediction.
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2.3

Substrates and effectors alter the carrier domain positioning equilibrium.

To assess the contribution of substrates and effectors to carrier domain
positioning, the crosslinking competent Q891C/N1102C SaPC was incubated with 300
μM BMOE for 2 minutes in the presence of various substrates and effectors (Figure III9). Both pyruvate and acetyl-CoA increased the amount of crosslinked dimer in the
presence of ADP and phosphonoacetate compared to dimer formation in the presence of
just ADP and phosphonoacetate. This suggests that pyruvate and acetyl-CoA both shift
the carrier domain positioning towards the CT domain on the opposing subunit.
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Figure III-9 Q891C/N1102C SaPC crosslinked in the presence of various substrates and effectors.
A. Q891C/N1102C SaPC crosslinked in the presence of various substrates and effectors. Q891C/N1102C
SaPC at 1 mg/mL was reacted with 300 μM BMOE for 120 s in the presence of a combination of 5 mM
phosphonoacetate, 0.25 mM acetyl CoA, 12 mM pyruvate and/or 5 mM adenosine 5’-diphosphate (ADP),
as listed below, then quenched with 13 mM DTT for 15 minutes. A. 5 μg was loaded in each lane. (1) No
Substrates; (2) Acetyl CoA (AC); (3) Acetyl-CoA, Pyruvate (Pyr); (4) ADP; (5) ADP, Pyruvate; (6)
Phosphonoacetate; (7) Phosphonoacetate, Pyruvate; (8) ADP, Phosphonoacetate; (9) ADP,
Phosphonoacetate, Pyruvate; (10) ADP, Phosphonoacetate, Acetyl-CoA; (11) ADP, Phosphonoacetate,
Pyruvate, Acetyl-CoA; (12) Phosphonoacetate, Acetyl-CoA; (13) Phosphonoacetate, Pyruvate, AcetylCoA. The molecular weights for the ladder on the right are shown in kDa. B. A densitometry analysis was
performed with the relative monomer density shown for each ligand combination.
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The rate of inactivation was determined for Q891C/N1102C SaPC reacted with
BMOE crosslinker in the presence of ADP and phosphonoacetate in combination with
pyruvate and acetyl-CoA (Figure III-10). It was necessary to include ADP and
phosphonoacetate in these measurements to reduce the inactivation rates into a
measurable range. These data were fit to a single exponential decay (Equation 1), where
the fastest rate of inactivation was observed in the absence of substrates (Figure III-10;
Table III-3). This indicates that the BCCP domain explores an ensemble of
conformations in the absence of substrates, trapping the carrier domain in an
intermolecular conformation in a time-dependent manner. The presence of ADP and
phosphonoacetate reduced the rate of inactivation ~7-fold, consistent with BC domain
substrates drawing the carrier domain equilibrium position towards the BC domain.
Conversely, the addition of acetyl-CoA increased the rate of inactivation, consistent with
a reduction in the activation energy barrier for the translocation of the carrier domain
from the BC to the CT domain. The combination of acetyl-CoA and pyruvate produced
the fastest rates of inactivation in the presence of ADP and phosphonoacetate (Figure III10; Table III-3).
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Figure III-10 Inactivation kinetics for Q891C/N1102C SaPC crosslinked with BMOE in the presence
of various substrates.
Inactivation kinetics for Q891C/N1102C SaPC crosslinked with BMOE in the presence of various
substrates. Q891C/N1102C SaPC was reacted with 300 μM BMOE in 5% DMSO for 10 s, 30 s, 1 min, 2
min, 4 min, 8 min, or 15 min and then quenched with 13 mM DTT for 15 min. Each sample was then
assayed in triplicate for catalytic activity using the malate dehydrogenase coupled enzyme assay. The initial
velocity (vi) was determined and divided by the initial velocity determined after incubating the same
enzyme with 5% DMSO for 15 min (vo). The error bars represent the standard deviation obtained from each
sample assayed in triplicate. Rates were measured in the absence of added ligands (purple circles), in the
presence of 5 mM ADP and 5 mM phosphonoacetate (blue squares), in the presence of 5 mM ADP, 5 mM
phosphonoacetate, and 12 mM pyruvate (green triangles), in the presence of 5 mM ADP, 5 mM
phosphonoacetate, and 0.25 mM acetyl-CoA (orange inverted triangles), or in the presence of 5 mM ADP,
5 mM phosphonoacetate, 12 mM pyruvate, and 0.25 mM acetyl-CoA (red diamonds).
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Table III-3 Observed rates of inactivation for the different substrate combinations used during
inactivation kinetics experiments with Q891C/N1102C SaPC.

ADP

Phosphonoacetate

Pyruvate

Acetyl-CoA

kobs (s-1)*

0

0

0

0

0.057 ± .014

5 mM

5 mM

0

0

0.005 ± .001

5 mM

5 mM

0

0.25 mM

0.011 ± .001

5 mM

5 mM

12 mM

0

0.005 ± .001

5 mM

5 mM

12 mM

0.25 mM

0.017 ± .002

* Reported errors represent the standard errors calculated from iterative non-linear curve fitting in GraphPad
Prism. The data were fit to data where each data point was plotted as the average ± standard deviation of 3
independent determinations.

The effects of substrates on BCCP domain positioning were further evaluated by
following changes in ITF intensity. The rapid acquisition of ITF data in a stopped-flow
instrument permitted a direct analysis of the effect of substrates and effectors on BCCP
domain positioning, without requiring the inclusion of ADP and phosphonoacetate in all
experiments. Q891C/N1102C SaPC was mixed with various substrates and the change in
ITF intensity was monitored continuously for 120 seconds. The presence of ADP and
phosphonoacetate decreased the observed ITF intensity, as shown in the first 120 seconds
of Figure III-11, consistent with the data presented in Figure III-6A. After the system was
allowed to reach equilibrium, the crosslinker was subsequently added to observe the
impact of the ligand on the rate at which the system re-equilibrates to the trapped
conformation. The data were fit to a single exponential equation (Equation 2). After
addition of the crosslinker, ITF was followed for an additional 120 seconds. The presence
of ADP and phosphonoacetate substantially reduced the rate of increase in the ITF
intensity, relative to the combination of either or both acetyl-CoA and/or pyruvate with
ADP and phosphonoacetate (Figure III-11). A comparison of the observed rates of carrier
domain repositioning, measured by each approach, is summarized in Table III-2. This

86
reveals remarkable agreement between the measurements, despite the different methods
used.

Figure III-11 SaPC ITF intensity in the presence of substrates/effector.
Q891C/N1102C SaPC was first mixed with ligand at t = 0 and the ITF intensity was recorded for 120
seconds. Q891C/N1102C SaPC, preincubated with the ligand, was then mixed with ligand and 200 μM
BMOE, to the same final concentrations, and the ITF intensity was recorded for 120 seconds (denoted as
beginning at 140 seconds). In all cases Q891C/N1102C SaPC was mixed to a final concentration of 0.175
mg/mL with buffer (purple), 12 mM final concentration of pyruvate (pink), 0.25 mM final concentration of
acetyl-CoA (green), or 5 mM final concentrations each of ADP and phosphonoacetate (blue) in a stoppedflow instrument. Tryptophan was excited at 295 nm and ITF emission was recorded at 350 nm.

Using ITF intensity as a direct measure of carrier domain positioning, we sought
to investigate the role of two allosteric effectors in carrier domain positioning: acetylCoA and L-aspartate. Acetyl-CoA enhances the coupling efficiency between the two halfreactions of PC (Zeczycki, et al., 2011B). Westerhold et al. proposed that the enhanced
coupling efficiency in the presence of acetyl-CoA is mediated by the carrier domain
(Westerhold, et al., 2017). In the present study, acetyl-CoA increased the ITF intensity,
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consistent with the carrier domain positioning equilibrating to favor an intermolecular
interaction with the CT domain (Figure III-11). While acetyl-CoA does not, on its own,
alter the observed rate of ITF intensity change, the combination of pyruvate and acetylCoA leads to a 360% increase in the observed rate of ITF intensity change in the presence
of BMOE (t test; p< 0.01) (Table III-4, Figure III-12). Acetyl-CoA also increased the
observed rate of ITF intensity change when ATP was present in combination with
BMOE. These data indicate that acetyl-CoA reduces the kinetic barrier for the
translocation of the carrier domain in the presence of substrates.

Figure III-12 Q891C/N1102C SaPC crosslinked in the presence of ligands and monitored for change
in ITF intensity.
A final concentration of 0.175 mg/mL Q891C/N1102C SaPC was mixed with either buffer or various
substrates at final concentrations listed in the Methods section, with 200 μM BMOE present at 0 s in a
stopped-flow instrument with tryptophan excitation at 295 nm and emission measured at 350 nm. A. SaPC
was mixed with either buffer (black), buffer + BMOE (purple), ATP + BMOE (orange), acetyl-CoA and
BMOE (green), or ATP + acetyl-CoA + BMOE (blue). B. SaPC was mixed with either buffer (black),
buffer+BMOE (purple), acetyl-CoA + BMOE (green), pyruvate + BMOE (orange), or acetyl-CoA +
pyruvate +BMOE (blue). Dashed lines represent the fit of the data to Equation 2.
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Table III-4 The effect of ligands on the observed rates of ITF intensity change.
substrate
(+ BMOE)

Q891C/N1102C SaPC kobs (s-1)

kobs / (kobs [No Substrate])

None

[4.8 ± 1.0] x 10-2

-

ATP

[3.0 ± 0.3] x 10-2

0.63

Acetyl-CoA + ATP

[3.6 ± 0.3] x 10-2

0.75

Acetyl-CoA

[5.0 ± 0.3] x 10-2

1.0

Pyruvate + AcetylCoA

[17.4 ± 2.6] x 10-2

3.6

L-Aspartate

[3.4 ± 1.0] x 10-2

0.70

None*

[7.3 ± 0.2] x 10-2

-

Pyruvate*

[8.1 ± 0.1] x 10-2

1.1

* Assay performed independently from above data. (n = 3; errors represent standard deviations)

L-aspartate

is an allosteric inhibitor of microbial PC enzymes (Osmani, et al,

1981; Cazzulo and Stoppani, 1968; Jitrapakdee, et al., 2007; Sirithanakorn, et al., 2014).
L-aspartate

inhibition is competitive with respect to acetyl-CoA and its effects are

independent of the coupling between MgATP cleavage and oxaloacetate formation
(Sirithanakorn, et al., 2014). Sirithanakorn et al. proposed that L-aspartate may inhibit
carboxybiotin formation or slow the rate of carrier domain translocation between the
active sites (Sirithanakorn, et al., 2014). When L-aspartate is mixed with Q891C/N1102C
SaPC, no ITF intensity change is observed (Figure III-13A), in contrast to what is
observed with the allosteric activator, acetyl-CoA. However, when Q891C/N1102C
SaPC is crosslinked in the presence of L-aspartate, the observed rate of ITF intensity
change is 30% slower (t test; p < 0.05) (Table III-4, Figure III-13B) than the rate in its
absence. This indicates that while L-aspartate may not alter the ground state energy of the
enzyme, it has a kinetic effect that reduces the rate of carrier domain repositioning.
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Figure III-13 Effect of L-aspartate on Q891C/N1102C SaPC carrier domain positioning and
crosslinking rates.
Data was collected with a stopped-flow instrument with tryptophan excitation at 295 nm and ITF emission
measured at 350 nm. A. SaPC was mixed with either buffer (black) or a final concentration of 10 mM Laspartate (blue) at 0 sec. B. SaPC was mixed with either buffer (black), buffer + 200 μM BMOE (purple),
10 mM L -aspartate + 200 μM BMOE (orange), or 0.25 mM acetyl-CoA (green) at 0 sec. Dashed lines
represent the fit of the data to Equation 2.

3. Discussion
The carrier domain of PC is known to translocate during catalysis between an
intramolecular interaction with the BC domain and an intermolecular interaction with the
CT domain on the opposing subunit (Figure 1) (St. Maurice, et al., 2007; Xiang and
Tong, 2008; Lasso, et al., 2014; Liu, et al., 2018). Here, we directly observe the
positioning of the PC carrier domain, independent of catalytic turnover, using a range of
techniques that rely on trapping the carrier domain in an intermolecular conformation, in
close proximity to the CT domain. Several models of PC catalysis propose that the carrier
domain is governed by an induced conformational change: the carrier domain remains in
proximity of the BC domain until a CT domain ligand binds, and is subsequently induced
to translocate to the CT domain upon the binding of a CT domain ligand (Easterbrook-
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Smith, et al., 1976; Goodall, et al., 1981; Attwood and Wallace, et al., 1986). However,
several structures of PC reveal the carrier domain participating in an intermolecular
interaction with the CT domain, even in the absence of ligands. These structures suggest
that the carrier domain can sample a wide range of conformations, consistent with a
conformational selection model where substrates and effectors serve to shift the
equilibrium positioning of the carrier domain from one domain to another during
catalysis. A conformational selection model is in opposition to previous interpretations,
but it is well supported by the direct observations of carrier domain positioning presented
in this study. It is particularly noteworthy that, regardless of the presence or identity of
the ligands, multiple approaches demonstrate that the carrier domain can be trapped in
proximity to the CT domain. This can only be the case if, under all conditions, the carrier
domain regularly samples positions proximal to the CT domain, consistent with a
conformational selection model. A similar model has recently been proposed to govern
conformational dynamics in the nonribosomal polypeptide synthase, gramicidin
synthetase I from Aneurinibacillus migulanus. Positional changes of the carrier domain in
gramicidin synthetase I correlate with the presence of bound ligands, where the carrier
domain samples multiple conformations in a dynamic equilibrium (Alfermann, et al.,
2017). The carrier domains of polyketide synthases, such as 6-deoxyerythronolide B
synthase (DEBS), may also be governed by conformational selection, with the carrier
domain positional equilibrium shifted by a turnstile mechanism that ensures
synchronization of the assembly line-style reactions (Lowry, et al., 2016).
The observed rates of carrier domain re-equilibration are remarkably consistent
across multiple methods of observation (Table 1). The general crosslinking approach,
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therefore, provides multiple ways to independently measure rates of carrier domain
repositioning, absent of catalytic turnover. It should be noted that the observed rates of
repositioning are two orders of magnitude lower than the kcat value and are not a suitable
estimate of carrier domain translocation rates during catalytic turnover. Rather, the
observed rate constants represent the re-equilibration of the BCCP domain to the exobinding site within an ensemble population and include the chemical crosslinking steps
which are likely to be slow relative to the rate of carrier domain translocation. Nevertheless,
the relative rates of re-equilibration clearly indicate that the carrier domain is subject to
conformational selection and that ligands alter the equilibrium position of the carrier
domain.
Substrates and ligands shift the carrier domain equilibrium as expected. BC domain
ligands reduce the rate of intermolecular crosslinking (Figures 2 and 6, Tables 1, 2, and 3)
and shift the carrier domain equilibrium away from the CT domain (Figures 4 and 7),
consistent with proposals that BC domain ligands shift the carrier domain towards the BC
domain (Easterbrook-Smith, et al., 1976; Goodall, et al., 1981; Attwood and Wallace,
1986). These data are consistent with a ground state stabilization of the BC-BCCP domain
interaction, resulting in a higher activation energy barrier and slower rate of reequilibration to the trapped intermolecular interaction with the CT domain. X-ray crystal
structures show that the active site lid of the BC domain partially closes when Mg2+ and
ATP are bound in the active site (Thoden, et al., 2000). When the BCCP domain interacts
with the BC domain, the carrier domain is positioned directly against this tightly closed lid
of the BC domain (Lietzan, et al., 2011). The lid closure that accompanies ligand binding
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produces the binding interface for the carrier domain, stabilizing the BCCP-BC domain
conformation, and shifting the BCCP positioning equilibrium toward the BC domain.
Pyruvate, the CT domain substrate, increased the kobs for intermolecular
crosslinking (Figures 6 and 7; Tables 1 and 2). These results are consistent with
observations that high concentrations of pyruvate inhibit the biotin-dependent ATPase
reaction in PC (Zeczycki, et al., 2009). The conformational selection model allows that the
carrier domain samples multiple positions and that the carrier domain positional
equilibrium shifts to the CT domain as a consequence of biotin-dependent interactions with
CT domain substrates (Lietzan, et al., 2013A). Similar interactions are thought to govern
carrier protein positioning of SoxYZ with SoxB. In the substrate-unbound state, a mobile
loop clashes with the SoxYZ binding site whereas, in the presence of substrate, the loop
shifts to favor the SoxYZ interaction with SoxB (Grabarczyk, et al., 2015). These systems
offer clear, simple examples of how substrates can locally shift carrier domain positioning
through conformational selection, without the need to invoke long-range induced
conformational changes to control carrier domain positioning.
Carrier domain positioning in the CT domain active site is proposed to be
mediated by biotin (Lietzan, et al., 2013A). The carrier domain was trapped in an
intermolecular crosslink, even in the absence of biotin (Figure S3), demonstrating that the
carrier domain does not require biotin to adopt an intermolecular position. However,
biotinylation strongly influences the carrier domain positioning equilibrium and the
sensitivity of the enzyme to ligands. The positional equilibrium shifts dramatically, as
observed by a greater than two-fold shift in the amount of uncrosslinked monomer at
equilibrium (Figure S3). Furthermore, the unbiotinylated enzyme becomes insensitive to
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the BC domain ligands, ADP and phosphonoacetate: in both their presence and absence,
the kobs for the unbiotinylated enzyme is equivalent to the rate observed for the
biotinylated enzyme in the absence of substrates. Thus, biotin is necessary for the carrier
domain to be sensitive to the presence of BC domain substrates and is critical to
mediating the binding interactions with both the BC and CT domain active sites.
The allosteric activator, acetyl-CoA, increased the observed fluorescence signal
intensity, indicating that acetyl-CoA shifts the carrier domain equilibrium towards the
opposing CT domain (Figures 4A and 7). The presence of acetyl-CoA also increased the
kobs for inactivation (Figure 6), even when ADP and phosphonoacetate were also present,
further suggesting that acetyl-CoA favors an intermolecular positioning for the carrier
domain. This agrees with our recent observation that acetyl-CoA uniquely activates an
intermolecular catalytic pathway in which the carrier domain translocates to the CT
domain on an opposing subunit (Liu, et al., 2018). The current findings suggest that
acetyl-CoA activates that translocation pathway by favoring intermolecular carrier
domain positioning at the CT domain. Contrary to the effect of acetyl-CoA on carrier
domain positioning, L-aspartate had a negligible effect on carrier domain positioning, but
it moderately reduced the observed rate of carrier domain intermolecular crosslinking
(Figures S6A and S6B). This suggests that at least a portion of the inhibitory effect of Laspartate derives from reducing the rate of carrier domain translocation, as hypothesized
by Sirithanakorn, et al (Sirithanakorn, et al., 2014).
The current study leads to an updated model of conformational selection for
carrier domain positioning in PC. The carrier domain exists in an ensemble of
conformations, where ligand binding shifts the equilibrium to favor those conformations
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that have a higher affinity for the ligand (Boehr, et al., 2009). Prior structural data suggest
how these equilibrium shifts can occur. BC domain substrates promote the closing of the
B-subdomain lid, generating a favorable binding site for the carrier domain. Similarly in
the CT domain, the presence of a CT domain substrate or substrate analogue promotes
the formation of a biotin-binding pocket that favors the positioning of biotin in the CT
domain active site, shifting carrier domain positioning towards the CT domain (Lietzan,
et al., 2013A). Common to both cases, biotin is chiefly responsible for interacting with
residues in each active site, mediating the shift in equilibrium positioning of the carrier
domain. However, independent of biotin, the carrier domain actively explores what is
likely to be a wide variety of conformations. Both biotin and active site ligands promote
interactions at the individual domains to shift the conformational equilibrium. Allosteric
activation by acetyl-CoA facilitates the release of the carrier domain from the BC domain
and promotes the intermolecular positioning of the carrier domain near the CT domain
active site. Conformational selection offers a simple and updated model to explain the
kinetic behavior of PC in response to substrates and allosteric effectors. Such a model is
highly applicable to the positioning and long-range translocation of carrier domains and
carrier proteins in a range of other complex multi-modular enzyme systems.
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IV. THE CARRIER DOMAIN POSITIONAL EQUILIBRIUM OF S. AUREUS
PYRUVATE CARBOXYLASE IS GOVERNED BY INTERACTIONS BETWEEN
BIOTIN AND ACTIVE SITE RESIDUES

1. Introduction

In chapter III, I demonstrated that the carrier domain positioning of SaPC is
governed by conformational selection. Substrates shift the carrier domain positional
equilibrium while acetyl-CoA favors an intermolecular positioning of the carrier domain
in the presence of substrates. While it is clear from chapter III that substrates, allosteric
effectors and biotin alter the equilibrium positioning of the carrier domain, the molecular
interactions underlying these positional shifts are not well described.
Carrier domains are used in multi-domain enzymes to shuttle intermediate
products between active sites. The molecular interactions that contribute to carrier
domain positioning represent an area of intense study in many carrier-domain enzymes.
For example, the interaction between the acyl carrier protein (ACP) and the microbial
fatty acid synthase pathway enzyme FabA was observed to be regulated by electrostatic
interactions between the ACP and the surface of FabA, gating residues at the opening to
the active site, and the size of the active site pocket (Finzel, et al., 2015). The
conformational equilibrium of the nonribosomal peptide synthase gramicidin synthetase I
from Aneurinibacillus migulanus has been found to be shifted by product inhibition, with
a series of interactions between residues and substrates and intermediate products
proposed to be responsible for this shift. (Alfermann, et al., 2017; Branchini, et al., 2011).
In the Sox pathway, the interaction of the carrier protein SoxYZ with the enzyme SoxB
has been found to be controlled, in part, by the positioning of a surface mobile loop that
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exists in different conformations dependent upon the presence of substrate (Grabarczyk,
et al., 2015). Studies investigating carrier protein-catalytic domain interactions have
detailed numerous mechanisms governing the favorability of these interactions as the
presence and identity of ligands change. While the field has begun to elucidate these
mechanisms, the descriptions are currently limited to just a few discrete examples,
precluding a general description of common mechanism(s) responsible for altering carrier
domain positioning. Studies on the interactions between biotin and active-site residues
and their contributions to shifting carrier domain positioning in PC will provide fresh
examples of how carrier domain positioning is influenced by molecular level interactions.
A number of kinetic and structural studies in PC have sought to unveil the
molecular basis for carrier domain positioning. Two x-ray crystal structures of PC offer
useful insights into how carrier domain equilibrium positioning may be shifted through
interactions with the BC and CT domains. The structure of R. etli PC (RePC) cocrystallized with ADP and phosphonoacetate, captured the interaction between the carrier
domain and the BC domain (Lietzan, et al., 2011). In this structure, biotin was occluded
from the BC domain active site by a salt bridge formed between Arg353 and Glu248.
This conserved pair of residues was proposed to act as a molecular gatekeeper,
preventing carboxybiotin from returning to the active site where it could undergo abortive
decarboxylation (Lietzan, et al., 2011). Similarly, a structure of the isolated CT domain of
RePC revealed that a flexible loop in the CT domain active site alters its conformation
when pyruvate is bound, providing a stabilizing interaction between the sulfur in the
thiophene ring of biotin and the aromatic ring of Tyr6285. Another CT domain active site
residue, Thr882 in RePC, was shown to play a critical role in shuttling a proton between
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the biotin enolate intermediate and pyruvate and was also proposed to play a role in
stabilizing the positioning of biotin in the CT domain active site through a hydrogenbonding interaction with the N-1 of biotin6. Kinetic studies on a site-directed mutation of
this residue (T882A) were interpreted to suggest that Thr882 is important in carrier
domain positioning at the CT domain. Together, conserved residues in both the BC and
CT domains are likely to make critical contributions to the positioning of the carrier
domain through their interactions with biotin. However, the hypothesized roles of these
residues are based on static structures and indirect kinetic studies that do not provide
dynamic information on the interplay between ligand, residue, and carrier domain
positioning.
In this chapter, I seek to describe the role of three conserved residues that are
predicted to interact with biotin to better understand the mechanism of ligand-associated
carrier domain positioning changes in pyruvate carboxylase. Site-specific crosslinking is
monitored by intrinsic tryptophan fluorescence (ITF) to more precisely determine the
effects of ligands and the roles of the “gatekeeper” residues on carrier domain
positioning. Tyr621 (equivalent to Tyr628 in RePC) in S. aureus PC (SaPC) was shown
to have a crucial role in the positioning of the carrier domain, mutation of Glu243
(equivalent to Glu248 in RePC) was observed to shift carrier domain positioning towards
the BC domain, and mutation of Thr876 (equivalent to Thr882 in RePC) was also
observed to shift carrier domain positioning towards the BC domain while decreasing the
effect of pyruvate on carrier domain positioning.
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2. Results

2.1

Active Site Mutations Shift Carrier Domain Positioning

As described in chapter III, I have designed and validated a system to trap the
carrier domain in the exo-binding site through the introduction of site-specific Cys
residues and the maleimide-based homobifunctional crosslinker, BMOE (Figure III-1B).
This Q891C/N1102C (QN) mutant was used as a crosslinking-competent background
into which additional mutations of active site residues were introduced.
Three residues (Glu243, Thr876 and Tyr621) have been proposed to interact with
biotin and contribute to translocation of the carrier domain. Consequently, three
mutations were introduced into the Q891C/N1102C (QN) crosslinking-competent
background. The proposed role of these residues (E243A, T876A, and Y621) in catalysis
is summarized in Table IV-1. The catalytic activities of these mutants are reported in
Table IV-2 and are similar to the activities reported in previous studies of these mutations
(Lietzan, et al., 2011; Lietzan, et al., 2013).

Table IV-1 Summary of active site residues selected for mutation in PC.
Residue

Location

Proposed Function

Citation

Glu243

BC Domain

One of two “gatekeeper” residues that
control biotin access to active site

Lietzan, et al., 2011;
Zeczycki, et al., 2011

Tyr621

CT Domain

Stabilize biotin in active site

Lietzan, et al., 2013

Thr876

CT Domain

Proton shuttle during CT domain
reaction, H-bond to biotin

Zeczycki, et al., 2011
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Table IV-2 Kinetic characterization of Q891/N1102C SaPC and related mutants.
SaPC Mutant

Oxamate-induced
Pyruvate carboxylation
oxaloacetate
-1
kcat, min
decarboxylation kcat, min-1

ADP
Phosphorylation
kcat, min-1

Wild-Type

1440 ± 100

3.9 ± 0.1

0.63 ± 0.01

Q891C/N1102C

440 ± 10

19 ± 1

2.1 ± 0.1

Q891C/N1102C/E243A

2.2 ± 0.1

20 ± 1

3.1 ± 0.1

Q891C/N1102C/Y621A

14 ± 0.2

0.15 ± 0.02

0.47 ± 0.02

Q891C/N1102C/T876A

N/A

N/A

0.62 ± 0.01

The triple mutants were individually mixed with BMOE and were monitored for
changes in ITF intensity, to determine the role these residues play in carrier domain
positioning. The data were fit to Equation 2, which yields an observed rate constant (kobs)
and an observed amplitude for ITF intensity change. In the interpretation of these data,
the kobs is considered to be proportional to the kinetic barrier associated with the carrier
domain adopting a new conformation. The observed amplitude represents the relative
proportion of the carrier domain population that shifts from the initial equilibrium to the
crosslinked conformation. As reported in Figure IV-1, both of the CT domain mutations
(T876A or Y621A) resulted in an increase in kobs. It was not surprising to observe an
increase in kobs considering that Thr876 and Tyr621 are proposed to interact with and
stabilize biotin in the CT domain active site (Lietzan, et al., 2013). Perhaps, with these
residues mutated, the carrier domain has more freedom to adopt a wider range of
conformations and movements that increase the rate of crosslinking to the exo-binding
site.

100

Figure IV-1 Observed rates and amplitudes of ITF change from QN SaPC mutants during
crosslinking with BMOE
Q891C/N1102C (QN) SaPC, Q891C/N1102C/E243A (QNE) SaPC, Q891C/N1102C/T876A (QNT) SaPC,
and Q891C/N1102C/Y621A (QNY) SaPC were mixed with BMOE at 0 sec. in a stopped-flow instrument
with tryptophan excitation at 295 nm and ITF emission measured at 350 nm. A single exponential decay
equation was fit to the data. A. The relative change in kobs is the kobs obtained for each of the three activesite residue mutants divided by the kobs obtained from the QN background. All measurements were made in
triplicate. Error bars represent the standard deviation. B. The amplitudes of ITF signal change from the
single exponential decay for each of the three active-site residue mutants obtained in A. were divided by
the amplitude change obtained for the corresponding crosslinking background to yield a relative % change.
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The Y621A mutation produced a drastically different behavior than the other
mutations, with a large increase in the magnitude of the ITF signal change observed in
the crosslinked Q891C/N1102C/Y621A (QNY) SaPC mutant compared to the QN
crosslinking background. It is important to note that crosslinking still occurs in the QNY
mutant, as confirmed by the formation of crosslinked dimers of QNY SaPC when
analyzed by SDS-PAGE (Figure IV-2A). Interestingly, the ITF signal decreases for the
QNY mutant in the presence of crosslinker, which is opposite to the behavior observed in
all other cases (Figure IV-2B). This dramatic shift in initial equilibrium positioning of the
carrier domain, observed by the large change in amplitude, may demonstrate that Tyr621
has an important role in establishing the carrier domain positional equilibrium (Figure
IV-1B). In contrast to the QNY mutant, the amplitude of the ITF signal change during
crosslinking of the Q891C/N1102C/T876A (QNT) SaPC mutant remained similar to the
QN crosslinking background, suggesting that the baseline equilibrium positioning of the
carrier domain was not significantly shifted by this mutation.
The observed rate of change in the ITF intensity increased in the Q891C/N1102C/
E243A (QNE) SaPC mutant. The overall signal evolution of the ITF signal appeared
similar to that of the crosslinking background as shown in Figure IV-2. The amplitude of
the ITF signal changes increased in the QNE mutant compared to background, indicating
that the carrier domain equilibrium has shifted towards the BC domain in this mutant.
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Figure IV-2 QN SaPC mutants crosslinked and ITF intensity changes.
A. SaPC mutants as listed below at 1 mg/mL were reacted with 5% DMSO or 300 μM BMOE for 120 s,
then quenched with 13 mM DTT for 15 minutes. 5 μg of SaPC was loaded in each lane. (1)
Q891C/N1102C w/ DMSO (2) Q891C/N1102C w/ BMOE (AC); (3) Q891C/N1102C/E243A w/ DMSO;
(4) Q891C/N1102C/E243A w/ BMOE; (5) Q891C/N1102C/Y621A w/ DMSO; (6)
Q891C/N1102C/Y621A w/ BMOE; (7) Q891C/N1102C/T876A w/ DMSO; (8) Q891C/N1102C/T876A w/
BMOE. The molecular weights for the ladders are shown in kDa. B. Q891C/N1102C SaPC (red),
Q891C/N1102C/E243A SaPC (gold), Q891C/N1102C/T876A SaPC (green), or Q891C/N1102C/Y621A
SaPC (blue) was mixed with a final concentration of 200 μM BMOE at t = 0 and the ITF intensity was
recorded for 120 seconds. Tryptophan was excited at 295 nm and ITF emission was recorded at 350 nm.
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2.2

Mutation of Glu243 Shifts Carrier Domain Positioning Towards the BC Domain.

Glu243 was proposed to serve as one of two residues that serve as “gatekeepers”
to prevent the return of carboxybiotin to the BC domain active site where abortive
decarboxylation could occur (Lietzan, et al., 2011). To further investigate the role of
Glu243, the response of the QNE system to various substrates and effectors was
evaluated in relation to the QN control.
The observed rates of ITF intensity change were quite similar for the QNE mutant
relative to the QN background and followed the same trends in the response to ligands
(Figure IV-3A). However, the relative amplitude of ITF signal increased when the QNE
enzyme was crosslinked in the presence of BC domain ligands compared to the QN
background (Figure IV-3B). This is consistent with an overall shift in carrier domain
equilibrium positioning towards the BC domain in the QNE mutant, particularly in the
presence of BC domain ligands. The E243A mutation seems to have no appreciable effect
on the shift in carrier domain positioning in the presence of pyruvate with similar kobs and
observed amplitudes of ITF signal change compared to those observed in the crosslinking
background (Figure IV-3). In QNE SaPC and in the presence of acetyl-CoA, kobs was
~19% lower than kobs in the absence of acetyl-CoA (p < .001), suggesting that this
mutation has raised a kinetic barrier to carrier domain repositioning in the presence of
acetyl-CoA (Figure IV-3A). The amplitude of observed ITF signal change also increased
in the QNE mutant in the presence of acetyl-CoA compared to the QN background,
indicating that an equilibrium shift has occurred towards the BC domain in this mutant
(Figure IV-3B).
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Figure IV-3 Observed rates and amplitudes of ITF change from Q891C/N1102C/E243A SaPC during
crosslinking with BMOE in the absence/presence of ligands.
A. Q891C/N1102C SaPC (black) and Q891C/N1102C/E243A SaPC (pink) were incubated for a minimum
of 10 minutes with 2.5 mM ATP, 0.25 mM acetyl-CoA, 12 mM sodium pyruvate, 5 mM ADP, or 5 mM
phosphonoacetate (PPA) and then mixed with BMOE and an equal concentration of the substrate/effector
at 0 sec. in a stopped-flow instrument with tryptophan excitation at 295 nm and ITF emission measured at
350 nm. Equation II-2 was fit to the data and the kobs obtained for each of the three active-site residue
mutants compared to the kobs obtained from the corresponding crosslinking background mutant. All
measurements were taken in triplicate with the error bars representing the standard deviation in the rate. B.
The amplitudes of ITF signal change from the single exponential equation for each of the three active-site
residue mutants described in panel A were compared to the amplitude obtained for the corresponding
crosslinking background.
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2.3

Thr876 Mediates Carrier Domain Positioning in Response to Pyruvate

To investigate the role of the CT domain active site threonine (Thr876) in carrier
domain positioning, changes in the amplitude and rates of ITF signal changes were
measured in the QNT enzyme and compared to the response of the QN background. In
the presence of ATP or ADP, the observed rates of ITF intensity change for the QNT
mutant were similar to the observed rates in the QN background (Figure IV-4A).
However, the amplitude of ITF signal change was larger in the presence of ATP or ADP,
suggesting a shift in carrier domain equilibrium towards the BC domain when these
ligands are present (Figure IV-4B). The presence of ADP and phosphonoacetate had a
major impact on the observed rate of ITF intensity change; the kobs for the QNT mutant
was only 2% of kobs measured for the QN background in the presence of ADP and
phosphonoacetate (Figure IV-4A). Furthermore, with ADP and phosphonoacetate
present, the amplitude of the ITF intensity change was almost 4-fold higher for the QNT
mutant relative to the QN background, highlighting a major shift in carrier domain
positioning for the T876A SaPC mutant towards the BC domain (Figure IV-4B).
In the presence of pyruvate or acetyl-CoA, the observed rates of ITF intensity
change were lower in the QNT mutant compared to the QN background (Figure IV-4A).
Pyruvate also had a reduced impact on the amplitude of ITF signal change in the QNT
mutant compared to the QN background, suggesting that the effect of pyruvate on carrier
domain positioning is diminished in the QNT mutant (Figure IV-4B). In the presence of
acetyl-CoA, the amplitude of ITF signal change was similar in the QNT mutant compared
to the QN background. Considering that acetyl-CoA decreased the kobs for the QNT
mutant compared to the QN background but had a more minimal effect on the amplitude
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compared to the QN background, this suggests that a kinetic barrier in the adoption of the
crosslinking conformation in the presence of acetyl-CoA has been raised in this mutant
(Figure IV-4B).

107

Figure IV-4 Observed rates and amplitudes of ITF change from Q891C/N1102C/T876A SaPC during
crosslinking with BMOE in the absence/presence of ligands.
A. Q891C/N1102C SaPC (black) and Q891C/N1102C/T876A SaPC (purple) were incubated for a
minimum of 10 minutes with 2.5 mM ATP, 0.25 mM acetyl-CoA, 12 mM sodium pyruvate, 5 mM ADP, or
5 mM phosphonoacetate (PPA) and then mixed with BMOE and an equal concentration of the
substrate/effector at 0 sec. in a stopped-flow instrument with tryptophan excitation at 295 nm and ITF
emission measured at 350 nm. A single exponential decay equation was fit to the data and the kobs was
determined for each of the three active-site residue mutants compared to the kobs obtained from the QN
crosslinking background mutant. All measurements were taken in triplicate with the standard deviation in
the rate shown as the error bars. B. The amplitudes of ITF signal change from Equation II-2 for each of the
three active-site residue mutants described in panel A were compared to the amplitude obtained for the
corresponding QN crosslinking background.
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2.4
CT Domain Tyr621 contributes to the kinetics and thermodynamics of carrier
domain positioning.

Tyr621 forms a stabilizing interaction with the thiophene ring of biotin in the CT
domain (Lietzan, et al., 2013A). To investigate the contribution of this residue to carrier
domain positioning, changes in the amplitude and rates of ITF intensity changes were
measured in the QNY mutant relative to the QN background. The overall change in
observed ITF signals were quite different than those observed in any other mutant, with
the ITF signal decreasing upon introduction of the crosslinker (Figures IV-2). It must be
acknowledged that the dramatic change in the observed ITF signal may be the result of a
change in this protein that may render this data unable to be interpreted in the same
manner used for the other mutations in this study. It is possible that as a result of this
mutation, intrinsic fluorescence has changed in a way that is not related to carrier domain
positioning. In this section, the QNY mutant data will be interpreted in the same manner
under the assumption that carrier domain positioning was linked to changes in Trp
fluorescence similar to the other mutants with the understanding that there is a large
caveat to this until it can be shown that this assumption is valid. This is further discussed
in Chapter VI.
In the presence of BC domain ligands or acetyl-CoA, the measured kobs
values for the QNY mutant are relatively unchanged, in stark contrast to observations in
the QN background (Figure IV-5A). The magnitude of the measured amplitudes
decreased in the presence of BC domain ligands in the QNY mutant, indicating that the
equilibrium position of the carrier domain had shifted away from the BC domain (Figure
IV-5B). This result may support previous observations that alterations to one active site
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can have an effect on a separate active site, suggesting communication between the BC
and CT domains (Westerhold, et al., 2016; Lietzan, et al., 2014).
However, in the presence of pyruvate, there was an increase in the measured kobs
(Figure IV-5A), combined with a large increase in the magnitude of the amplitude change
for the QNY SaPC, which is opposite to what was observed for the QN background
(Figure IV-5B). The observation that the presence of pyruvate still has an effect on
carrier domain positioning, despite this mutation, suggests that Y621A is not the sole
residue responsible for mediating the effect of pyruvate on carrier domain positioning.
The effect of acetyl-CoA on the measured ITF amplitude changes also diminished
(Figure IV-5B), suggesting that Tyr621 mediates the effect of acetyl-CoA on carrier
domain positioning.
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Figure IV-5 Observed rates and amplitudes of ITF change from Q891C/N1102C/Y621A SaPC during
crosslinking with BMOE in the absence/presence of ligands.
A. Q891C/N1102C SaPC (black) and Q891C/N1102C/Y621A SaPC (green) were incubated for a
minimum of 10 minutes with 2.5 mM ATP, 0.25 mM acetyl-CoA, 12 mM sodium pyruvate, 5 mM ADP, or
5 mM phosphonoacetate (PPA) and then mixed with BMOE and an equal concentration of the
substrate/effector at 0 sec. in a stopped-flow instrument with tryptophan excitation at 295 nm and ITF
emission measured at 350 nm. Equation II-2 was fit to the data and the kobs obtained for each of the three
active-site residue mutants compared to the kobs obtained from the corresponding crosslinking background
mutant. All measurements were taken in triplicate with the error bars representing the standard deviation in
the rate. B. The amplitudes of ITF signal change from the single exponential equation for each of the three
active-site residue mutants described in panel A were compared to the amplitude obtained for the
corresponding crosslinking background.
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3. Discussion
Regulation of carrier domain positioning is crucial for the coordination of multistep reactions in multi-domain enzymes and for the protection of reaction intermediates.
However, the molecular mechanism linking the presence of ligand and an observed shift
in carrier domain positioning or translocation pathway remains unclear (Lowry, et al.,
2016; Liu, et al., 2018) or unconfirmed (Alfermann, et al., 2017). The studies presented
here sought to directly observe carrier domain positioning in order to provide insights
into molecular level contributions from key active site residues to carrier domain
positioning.
Glu243 Acts to Shift Carrier Domain Positioning Away from BC Domain. In the
absence of substrates, the E243A SaPC mutant shows an increase in the ITF signal
amplitude when crosslinked with BMOE in the QN crosslinking background (QNE)
(Figure IV-1B). This suggests that loss of the Glu243 “gatekeeper” residue shifts the
carrier domain position towards the BC domain. This is consistent with observations by
Lietzan, et al. that the salt bridge interaction between Glu243 and Arg346 (analogous to
RePC Arg353) serves to control carboxybiotin access to the active site (Lietzan, et al.,
2011; Zeczycki, et al., 2011A). The loss of this gatekeeping residue resulted in a greater
observed amplitude of ITF signal change, indicating that the carrier domain equilibrium
had shifted towards the BC domain as a result of this mutation, as might be expected with
greater biotin access to the active site.
The relative increase in the ITF signal amplitude for QNE in the presence of BC
domain ligands further supports the idea that Glu243 functions to regulate biotin access
to the BC domain active site (Figure IV-3B). Thus, mutations of these gatekeeper
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residues allow greater biotin access to the BC domain active site. It is, therefore,
unsurprising that the current data with the QNE mutant is consistent with a shift in the
carrier domain positioning towards the BC domain when the Glu243 gatekeeper residue
is mutated to an alanine. With the gate-closing mechanism disrupted, biotin would have
greater access to the BC domain active site in the presence of BC domain reaction
products, such as ADP, further stabilizing the BCCP-BC domain interaction. However,
there is likely more than one mechanism to regulate carrier domain interactions with the
BC domain given observations that ADP or ADP/PPA shift carrier domain positioning
towards the BC domain in the QN background. This is likely to include the formation of
the BC domain / carrier domain interface by the B-subdomain lid closure in the presence
of BC domain ligands (Menefee and Zeczycki, 2014). Thus, even if ADP is bound and
the gatekeeper residue system is blocking biotin access to the active site, the carrier
domain may still have a favorable interface to remain docked at the BC domain active
site.
Tyr621 has a critical role in carrier domain positioning. Tyr621 was proposed to
stabilize the positioning of biotin in the CT domain active site (Lietzan, et al., 2013A).
The Y621A SaPC mutant displayed a dramatically different ITF signal behavior than any
other SaPC variant. This could be the result of either a large shift in initial carrier domain
equilibrium positioning or a failure of the carrier domain to adopt the final crosslinking
conformation. However, as shown in Figure IV-2A, this mutant still adopts the
intermolecular crosslinking conformation, with crosslinked dimers formed when the
QNY mutant was reacted with BMOE. This indicates that initial carrier domain
positioning equilibrium was strongly shifted as a result of this mutation, which led to the
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dramatic difference in ITF signal change behavior as the carrier domain was crosslinked
to the final intermolecular conformation. In the absence of ligands, the observed rate
constants for ITF signal change were also increased two-fold in the QNY mutant
compared to the QN background (Figure IV-5A) suggesting that a kinetic barrier to the
carrier domain repositioning has been reduced. This could result from the carrier domain
being less anchored at the CT domain due to the disruption of the proposed biotintyrosine interaction and, therefore, the carrier domain is freed to adopt a variety of
conformations.
The accompanying large change in amplitude upon crosslinking the QNY mutant
compared to the QN background suggests a relatively large thermodynamic change in the
BCCP-CT domain interaction, which resulted in a shift in carrier domain positioning
(Figure IV-1B). This supports the hypothesis proposed by Lietzan, et al. that sulfur-pi
interaction between the sulfur in the thiophene ring of biotin and the aromatic ring of
Tyr621 contributes to the positioning of biotin in the CT domain active site5. In the
Y621A mutation (QNY) this stabilizing interaction is lost, reestablishing a new initial
equilibrium for the carrier domain position, as evidenced by the general reversal in
behavior. An increase in the observed amplitude upon crosslinking is interpreted as a
shift in the initial carrier domain positional equilibrium towards the BC domain. Thus,
the decrease in amplitude observed in Figure IV-1B indicates an equilibrium shift away
from the BC domain, perhaps towards the exo-binding site.
As introduced in Section I.2.3, Tyr621 links pyruvate binding in the active site to
biotin binding. Curiously, the response of the carrier domain to the presence of pyruvate
was not abolished in this mutant. In fact, it was observed that the magnitude of the
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amplitude during crosslinking decreased in the presence of pyruvate (Figure IV-5B),
indicating that more than one residue may be responsible for interacting with both
pyruvate and biotin. The Sox B and Sox YZ interaction behaves in a similar manner, with
a substrate stabilizing a particular active-site conformation that itself favors interaction of
the Sox B enzyme with the Sox YZ carrier domain (Grabarczyk, et al., 2015).
The observed amplitude change in the presence of acetyl-CoA, however, was
dramatically reduced in this mutant (Figure IV-5B). Acetyl-CoA favors the symmetrical
conformation of PC which includes the carrier domain being positioned intermolecularly
(Lasso, et al., 2014; Sirithanakorn, et al., 2016). These results suggest that while acetylCoA may have an effect at the N-terminal portion of the carrier domain, where its
binding site is located, the stabilization of biotin by Tyr621 in the CT domain active site
is necessary for stable adoption of the carrier domain conformation favored by acetylCoA. Without Tyr621, biotin and the flexible carrier domain have lost the anchoring site
for biotin, destabilizing the intermolecular carrier conformation.
Thr876 contributes to shifts in carrier domain positioning. Thr876 acts to shuttle
a proton between the biotin enolate and pyruvate during pyruvate carboxylation and it is
within hydrogen-bonding distance to the N-1 position of biotin (Zeczycki, et al., 2009).
As such, it may play a role in shifting carrier domain positioning. The T876A mutant
displayed the smallest ITF amplitude changes in the absence of ligands compared to the
QN crosslinking background (Figure IV-1B). Unexpectedly, the presence of pyruvate
also led to a smaller amplitude of ITF signal change in this mutant (Figure IV-4)
compared to the QN background, suggesting that this mutation reduced the impact of
pyruvate on carrier domain repositioning. This result could have two different
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explanations. First, the biotin-stabilizing hydrogen bonding network that normally forms
in the presence of pyruvate has been disrupted. Second, the alanine introduced at this
position has an unfavorable interaction with pyruvate, leading to conformational changes
that disfavor the positioning of biotin in the active site.
The presence of BC domain ligands led to an increase in the observed ITF
amplitude change for the QNT mutant, including a dramatic increase observed in the
presence of ADP and phosphonoacetate (Figure IV-4B). This coincided with a dramatic
reduction in the observed rate constant with ADP and phosphonoacetate (Figure IV-4A),
further suggesting that the carrier domain favors an interaction with the BC domain in
this mutant. This supports the observation by Zeczycki, et al. that mutation of Thr882 in
RePC (equivalent to Thr876 in SaPC) led to an increased rate of ADP phosphorylation in
the BC domain, which was further accelerated in the presence of free biotin (Zeczycki, et
al., 2009). The authors of that study proposed that the Thr882 mutation shifted carrier
domain positioning towards the BC domain, where the increased local concentration of
biotin in the active site contributed to accelerating the rate of ADP phosphorylation. The
data presented here also indicates that mutation of Thr876 shifts carrier domain
positioning towards the BC domain.
In summary, direct observations of carrier domain positioning in SaPC
demonstrate that carrier domain positioning is shifted by interactions between biotin and
specific conserved active-site residues. These residues control the access of biotin to the
active site, which leads to shifts in carrier domain positioning. While multi-domain
enzymes are diverse, the directionality of these reactions and the mechanism by which
carrier domain translocation is controlled is becoming clearer as a result of studies like
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these. In the related biotin-dependent enzyme, acetyl-CoA carboxylase from
Saccharomyces cerevisiae, it has been shown that the conformational flexibility of the
enzyme is controlled by the binding of a regulatory loop to an allosteric site that restricts
conformational flexibility and disfavors a catalytically-relevant high-energy
conformation (Hunkeler, et al., 2016). The binding of acetyl-CoA in pyruvate
carboxylase may have a similar role, confining the flexible carrier domain to promote an
intermolecular, catalytically-relevant conformation at the CT domain active site that is
stabilized through the biotin-Tyr621 interaction in SaPC. The results described in this
chapter clarify how carrier domain positioning, governed by conformational selection,
can be shifted by ligand binding events in SaPC. These findings may be useful in
explaining how carrier domain translocation can be controlled at the molecular level by
similar interactions in many other complex multi-domain enzyme systems.
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V. THE EFFECTS OF LIGANDS AND ACTIVE SITE MUTATIONS ON CARRIER
DOMAIN TRANSLOCATION IN S. AUREUS PYRUVATE CARBOXYLASE

1. Introduction
Chapters III and IV summarized the effect of ligands on carrier domain
positioning and clarified the relationship between active site residues and carrier domain
positioning. The carrier domain is governed by conformational selection, where ligand
binding serves to shift the carrier domain positioning equilibrium. The QN crosslinking
system was based on a structure where biotin occupies the exo-binding site and not the
CT domain active site. In an effort to discern between carrier domain interactions at the
active site and carrier domain interactions at the exo-binding site, a new system was
created: D907C/Q1118C (DQ) SaPC (Figure V-1A).
Many studies were performed in the DQ system, which showed quite different
behavior relative to the QN system described in the previous chapters. The studies in the
DQ system described in this chapter were initially interpreted to inform on the
differences between the exo-binding site-carrier domain conformation as compared to the
CT domain active site-carrier domain conformation. However, in a series of experiments
run only weeks prior to the submission of this dissertation (as described in the Results
section), it was revealed that the DQ mutant behaves identically to a single Q1118C
SaPC mutant. Thus, all of the data collected in the DQ system, in fact, represents a
BCCP-BCCP crosslink rather than a BCCP-CT crosslink. While the BCCP dimer is not
expected to be a catalytically relevant conformation, it does represent a novel state in
which the carrier domain is trapped in the process of translocating between active sites.
Given the late breaking nature of this result, it was not possible to regenerate all of the
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mutations, originally generated in the DQ background, in the single Q1118C background.
This chapter will demonstrate that the DQ mutant and the Q1118C single mutant are
indistinguishable in their behavior and will then investigate the impact of ligands and
mutations in the DQ double mutant system. All results with the DQ system will be
interpreted as being due exclusively to the Q1118C-Q1118C crosslink.

2. Results

2.1

Characterization of the D907C/Q1118C SaPC Crosslinking System

A second conformation, observed in X-ray crystal structures of SaPC, was used to
direct the design of a crosslink trap in which the carrier domain was bound in the
catalytically competent conformation, with biotin extending into the CT domain active
site (Figure V-1B). This was designed to facilitate the detection and comparison of two
different conformational states for the BCCP domain. To trap this second conformation,
Asp907 on the CT domain and Gln1118 on the BCCP domain were mutated to cysteines
to generate the double mutant D907C/Q1118C SaPC (DQ) based on the X-ray crystal
structure of SaPC (PDB ID: 3BG5) (Xiang and Tong, 2008).
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Figure V-1 SaPC carrier domain motions and conformations.
A. A schematic of the PC tetrameric structure and intermolecular carrier domain translocation. BC
domains are colored in blue, CT domains in yellow, and the BCCP carrier domain in red. A hypothetical
intermolecular translocation pathway is traced for a single carrier domain from the BC domain of its own
subunit to the active site in the CT domain of a neighboring subunit. B. The SaPC X-ray crystal structure
(PDB ID: 3BG5) showing the BCCP domain of one subunit (red) interacting at the active site of the CT
domain on the opposing subunit (yellow). The Mn2+ ion, colored as a grey sphere, and pyruvate are shown
in the CT domain active site. Asp907 on the CT domain and Gln1118 on the BCCP domain were both
mutated to cysteine to enable maleimide-based crosslinking to trap the BCCP domain in an intermolecular
conformation.

SDS-PAGE analysis of crosslinking in the DQ double-mutant compared with the
Q1118C single-mutant, however, revealed that the crosslinking levels for both mutants
were very similar (Figure V-2A). To confirm this, Q1118C SaPC was analyzed for ITF
intensity changes during crosslinking and compared to D907C/Q1118C SaPC. The ITF
signals obtained from crosslinking both of these mutants are virtually identical (Figure V2B). Thus, the D907C/Q1118C system is equivalent to Q1118C alone and represents a
BCCP-BCCP dimerization and not the BCCP-CT interaction. This interaction could not
have been predicted from the X-ray crystal structure of a BCCP dimer from E. coli
acetyl-CoA carboxylase (PDB ID: 1BDO), which shows that the BCCP domain dimer
that forms in the crystal lattice positions these residues on opposite sides of the dimer
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(Figure V-2). While this system does not capture the desired BCCP-CT domain
interaction, it is interesting that Q1118C can crosslink only when both of the BCCP
domains are in motion, away from either active site. Consequently, this system can be
used to report on how ligands and mutations impact the translocation of the BCCP
domain, even if the final position captured in these crosslinks is not catalytically relevant.
All of the DQ SaPC data was collected prior to making this observation. The latebreaking nature of this result prevents the re-collection of this data in the Q1118C SaPC
system alone. For the remainder of this chapter, the data in the DQ system will be
analyzed on the assumption that the carrier domain is being trapped in a BCCP-BCCP
crosslink during translocation.
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Figure V-2 D907C/Q1118C SaPC mutants crosslinked.
A. SaPC mutants as listed below at 1 mg/mL were reacted with 5% DMSO or 300 μM BMOE for 120 s,
then quenched with 13 mM DTT for 15 minutes. 5 μg was loaded in each lane. (1) D907C/Q1118C w/
DMSO; (2) D907C/Q1118C w/ BMOE; (3) Q1118C w/ DMSO; (4) Q1118C w/ BMOE. The molecular
weights for the ladders on the left and right are shown in kDa. B. SaPC mutants mixed with 200 μM
BMOE and ITF intensity changes measured. D907C/Q1118C SaPC (grey/black) or Q1118C SaPC (red)
were mixed with a final concentration of 200 μM BMOE at t = 0 and the ITF intensity was recorded for
120 seconds. Tryptophan was excited at 295 nm and ITF emission was recorded at 350 nm.
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Figure V-3 Acetyl-CoA Carboxylase BCCP Domain Dimer Comparison
The BCCP dimer of acetyl-CoA carboxylase from E. coli (yellow; PDB ID: 1BDO) is shown overlayed
with the S. aureus PC BCCP domain (green; PDB ID: 3BG5) The S. aureus PC BCCP domain is overlayed
over each subunit of the acetyl-CoA carboxylase dimer. Shown in sticks are Gln1118 (Gln1150 in H.
sapiens numbering).

The DQ SaPC mutants were subjected to the same experimental setup as in
Chapter III. Rates of ITF signal change were determined by fitting the data to a single
exponential decay equation. As shown in Figure V-4 and summarized in Table V-1, the
presence of acetyl-CoA increased kobs 2.5-fold compared to the rate observed in the
absence of ligands, a remarkably more pronounced response to acetyl-CoA compared to
the QN crosslinking background. The ITF signal observed when acetyl-CoA was mixed
with DQ SaPC appears virtually identical to the ITF signal observed when DQ SaPC was
mixed with BMOE (Figure V-4B), suggesting that acetyl-CoA on its own promotes a
conformation very similar to the BCCP-BCCP crosslinked conformation trapped by
BMOE. Similar to what was observed in QN SaPC, the rate of ITF signal change during
crosslinking increased when acetyl CoA was combined with ATP, as compared to the
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sample incubated with ATP alone (Figure V-4A). However, the addition of acetyl-CoA to
ATP resulted in a much more pronounced increase in the rate for the DQ crosslinking
system (2.5-fold faster; 150% increase over ATP alone) compared to the QN crosslinking
system (~20% increase over ATP alone). These relative rates are summarized in Tables
III-4 for the QN system and V-1 for the DQ system.

Figure V-4 D907C/Q1118C SaPC crosslinked in the presence of ligands and monitored for change in
ITF intensity.
A final concentration of 0.175 mg/mL D907C/Q1118C (DQ) SaPC was mixed with either buffer or various
substrates at final concentrations listed in the Methods section, with 200 μM BMOE present at 0 s in a
stopped-flow instrument with tryptophan excitation at 295 nm and emission measured at 350 nm. A. DQ
SaPC was mixed with either buffer (black), buffer + BMOE (purple), ATP + BMOE (orange), acetyl-CoA
and BMOE (green), or ATP + acetyl-CoA + BMOE (blue). B. DQ SaPC was mixed with either buffer (black),
buffer+BMOE (purple), acetyl-CoA + BMOE (green), pyruvate + BMOE (orange), or acetyl-CoA + pyruvate
+BMOE (blue), or acetyl-CoA only (gold). Dashed lines represent the fit of the data to Equation 2.
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Table V-1 The effect of ligands on the observed rates of ITF intensity change.
substrate
(+ BMOE)
D907C/Q1118C SaPC kobs (s-1)
kobs / (kobs [No Substrate])
None

[1.3 ± 0.3] x 10-1

-

ATP

[0.7 ± 0.3] x 10-1

0.54

Acetyl-CoA + ATP

-1

[1.8 ± 0.3] x 10

1.4

Acetyl-CoA

[3.3 ± 0.7] x 10-1

2.5

-1

Pyruvate
Pyruvate + AcetylCoA

[2.6 ± 0.3] x 10

2.0

[4.9 ± 0.1] x 10-1

3.8

None*

[1.9 ± 0.2] x 10-1

-

-1

L-aspartate*
[1.3 ± 0.3] x 10
0.70
* Assay performed independently from above data. (n = 3; errors represent standard deviations)

The addition of pyruvate, the CT domain substrate, had a similar impact on the
observed rates of ITF intensity change for the DQ system as it did in the QN system
(Figure V-4B, Table V-1). Again, however, the effect was magnified in the DQ system:
while the observed rate increased only slightly with the addition of pyruvate in the QN
background (Table III-4), the observed rate increased two-fold in the DQ background.
Finally, in the DQ background, the combination of acetyl CoA and pyruvate resulted in a
nearly four-fold increase in the kobs compared to the kobs recorded in the absence of
ligands and a two-fold increase compared to pyruvate alone (Figure V-4B). This nearly
four-fold increase in kobs in the presence of acetyl-CoA and pyruvate is similar to the
observed increase in kobs in the QN system indicating that a kinetic barrier to
translocation (DQ) and intermolecular positioning (QN) was reduced in the presence of
these ligands.
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2.2

Active Site Mutations Contribute to Carrier Domain Positioning

This D907C/Q1118C (DQ) mutant was used as a crosslinking background in
which to further introduce mutations of active site residues that are proposed to interact
with biotin and influence the translocation of the carrier domain: Glu243, Thr876, and
Tyr621 (Lietzan, et al., 2011; Lietzan, et al., 2013) were each mutated to alanine in the
DQ crosslinking background. These mutations are the same as those introduced in the
QN crosslinking background and described in Chapter IV. The catalytic activities of
these mutants are shown in Table V-2 (Lietzan, et al., 2011; Lietzan, et al., 2013). All of
the mutants also form similar degrees of intermolecular crosslinks, (Figure V-5),
prompting the investigation of these mutants with the more sensitive ITF approach.

Figure V-5 D907C/Q1118C SaPC mutants crosslinked.
A..SaPC mutants as listed below at 1 mg/mL were reacted with 5% DMSO or 300 μM BMOE for 120 s,
then quenched with 13 mM DTT for 15 minutes. 5 μg was loaded in each lane. (1) D907C/Q1118C w/
DMSO; (2) D907C/Q1118C w/ BMOE; (3) Q1118C w/ DMSO; (4) Q1118C w/ BMOE; (5)
D907C/Q1118C/E243A w/ DMSO; (6) D907C/Q1118C/E243A w/ BMOE; (7) D907C/Q1118C/Y621A w/
DMSO; (8) D907C/Q1118C/Y621A w/ BMOE; (9) D907C/Q1118C/T876A w/ DMSO; (10)
D907C/Q1118C/T876A w/ BMOE. The molecular weights for the ladders on the left and right are shown
in kDa.
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Table V-2 Kinetic characterization of D907C/Q1118C SaPC and related mutants
SaPC Mutant

Pyruvate carboxylation
kcat, min-1

Wild-Type

1440 ± 100

D907C/Q1118C

740 ± 10

D907C/Q1118C/E243A

3.3 ± 0.2

D907C/Q1118C/Y621A

8.8 ± 0.2

D907C/Q1118C/T876A

N/A

Each of the three mutants were individually mixed with 200 μM BMOE and the
changes in ITF intensity were recorded to gain an initial determination of the role played
by these residues in carrier domain translocation. Representative ITF signal changes upon
introduction of the BMOE crosslinker are shown in Figure V-6.
Overall, increases in kobs in the DQ crosslinking background with either the
Y621A or T876A mutation suggest that these mutations reduce kinetic barriers to carrier
domain translocation (Figure V-7A). The amplitude of the ITF signal change during
crosslinking of the DQT mutant remained similar to the DQ crosslinking background,
suggesting that baseline equilibrium positioning of the carrier domain wasn’t shifted by
this mutation. The DQY mutant displayed a large shift in amplitude compared to the DQ
crosslinking background (Figure V-7B), similar to what was observed in the QN
crosslinking system.
The amplitude of the ITF signal change increased slightly in the DQE mutant
compared to the DQ crosslinking background, suggesting that carrier domain equilibrium
has shifted towards the BC domain in this mutant (Figure V-7B), in agreement with the
conclusions from the QN system in Chapter IV. The rate of ITF signal change during
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crosslinking decreased in DQE SaPC compared to the DQ crosslinking background,
indicating that carrier domain translocation has become more kinetically unfavorable as a
result of this mutation (Figure V-7A).

Figure V-6 DQ SaPC Mutants ITF intensity changes during crosslinking.
D907C/Q1118C SaPC (red), D907C/Q1118C/E243A SaPC (gold), D907C/Q1118C/T876A SaPC (green),
or D907C/Q1118C/Y621A SaPC (blue) was mixed with a final concentration of 200 μM BMOE at t = 0 and
the ITF intensity was recorded for 120 seconds. Tryptophan was excited at 295 nm and ITF emission was
recorded at 350 nm.
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Figure V-7 Observed rates and amplitudes of ITF change from DQ SaPC mutants during
crosslinking with BMOE
D907C/Q1118C (DQ) SaPC, D907C/Q1118C/E243A (DQE) SaPC, D907C/Q1118C/T876A (DQT) SaPC,
and D907C/Q1118C/Y621A (DQY) SaPC were mixed with BMOE at 0 sec. in a stopped-flow instrument
with tryptophan excitation at 295 nm and ITF emission measured at 350 nm. A single exponential decay
equation was fit to the data. A. The relative change in kobs is the kobs obtained for each of the three activesite residue mutants divided by the kobs obtained from the QN background. All measurements were made in
triplicate. Error bars represent the standard deviation. B. The amplitudes of ITF signal change from
Equation II-2 for each of the three active-site residue mutants obtained in panel A were divided by the
amplitude change obtained for the corresponding crosslinking background to yield a relative % change.
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2.3

Mutation of Glu243 Shifts Carrier Domain Positioning Towards BC Domain.

The observed rates of crosslinking of the DQE mutant were attenuated in the
presence of BC domain ligands compared to the DQ crosslinking background (Figure V8A). This is matched by a smaller increase in amplitude of ITF signal change for the
DQE mutant compared to the DQ background (Figure V-8B). In this mutant, biotin has
increased access to the active site. As a result of this, the carrier domain may have
already adopted the positional equilibrium favored by these substrates, which would
lessen the effect of the substrate on carrier domain positioning.
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Figure V-8: Observed rates and amplitudes of ITF change from D907C/Q1118C/E243A SaPC during
crosslinking with BMOE in the absence/presence of ligands.
A. D907C/Q1118C SaPC (black) and D907C/Q1118C/E243A SaPC (pink) were incubated for a minimum
of 10 minutes with 2.5 mM ATP, 0.25 mM acetyl-CoA, 12 mM sodium pyruvate, 5 mM ADP, or 5 mM
phosphonoacetate (PPA) and then mixed with BMOE and an equal concentration of the substrate/effector
at 0 sec. in a stopped-flow instrument with tryptophan excitation at 295 nm and ITF emission measured at
350 nm. Equation II-2 was fit to the data and the kobs obtained for each of the three active-site residue
mutants compared to the kobs obtained from the corresponding crosslinking background mutant. All
measurements were taken in triplicate with the error bars representing the standard deviation in the rate. B.
The amplitudes of ITF signal change from the single exponential equation for each of the three active-site
residue mutants described in panel A were compared to the amplitude obtained for the corresponding
crosslinking background.
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2.4

Thr876 Mediates Translocation of the Carrier Domain in Response to Pyruvate

The observed rates of ITF intensity change in DQT SaPC were similar to those in
the DQ background in the presence of BC domain ligands (Figure V-9A). The amplitudes
of ITF signal change (Figure V-9B) in the presence of these ligands were also similar to
background, in stark contrast to the observations in QNT SaPC, especially in the presence
of ADP and phosphonoacetate. While the large drop in kobs in DQT in the presence of
ADP and phosphonoacetate is similar to that observed in QNT, the difference in how the
amplitudes vary is astounding. The lack of difference in observed amplitudes in DQT
compared to the DQ background indicates that the thermodynamics of translocating have
not changed as a result of this mutation in the presence of ADP and phosphonoacetate.
Rather, the large increase in amplitude observed in QNT compared to QN in the presence
of these ligands indicates a large equilibrium positioning shift towards the BC domain.
The observed amplitudes in DQT were similar to those of the DQ background in
the presence of pyruvate (Figure V-9B). However, the observed rate dramatically
decreased in the presence of pyruvate in the DQT SaPC mutant compared to the DQ
background (Figure V-9A). Combined with a similar effect observed in the QNT SaPC
mutant, these observations strongly suggest that Thr876 mediates the effect of pyruvate
on carrier domain translocation (DQT) and positioning (QNT). In the presence of
pyruvate with this mutation, there is a larger kinetic barrier to overcome to translocate or
adopt positioning in the exo-binding site. Finally, the observed rate of ITF intensity
change in DQT SaPC in the presence of acetyl-CoA increased approximately 4-fold
compared to in the absence of acetyl-CoA suggesting that a kinetic barrier to the
translocation of the carrier domain has been reduced by the mutation of this active site
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threonine (Figure V-9A). A larger change in the amplitude of ITF signal change in the
presence of acetyl-CoA compared to the DQ crosslinking background in the presence of
acetyl-CoA indicates that carrier domain translocation may be more thermodynamically
favorable as a result of this mutation in the presence of acetyl-CoA.
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Figure V-9: Observed rates and amplitudes of ITF change from D907C/Q1118C/T876A SaPC during
crosslinking with BMOE in the absence/presence of ligands.
A. D907C/Q1118C SaPC (black) and D907C/Q1118C/T876A SaPC (purple) were incubated for a
minimum of 10 minutes with 2.5 mM ATP, 0.25 mM acetyl-CoA, 12 mM sodium pyruvate, 5 mM ADP, or
5 mM phosphonoacetate (PPA) and then mixed with BMOE and an equal concentration of the
substrate/effector at 0 sec. in a stopped-flow instrument with tryptophan excitation at 295 nm and ITF
emission measured at 350 nm. Equation II-2 was fit to the data and the kobs obtained for each of the three
active-site residue mutants compared to the kobs obtained from the corresponding crosslinking background
mutant. All measurements were taken in triplicate with the error bars representing the standard deviation in
the rate. B. The amplitudes of ITF signal change from the single exponential equation for each of the three
active-site residue mutants described in panel A were compared to the amplitude obtained for the
corresponding crosslinking background.
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2.5
CT Domain Tyr621 Has A Crucial Role in Mediating Carrier Domain Positional
Response to Pyruvate and Acetyl-CoA

As described in Chapter IV and Chapter VI, this data may not be able to be
interpreted in the same manner as the other mutants given the dramatic difference in ITF
signals observed. The observed rate of ITF intensity change varied similarly in the DQY
mutant as in the QNY mutant, with only small decreases in kobs in the presence of BC
domain ligands (Figure V-10A), further evidence that alterations to one domain, such as
the Y621A CT domain mutation, may affect the behavior of the other active site, as
discussed in Chapter IV. While acetyl-CoA dramatically increased kobs in the DQ
crosslinking background, it had virtually no effect in DQY SaPC (Figure V-10A). The
effect of acetyl-CoA on the amplitude of the ITF signal changes is also diminished
(Figure V-10B). Combined with the observations from QNY SaPC, this strongly suggests
that Tyr621 is necessary for acetyl-CoA to affect carrier domain positioning (QNY) and
translocation (DQY). The effect of pyruvate on observed rates of ITF intensity change
was also reduced in this mutant, but not completely abolished (Figure V-10A). Similar to
QNY SaPC, a large increase in the magnitude of the amplitude change was observed in
DQY SaPC when crosslinked with pyruvate, as well, indicating that both carrier domain
positioning (QNY) and translocation (DQY) in this mutant still responds to the presence
of pyruvate (Figure V-10B).
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Figure V-10: Observed rates and amplitudes of ITF change from D907C/Q1118C/Y621A SaPC
during crosslinking with BMOE in the absence/presence of ligands.
A. D907C/Q1118C SaPC (black) and D907C/Q1118C/Y621A SaPC (green) were incubated for a
minimum of 10 minutes with 2.5 mM ATP, 0.25 mM acetyl-CoA, 12 mM sodium pyruvate, 5 mM ADP, or
5 mM phosphonoacetate (PPA) and then mixed with BMOE and an equal concentration of the
substrate/effector at 0 sec. in a stopped-flow instrument with tryptophan excitation at 295 nm and ITF
emission measured at 350 nm. Equation II-2 was fit to the data and the kobs obtained for each of the three
active-site residue mutants compared to the kobs obtained from the corresponding crosslinking background
mutant. All measurements were taken in triplicate with the error bars representing the standard deviation in
the rate. B. The amplitudes of ITF signal change from the single exponential equation for each of the three
active-site residue mutants described in panel A were compared to the amplitude obtained for the
corresponding crosslinking background.
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3. Discussion
In the current study, the crosslinking system, D907C/Q1118C SaPC, was
designed to trap the carrier domain in a conformation with biotin projecting into the CT
domain active site. An important control experiment was overlooked in the initial
evaluation of this system and the Q1118C mutation was not assessed until after all the
data had been collected on the DQ system. Due to the observation that the single Q1118C
mutation readily crosslinked two BCCP domains through a Q1118C-Q1118C crosslink,
the trapped conformation captured in the DQ system actually represents the carrier
domain in a state of translocation, outside of either active site. However, due to the
absence of single mutant controls for these experiments, the data is being interpreted as it
is, but there is added uncertainty to the validity of these interpretations. For instance,
some amount of D907C-Q1118C crosslinking may result in the presence of some or all
of these mutations or in the presence of ligands, which would substantially weaken these
interpretations.
The presence of acetyl-CoA resulted in a 2.5-fold increase in observed ITF
signal change rates when crosslinking compared to the rate observed in the absence of
ligands, in stark contrast to the negligible effect of acetyl-CoA on observed rates in the
QN crosslinking background (Table V-1, Figure V-4). A moderate downward amplitude
change was also observed in the presence of acetyl-CoA, which is interpreted to suggest a
shift in carrier domain positioning away from the BC domain in favor of translocation.
This data suggests that the presence of acetyl-CoA favors the release of the carrier
domain from the BC domain for translocation. In order to crosslink the carrier domain in
this system, the carrier domain must be in motion. Since acetyl-CoA increases the kobs
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2.5-fold compared to its absence, translocation of the carrier domain between sites is
increasing. The presence of pyruvate led to a two-fold increase of kobs while the
combination of pyruvate and acetyl-CoA during crosslinking in DQ SaPC produced a
nearly four-fold increase in kobs compared to kobs in the absence of ligands or a two-fold
increase compared to kobs in just the presence of pyruvate (Table V-1, Figure V-4),
suggesting a large drop in the kinetic barrier for translocation between sites. This result is
consistent with observations of a 2-fold activation of SaPC catalytic activity by acetylCoA (Yu, et al., 2009).
The amplitude of ITF signal changes during crosslinking in the presence of BC
domain ligands was observed to be smaller in DQE SaPC than in the DQ SaPC
crosslinking background (Figure V-8B), suggesting that the mutation shifts the carrier
domain positioning equilibrium towards the BC domain. Combined with the reduced
observed rate of crosslinking in the absence of substrates and the reduced effect of BC
domain substrates on kobs, these results are consistent with the proposal that Glu243 is
part of a gatekeeper system to control the access of biotin to the BC domain active site.
The E243A mutation in SaPC resulted in a larger kinetic barrier for carrier domain
translocation. This greater kinetic barrier is a consequence of stabilizing the BCCP-BC
domain interaction in the ground state. This is illustrated in Figure V-11.
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Figure V-11: Free energy diagram for DQE SaPC
A potential energy landscape is shown for the DQE SaPC mutant. The Gibbs free energy (G) is plotted
against the translocation progress of BCCP between the BC and CT domains. The kinetic barrier is
represented by a dashed black line. The wild-type reaction is represented in black while the mutation is
represented in red.

Observed ITF signal change rates during crosslinking were increased in the DQY
SaPC mutant by 50% compared to the observed rates in the DQ background (Figure V8A), suggesting that the carrier domain was less anchored in the CT domain and freer to
translocate and adopt a variety of conformations. Just as in the QNY system, a large
increase in amplitude was observed in DQY SaPC, indicating a shift in carrier domain
positioning towards the BC domain (Figure V-10B) as illustrated in Figure V-12. This is
consistent with the proposal that Tyr621 stabilizes carrier domain positioning in the CT
domain in the presence of pyruvate (Lietzan, et al., 2013). The loss of this stabilizing
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interaction in the CT domain of this mutant, results in a shift in carrier domain
positioning towards the BC domain.
The effect of acetyl-CoA in the DQY SaPC mutant was nearly abolished with no
significant difference in the kobs between the DQY SaPC and the DQ crosslinking
background (Figure V-10A). Similarly, the observed amplitude in the presence of acetylCoA was also reduced in this mutant (Figure V-10B). These results indicate that the
biotin-binding pocket in the CT domain active site plays an important role in mediating
the effect of acetyl-CoA on carrier domain translocation. While acetyl-CoA binds near
the flexible linker to the carrier domain, the flexible carrier arm is ultimately stabilized by
interactions with biotin, such as those at the cleft of the exo-binding site. For example,
the interaction between Tyr621 and biotin stabilizes the carrier domain in an
intermolecular position. Acetyl-CoA has been shown to favor that conformation. In the
absence of this Tyr621-biotin interaction, the carrier domain is granted greater
translocational freedom.
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Figure V-12: Free energy diagram for DQY SaPC
A potential energy landscape is shown for the DQY SaPC mutant. The Gibbs free energy (G) is plotted
against the translocation progress of BCCP between the BC and CT domains. The kinetic barrier is
represented by a dashed black line. The wild-type reaction is represented in black while the mutation is
represented in red.

The T876A mutant displayed the smallest amplitude changes in the absence of
ligands compared to DQ crosslinking background (Figure V-7B). A remarkably
decreased kobs in the presence of pyruvate was observed in DQT SaPC with a rate ~20%
of that observed in the DQ background (Figure V-9A). The decreased observed rates of
ITF intensity change in the presence of pyruvate for this mutant support the hypothesis
by Zeczycki, et al. that biotin positioning is stabilized in the CT domain active site by the
T876A mutant in the presence of pyruvate (Zeczycki, et al., 2009). With the DQ SaPC
system capturing the translocation of the carrier domain, a decreased kobs indicates that
the combination of this active site mutation and the presence of pyruvate has increased a
kinetic barrier to carrier domain translocation.
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The observed amplitude in the DQT mutant did not significantly change
compared to the DQ crosslinking background in the presence of BC domain ligands,
suggesting that mutation to the CT domain Thr876 did not alter the ground state free
energies in the presence of ATP or ADP (Figure V-9B). However, there was a dramatic
reduction in kobs for the DQT SaPC in the presence of ADP and phosphonoacetate,
compared to the DQ crosslinking background (Figure V-9A), indicating that the carrier
domain is favored to remain interacting with the BC domain in these mutants as a
consequence of a larger kinetic barrier. These observations are consistent with the
observation by Zeczycki, et al. that mutation of Thr882 in RePC (the analogous residue to
Thr876 in SaPC) increased the rate of ADP phosphorylation in the BC domain (Zeczycki,
et al., 2009). The authors proposed that carrier domain positioning was shifted towards
the BC domain as a result of this mutation, increasing the presence of biotin in the active
site and accelerating the rate of ADP phosphorylation. The DQT data presented in this
chapter suggest that the thermodynamics of translocation largely weren’t affected by this
mutation, with the exception of pyruvate, as discussed. Rather, carrier domain
translocation has become more unfavorable due to an increase in the energy barrier for
translocation in the presence of ADP and phosphonoacetate, hinting at a complex change
in the energy landscape in this mutation. This special case is illustrated in Figure V-13
where both the lowering of a kinetic barrier by the mutation and the thermodynamic
change proposed by the addition of ADP and phosphonoacetate is shown. The reduced
Gibbs free energy of the BCCP-BC domain interaction in the presence of ADP and
phosphonoacetate results in both a shift in equilibrium positioning and a larger kinetic
barrier to translocation relative to the absence of ligands.
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In this chapter, I have presented data from a novel study investigating the kinetic
and thermodynamic effects of active site mutations in PC on carrier domain translocation
by directly observing the capture of the carrier domain “in flight”. These results have
further illustrated the important role each active site residue plays in shifting carrier
domain positioning and how carrier domain positioning can be controlled within the
conformational selection model.

Figure V-13: Energy landscape diagram for DQT SaPC
A potential energy landscape is shown for the DQE SaPC mutant. The Gibbs free energy (G) is plotted
against the translocation progress of BCCP between the BC and CT domains. The kinetic barrier is
represented by a dashed black line. The wild-type reaction is represented in black while the mutation is
represented in blue. The effect of the presence of ADP and phosphonoacetate (PPA) in the mutant on this
landscape is shown in red while in the DQT mutant it is shown in blue.
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VI.

CONCLUSIONS

1.
Mechanism Governing Carrier Domain Translocation in S. aureus Pyruvate
Carboxylase

In this section, the conformational selection model will be utilized to explain the
translocation of carrier domain in S. aureus pyruvate carboxylase. The application of this
model will attempt to integrate all of the results from the current study to generate a
comprehensive view of how carrier domain translocation is controlled. The contribution
of each domain to the regulation of carrier domain positioning will be discussed. A model
will be proposed for how acetyl-CoA may influence carrier domain positioning that
attempts to account for a wide-range of observations. Finally, the findings discussed here
will be compared to several multi-domain enzymes.
Conformational selection governs carrier domain positioning. As introduced in
Chapter I, the induced conformational change model would predict that the carrier
domain in PC remains in one conformation in the absence of a ligand (EasterbrookSmith, et al., 1976; Goodall, et al., 1981; Attwood and Wallace, 1986). Alternatively, the
conformational selection model predicts that the carrier domain exists in an ensemble of
conformations regardless of ligand present. The results presented in Chapter III all
support the conformational selection model as the mechanism governing carrier domain
positioning. The carrier domain was observed to position itself intermolecularly or get
trapped in the state of translocation between sites irrespective of the presence or identity
of ligands. Under no circumstances was the carrier domain unable to be trapped in either
“state”, consistent with the conformational selection model. It is important to note that an
assumption has been made that the QN crosslinking system can distinguish between the
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BCCP-exo binding site and BCCP-CT domain conformations. An X-ray crystal structure
of crosslinked PC or a comparison between the QN system and a system that traps the
carrier domain while interacting with the CT domain active site would provide evidence
for this, as no evidence currently exists. However, the distance between the Q891C and
N1102, which crosslink in the exo-binding site conformation, are ~22 Å apart when the
carrier domain is positioned with biotin in the CT domain active site (PDB ID: 3BG5).
This is a much greater distance than the 8 Å BMOE crosslinker used throughout these
experiments, which supports the ability of this system to distinguish the two
conformations.
BC domain ligands shift carrier domain positioning towards the BC domain as
observed by the increased observed amplitudes of ITF signal change when crosslinking
the carrier domain during translocation or in the exo-binding site conformation in the
presence of BC domain ligands compared to in the absence of ligands. Observed rates of
ITF signal change (kobs) decreased when the carrier domain was crosslinked in either
system in the presence of BC domain ligands, indicating that a kinetic barrier increased
for the translocation of the carrier domain and for the positioning of the carrier domain
away from the BC domain in the exo-binding site (Tables V-1, III-4). The observed
amplitudes also increased during crosslinking in the QN or DQ system in the presence of
BC domain ligands, indicating a shift in carrier domain positioning towards the BC
domain (Figures V-7B, IV-3B). The results presented here are also consistent with
observations in 1965 when Scrutton and Utter observed that BC domain substrates
protected PC from avidin deactivation (Scrutton and Utter, 1965). Avidin binds to the
carrier domain-tethered biotin, preventing it from contributing to catalysis. When biotin
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is positioned in the BC domain active site, such as when BC domain ligands are present,
biotin would be unavailable to react with avidin, leading to a reduction in deactivation by
avidin binding.
Pyruvate, the CT domain substrate, has the opposite effect, as expected, shifting
carrier domain positioning towards an intermolecular position. However, there is some
subtlety to this behavior. The creation of the two different crosslinking constructs has
allowed a finer determination to be made of what carrier domain state is favored in the
presence of pyruvate. The conformation in which the carrier domain is translocating
between active sites, trapped by D907C/Q1118C SaPC, is kinetically favored, with a 2fold increase in kobs when crosslinking in the presence of pyruvate. In contrast, the
presence of pyruvate only yields a 1.1-fold increase in kobs when crosslinking the carrier
domain in the exo-binding site conformation (Tables III-4, V-1). However, the observed
amplitudes do not differ much between crosslinking the carrier domain with biotin
positioned in the exo-binding site or in the translocation state. Pyruvate has been shown
to bind/unbind approximately twice per catalytic cycle, diffusing relatively easily into
and out of the active site (Warren G.B. and Tipton K.F., 1974, Cheung Y.F. and Walsh
C., 1976, Zeczycki, T.N., et al., 2011). When pyruvate dissociates, the biotin-binding
pocket that Lietzan, et al. observed would no longer be stabilized, making the BCCP-CT
interaction less favorable (Lietzan, et al., 2013). Therefore, the carrier domain would be
more likely to leave the CT domain after which BCCP-biotin would be free to translocate
and could become temporarily stabilized in the nearby exo-binding site, providing an
explanation for the similar amplitude changes observed in ITF signal changes when
crosslinking to either conformation. These observations also suggest that the role of the
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exo-binding site may be to stabilize the carrier domain close to the CT domain,
effectively increasing the local concentration of carboxybiotin.
My findings in favor of the conformational selection model are not inconsistent
with early kinetic observations in PC (Easterbrook-Smith, et al., 1976, Goodall, et al.,
1981, Attwood and Wallace, 1986) in which the authors followed the decarboxylation of
biotin and observed that the rate of biotin decarboxylation increased in the presence of
CT domain ligands. These results were interpreted to suggest that CT domain ligands
induce carrier domain translocation towards the CT domain. Rather, the carrier domain
positioning, which exists in an equilibrium, was shifted to favor the CT domain in the
presence of CT domain ligands. The CT domain promotes the decarboxylation of biotin,
so an increased presence of carboxybiotin in the CT domain naturally leads to an
increased rate of decarboxylation. Conversely, without a CT domain ligand present, the
carrier domain may still attain this conformation, but biotin would not be stabilized as the
active site tyrosine would not be properly positioned to stabilize biotin in the active site.
Thus, rates of carboxybiotin decarboxylation in the absence of a CT domain ligand would
be low.
Physiological Relevance. The induced conformational change model might seem
to be the more efficient model for governing carrier domain positioning in PC or other
enzymes since the carrier domain would only translocate to the next active site when the
relevant substrate is bound and the active site ready to accept the intermediate product
from the first active site. However, the KM value for many enzymes, the ligand
concentration at which half of the binding sites have ligand bound, is often close to the
physiological concentration of the respective substrate (Waelbroeck, 2007; Berg, et al.,

147
2002). If the assumption that all active sites must have substrate bound for an induced
conformational change to take place is valid, this model would lead to a less productive
enzyme when substrate concentrations are near or below KM. In this situation, substrate
could be bound without carrier domain translocation or reaction completion. However,
the conformational selection model would allow for comparatively more productivity in
these conditions. In a case where substrate concentrations are around the KM value,
approximately half of the active sites would have substrate bound. Thus, those active
sites would favor interactions with the carrier domain, leading to the formation of
product. Comparatively, if the same enzyme were governed by the induced
conformational change model, very little product would be formed since it would be rarer
to have all active sites bound with substrate to induce carrier domain translocation.
Overall, when substrate values are near or below KM, I believe that the conformational
selection would be favored for organismal fitness.
Conversely, if the assumption that all active sites must have substrate bound for
an induced conformational change to take place is not valid, there would not be such a
clear distinction between these models and organismal fitness. For example, if half of the
active sites were required to be bound with substrate for an induced conformational
change to take place, this model would perform similarly to the conformational selection
model when substrate concentrations are at KM, since by the definition of KM,
approximately half of the active sites would have substrate bound. The complexity of this
topic is highlighted by studies that have investigated proteins that can utilize both
models, dependent upon ligand concentration. Dihydrofolate reductase (DHFR) was
observed to operate via conformational selection at low ligand concentrations and via an
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induced fit mechanism at high ligand concentrations. At intermediate concentrations,
both mechanisms were observed to be in use (Hammes, et al., 2009; Grieves and Zhou,
2014). Thus, enzymes may have evolved more than one mechanism to ensure the
efficient coupling of reactions over a range of substrate concentrations.
BC domain interactions with the carrier domain. The interface between the carrier
domain and BC domain is composed of the B-subdomain lid, a solvent-exposed loop
belonging to the C-subdomain, and the carrier domain (Lietzan, et al., 2011). Only two
pairs of residues directly interact while the majority of contact between these domains are
non-specific, burying ~1200 Å2. Given the lack of direct or conserved interactions, it’s
reasonable to expect that changes in the positioning of the B-subdomain lid would alter
the docking favorability of the carrier domain to the BC domain. B-subdomain lid
conformations have been observed to shift to more closed conformations in the presence
of BC domain ligands in several crystal structures (Kondo S., et al., 2004, Thoden JB, et
al., 2000, Chou CL, et al., 2009, Chou CY and Tong L., 2011, Lietzan, et al., 2011). The
presence of tethered biotin was observed to lead to tighter lid closure than the presence of
free biotin (Lietzan, et al., 2011). This relationship between the presence of BC domain
ligands and the composition of the BCCP-BC domain interface may be the primary
mechanism in the BC domain to govern carrier domain positioning.
The second BC domain mechanism that may play a role in shifting carrier domain
positioning was observed by Lietzan, et al. in 2011 in an X-ray crystal structure of
T882A RePC that was co-crystallized with MgADP and phosphonoacetate (Lietzan, et al.
2011). In this structure, the carrier domain was docked at the BC domain, which was the
first high-resolution structure to capture this, but carboxybiotin was positioned outside of
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the active site. A pair of residues that were located between the active site and the entry
site for carboxybiotin, Arg353 and Glu248, were oriented such that a salt bridge formed
between them, stabilizing the positioning of Arg353 which was proposed to preclude
carboxybiotin access. The authors proposed that this interaction may prevent abortive
decarboxylation, serving as a mechanism to control carboxybiotin positioning. This
interaction between these residues and biotin had not since been studied to determine the
effect on carrier domain positioning.
As discussed in chapter IV and V, mutation of Glu243 in SaPC, the homolog of
Glu248 in RePC, resulted in a shift in carrier domain positioning towards the BC domain,
consistent with proposals that this residue may preclude carboxybiotin access to the BC
domain active site. Presumably, a more favorable interaction between the BC and BCCP
domains occurs with increased carboxybiotin access to the BC domain active site. When
crosslinking to the exo-binding site conformation, the presence of BC domain substrates
led to an increase in the observed amplitudes of ITF signal change in the E243A SaPC
mutant, indicating a greater shift in carrier domain positioning towards the BC domain as
a result of this mutation (Figure IV-3B). However, when capturing the translocating
carrier domain, the opposite results were observed, potentially indicating an increased
amount of carrier domain translocation (Figure V-8B). Rates of ITF signal change
remained unchanged in this mutant when crosslinking to the exo-binding site in the
presence of BC domain ligands (Figure IV-3A). However, the decrease in kobs was
attenuated when crosslinking in the DQE mutant with BC domain ligands present
compared to the decrease in kobs in the DQ background (Figure V-8A). While it might
seem that this indicates that this mutation has lowered a kinetic barrier to the
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translocation of the carrier domain in the presence of BC domain ligands, recall that in
the absence of any ligands, the kobs for this mutant was decreased compared to the DQ
background (Figure V-6). This indicates that the BC domain substrates have less of an
effect in this mutant because a kinetic barrier to carrier domain translocation has
increased as a consequence of the mutation itself. Conversely, the rate of crosslinking
translocating carrier domains in DQE was attenuated and indistinguishable from the
crosslinking background in the presence of pyruvate. This indicates that a kinetic barrier
has increased for the translocation of the carrier domain in the presence of pyruvate,
consistent with the effect observed in the presence of BC domain ligands.
CT domain interactions with the carrier domain. When the carrier domain is
positioned at the CT domain, there are several pairs of residues that engage in hydrogenbonding and many hydrophobic interactions occur, as well (Xiang S. and Tong L., 2008).
However, no alterations to the binding interface have been reported in the
presence/absence of ligands. Rather, small conformational changes occur in the active
site in the presence of a CT domain ligand, such as pyruvate (Lietzan, et al., 2013). The
carboxyl moiety of pyruvate was shown to form a salt bridge with the guanidinium group
of Arg621 (RePC numbering), which promoted the movement of an active site loop. This
loop movement ultimately resulted in a reorientation of Tyr628 (Tyr621 in SaPC) to
rotate towards the CT domain active site. Based on an overlay with H. sapiens PC, biotin
was proposed to position itself over this tyrosine in a stable interaction between the sulfur
of the thiophene ring of biotin and the aromatic ring of tyrosine. The rotation of tyrosine
towards the active site in the presence of pyruvate has been proposed to stabilize biotin in
the CT domain active site.
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The findings that I presented in chapters IV and V have shown the important role
of this residue in the positioning of the carrier domain with the CT domain. The BCCPCT domain interaction likely became less thermodynamically favorable in the presence
of pyruvate in the DQY mutant. This was observed as a large increase in kobs when
trapping the translocating carrier domain in the DQY mutant without any ligands present,
indicating that a kinetic barrier has decreased for the translocation of the carrier domain
(Figure V-7A). Similarly, a large change in the observed amplitude when trapping the
translocating carrier domain was observed in this mutant, indicating a large shift in
carrier domain equilibrium away from the BC domain, potentially towards the
translocation state and/or an intermolecular interaction (Figure V-7B). A large shift in
amplitude was also observed in the QNY mutant when crosslinking in the absence of
ligands, supporting the proposal that the carrier domain equilibrium has shifted towards
the exo-binding site (Figure IV-5B). It is clear that the kinetic and thermodynamic
landscape for carrier domain interaction with the CT domain has been dramatically
altered, presumably with the CT domain active site becoming more unfavorable for the
positioning of biotin and the carrier domain in this mutant.
Only minimal decreases in kobs were observed when crosslinking in the QNY or
DQY mutants in the presence of BC domain ligands (Figures IV-5A, V-10A). This was a
strange result in that a CT domain mutation altered the effect of BC domain ligands on
carrier domain positioning at the exo-binding site. This result may support previous
observations that mutations or ligand binding in one active site can have an effect on a
distant active site. This effect was recently observed in SaPC and RePC, respectively,
with results interpreted to suggest communication between the BC and CT domains
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(Westerhold, et al., 2016; Lietzan, et al., 2014). However, no specific mechanism for this
has been proposed or observed to date. Given that the symmetric/asymmetric
conformation of PC is linked to carrier domain positioning (St. Maurice, et al., 2007; Yu,
et al., 2009; Lasso, et al., 2014), this communication could be the result of shifts in the
carrier domain positional equilibrium caused by ligand binding or mutations that
influence the overall symmetric state of PC. If this were true, for example, the mutation
of Tyr621 would be predicted to disrupt acetyl-CoA binding. Since Tyr621 presumably
shifts the carrier domain equilibrium away from the CT domain, the asymmetric form of
PC would be more favorable. This form of PC has two binding sites for acetyl-CoA,
while the disfavored symmetric form has four binding sites (Lasso, et al., 2014). Thus,
this mutation may ultimately have an effect on the cooperativity and observed Hill
coefficients of acetyl-CoA binding.
Pyruvate was observed to still have an effect on kobs and amplitudes in the Y621A
mutants. The effect of pyruvate on carrier domain positioning may be reduced when
crosslinking in the DQY mutant compared to the QNY mutant, but there is still a
relatively large change in the amplitude of observed ITF signal change compared to in the
absence of pyruvate, indicating there is likely another interaction that occurs between
pyruvate binding and biotin (Figures IV-5B, V-10B). Interestingly, a difference exists in
the response to pyruvate between the QNY and DQY mutants. In the QNY mutant,
pyruvate increases the kobs compared to the QN background in the presence of pyruvate
(Figure IV-5A). Conversely, in the DQY mutant, this increase in kobs is attenuated (Figure
V-10A). Taken together, this suggests a reduced kinetic barrier for the positioning of the
carrier domain in the exo-binding site in the presence of pyruvate while pyruvate has a
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reduced effect on lowering the kinetic barrier for carrier domain translocation. In the
QNY system, the destabilization of the carrier domain in the CT domain by the loss of
the biotin-Tyr621 interaction can explain this observation. A reduced interaction energy
increases the off rate for the BCCP domain in the CT domain, thereby increasing the
likelihood of positioning at the exo-binding site. Similarly, without the Tyr621 residue to
“communicate” the presence of pyruvate to biotin and stabilize biotin in the CT domain,
the effect of pyruvate on translocation will be weakened, as observed, with the carrier
domain likely remaining stabilized in other low energy wells, such as the exo-binding site
or BC domain.
The second residue CT domain active site residue that biotin was proposed to
interact with is Thr876 in SaPC numbering (Thr882 in RePC). The N-1 position of biotin
is proposed to hydrogen-bond with this residue when biotin is positioned in the active site
(Zeczycki, et al, 2009). In the presence of ADP and phosphonoacetate, I observed that a
kinetic barrier has dramatically increased for the translocation of the carrier domain and
for the positioning of the carrier domain in the exo-binding site (Figures IV-4A, V-9A).
The carrier domain positioning was also observed to shift towards the BC domain with a
much larger amplitude in the presence of ADP and phosphonoacetate in QNT SaPC
compared to the QN background, whereas the amplitude is virtually unchanged when
crosslinking the translocating carrier domains (Figure V-9B). This large equilibrium shift
suggests Thr876 may have a role stabilizing biotin in the CT domain active site, where
this residue is located.
The observed behavior of the T876A mutants is also dramatically altered in the
presence of pyruvate. Whether crosslinking the carrier domain to the exo-binding site or
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crosslinking translocating carrier domains in the presence of pyruvate, a kinetic barrier
has increased, with slower rates of ITF signal change observed compared to the
crosslinking backgrounds (Figures IV-4A, V-9A). This observation strongly supports the
proposal by Zeczycki, et al. that because the T876A mutant cannot complete the protontransfer step, the reaction cannot be completed and biotin would remain in the CT domain
active site (Zeczycki, et al., 2009). If the carrier domain were “trapped” in the CT
domain, translocation would become more unfavorable, as well as positioning in the exobinding site.
A comparable observation to the QNY/DQY systems was made in the presence of
pyruvate in the QNT/DQT systems in that the effect of pyruvate was attenuated but not
abolished. This residue may be the other residue predicted above to mediate the effect of
pyruvate on carrier domain positioning and translocation. The CT domain active site has
a network of hydrogen bonds between pyruvate and biotin. Disruption of that by
mutation of this residue may explain these observations. An experiment observing the
effects of pyruvate on kobs and amplitudes in double mutant crosslinking systems in
which both Tyr621 and Thr876 are mutated would allow further clarification of the roles
of these residues in mediating the effect of pyruvate on carrier domain positioning.
Role of acetyl-CoA in carrier domain positioning. A multitude of kinetic and
structural studies have been performed to determine how acetyl-CoA activates PC.
Kinetic studies have determined that acetyl-CoA stimulates the BC domain reaction
(Attwood and Graneri, 1992; Branson, et al., 2002; Legge, Branson, and Attwood, 1996;
Phillips, et al., 1992; Jitrapakdee, et al., 2010) and not the CT domain reaction (Attwood
and Wallace, 1986). However, the exact mechanism by which this acceleration occurs is
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not known. It has been proposed that acetyl-CoA may promote Mg2+ binding (Attwood
and Graneri, 1992) or substrate binding in the BC domain (Legge, Branson and Attwood,
1996). The structure of RePC with acetyl-CoA bound did not show any significant
conformational change in the BC domain ligand binding sites, suggesting that the
activation effects of acetyl-CoA extend beyond the BC domain active site (St. Maurice, et
al., 2007) (Lietzan, et al., 2011).
Acetyl-CoA has also been shown to have a role in coupling the two half-reactions,
with the coupling efficiency being increased in the presence of acetyl-CoA. Because the
translocation of the carrier domain is what physically couples these reactions, it was
proposed that the translocation of the carrier domain was regulated by acetyl-CoA
(Zeczycki, et al., 2011B). Pyruvate and MgATP were also shown to be
thermodynamically linked in the presence of acetyl-CoA (Westerhold, et al., 2017). In the
same study, ATP cleavage was observed to be promoted by pyruvate binding in the CT
domain, which was suggested to show communication between the two active sites,
possibly connected by carrier domain translocation. Westerhold, et al. also showed that
activation entropy decreased in SaPC in the presence of acetyl-CoA, which the authors
suggested meant that carrier domain movement was restricted in the presence of acetylCoA (Westerhold, et al., 2017). While investigating carrier domain translocation
pathways, Liu, et al. (Liu, et al., 2018) showed that acetyl-CoA stimulates catalytic
activity for the translocation pathway between the intramolecular BC domain and
intermolecular CT domain, which is consistent with the observation by Westerhold, et al.
that activation entropy is decreased by acetyl-CoA. Finally, in studies investigating the
roles of allosteric binding site residues in RePC, it was proposed that acetyl-CoA favored
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the symmetric conformation of PC which is associated with the carrier domain positioned
across the face of the tetramer (Choosangtong, et al., 2015; Sirithanakorn, et al., 2016).
I have observed that acetyl-CoA, when mixed with SaPC, promotes a carrier
domain conformation very similar, if not identical, to that captured by crosslinking
translocating carrier domains (Figure V-4). A kinetic barrier for the translocation of the
carrier domain and for the intermolecular positioning of the carrier domain was lowered
when acetyl-CoA is added to either ATP or pyruvate (Figures IV-1, V-4). Further, a
decrease in the amplitude of the ITF signal when crosslinking to the exo-binding site
conformation was observed in the presence of acetyl-CoA, indicating an equilibrium
positioning shift of the carrier domain towards an intermolecular interaction (Figure IV3). A similar decrease in amplitude was observed when crosslinking translocating carrier
domains, suggesting that it has become more thermodynamically favorable to translocate
between active sites (Figure V-8). Further, I have observed that mutation of Tyr621
virtually abolished the effect of acetyl-CoA on carrier domain positioning and
translocation (Figures IV-5, V-10. While acetyl-CoA may promote positioning of the
carrier domain at or near the CT domain, without a way to stabilize the C-terminal side of
the flexible carrier domain in a specific conformation, such as when Tyr621 is mutated,
the effect of acetyl-CoA on carrier domain positioning was lost (Figures IV-5, V-10).
Based on these observations, I conclude that acetyl-CoA favors the release of the
carrier domain from the BC domain and stabilizes its positioning at or near the opposing
CT domain. The release of the carrier domain from the BC domain would allow the
opening of the B-subdomain lid, aiding the release of products and binding of Mg2+ and
nucleotides (Menefee and Zeczycki, 2014). Acetyl-CoA has been observed to decrease
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the affinity of chicken liver PC for nucleotides (Geeves, et al., 1995). This is consistent
with the B-subdomain lid attaining a more open conformation due to a shift in carrier
domain positioning away from the BC domain, allowing easier diffusion of ligands in
and out of the active site. Further, as introduced in Section I.2.2.2, the B-subdomain lid
must close for proper positioning of the P-loop, which aids in substrate binding. If the Bsubdomain lid is in a more open conformation, the P-loop would most likely be poorly
positioned to aid substrate binding, which could increase the dissociation constant.
However, the overall effect of acetyl-CoA on BC domain reaction steps is complex. For
instance, ATP-cleavage was determined to be the rate-limiting step in the acetyl-CoA
sensitive sheep and chicken liver PC enzymes (Goodall, et al., 1981; Attwood and
Wallace, 1986). Acetyl-CoA was also shown to increase the productive cleavage of ATP
in chicken liver PC (Legge, et al., 1996). Overall, differences exist between PCs from
different species in which step is rate-limiting, which could be a result of changes in the
locus of activation by acetyl-CoA (Adina-Zada, et al., 2012).
Overall, while it may seem contradictory to have evidence that acetyl-CoA
enhances BC domain catalysis and evidence that acetyl-CoA favors the release of the
carrier domain and translocation away from the BC domain, findings from a recent cryoEM study of SaPC help to unite these observations (Lasso, et al., 2014). In this study,
distinct populations of SaPC were observed in either the asymmetric conformation or the
symmetric conformation. In the asymmetric conformation, with the carrier domain
interacting with the BC domain, two binding sites for acetyl-CoA exist. Conversely, in
the symmetric conformation, four acetyl-CoA binding sites exist. Thus, irrespective of
the positioning of the carrier domain, acetyl-CoA could be present and enhancing BC
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domain catalysis. As acetyl-CoA concentrations increase, the symmetric conformation
would be favored, shifting carrier domain positioning towards an intermolecular
interaction. By promoting a specific or more limited set of conformations near the CT
domain, acetyl-CoA would be favoring the translocation pathway between the
intramolecular BC domain and intermolecular CT domain, as Liu, et al. observed (Liu, et
al., 2018). The constraint of favorable carrier domain conformations by acetyl-CoA
would also have the effect of reducing activation entropy, as the carrier domain’s
conformational flexibility would be reduced, as Westerhold, et al. observed (Westerhold,
et al., 2017).
Role of biotin in carrier domain positioning. While many studies suggest that
biotin plays a key role in the positioning of the carrier domain and coupling of the halfreactions, it has been difficult to study the role of biotin in carrier domain positioning
since the loss of biotin abolishes much of the catalytic activity of PC (Zeczycki, et al.
2009; Lietzan, et al., 2014; Menefee and Zeczycki, 2014). As my studies are independent
of catalytic activity and I can directly observe carrier domain positioning, the systems
presented here enable me to study the role of biotin in carrier domain positioning. The
loss of biotin was observed to greatly diminish carrier domain sensitivity to BC domain
substrates (Figure III-8). Unfortunately, ITF signals are dependent on the presence of
biotin, making more detailed observations impossible at the current time (Figure III-6C).
However, given the importance of the previously discussed residues that interact with
biotin to affect carrier domain positioning, I propose that biotin leads the interaction
between the carrier domain and the active sites/exo-binding site when establishing an
equilibrium or when an equilibrium shift occurs due to the presence of a ligand. An
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inability to stabilize a conformation due to a mutation of one of these residues, such as
Tyr621, results in dramatically altered carrier domain behavior.
However, biotin and the interactions with active site residues are not the sole
participant in shifting carrier domain positioning. In the unbiotinylated SaPC mutant, the
presence of ADP and phosphonoacetate still had some effect on carrier domain behavior
with the observed rate of crosslinking decreasing in the presence of the ligands (Figure
III-8). I believe that this result can be explained by the interface that is formed between
the carrier domain and the BC domain. With ligands bound, the B-subdomain lid of the
BC domain should be in a closed conformation, forming the final binding interface for
carrier domain docking (Menefee and Zeczycki, 2014). While biotin may not be present
to interact with the “gatekeeper” residue or enter the active site, the carrier domain would
encounter a favorable binding interface that would stabilize carrier domain positioning
and lead to a shift in equilibrium positioning.
Shifting energy landscapes in Q891C/N1102C/E243A SaPC mutant. The QNE
mutants was observed to have a higher kobs and an increased amplitude compared to the
QN SaPC background (Figure IV-1). The presence of ADP and phosphonoacetate during
crosslinking resulted in little change in kobs in the QNE mutant but an increase in
observed amplitude compared to in the absence of ligands in QNE SaPC (Figure IV-3).
This can be visualized in the energy landscape diagram shown in Figure VI-1. The
traditional interpretation is shown in Figure VI-1A with the E243A mutation lowering the
free energy of interaction in the BC domain, presumably due to greater biotin access of
the BC domain active site. This lower free energy would result in the observed increase
in amplitude during crosslinking in this mutant due to a shift in carrier domain
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positioning towards the BC domain (Figure IV-1B). A reduction in the kinetic barrier to
adoption of the BCCP-CT interaction is also shown to take the increased kobs into
account. The presence of ADP and phosphonoacetate is also shown to further reduce the
free energy of the BCCP-BC interaction as well, matching the increased amplitudes
observed (Figure IV-3B).
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Figure VI-1: Energy landscape diagram for QNE SaPC
A potential energy landscape is shown for the QNE SaPC mutant. The Gibbs free energy (G) is plotted
against the translocation progress of BCCP between the BC and CT domains. The kinetic barrier is
represented by a dashed black line. The wild-type reaction is represented in black while the mutation is
represented in blue. The effect of the presence of ADP and phosphonoacetate (PPA) in the QN mutant on
this landscape is shown in red while in the QNE mutant it is shown in blue. A. The traditional interpretation
is shown with the BC domain mutation affecting the BCCP-BC interaction. B. An alternate interpretation is
shown.
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However, an alternate interpretation is possible with the E243A mutation
resulting in an increase in the free energy of the BCCP-CT interaction (Figure VI-1B).
This increase in the free energy would result in a destabilization of the BCCP-CT
interaction, shifting carrier domain positioning towards the BC domain. This would also
have the effect of increasing the observed amplitude during crosslinking in this mutant
(Figure IV-1B). A reduction in the kinetic barrier to adoption of the BCCP-CT
interaction, similar to that in the traditional interpretation, is also shown to take the
increased kobs into account (Figure IV-1A). In this alternate interpretation, the presence of
ADP and phosphonoacetate have a similar reduction in the free energy of interaction for
the BCCP-BC, resulting in the increased amplitudes observed. Due to the increased shift
in carrier domain positioning due to the QNE mutation, the observed amplitude in the
presence of ADP and phosphonoacetate would be larger.
Shifting energy landscapes in Q891C/N1102C/T876A SaPC mutant. The QNT
mutant was observed to have a higher kobs but a negligible amplitude change compared to
the QN SaPC background (Figure IV-1). The presence of ADP and phosphonoacetate
during crosslinking resulted in a large decrease in kobs in the QNT mutant compared to in
the QN mutant. A large increase in observed amplitude compared to the observed
amplitude in the absence of ligands in QNT SaPC or compared to the QN mutant in the
presence of ADP and phosphonoacetate (Figure IV-4). This can be visualized in the
energy landscape diagram shown in Figure VI-2. The traditional interpretation is shown
in Figure VI-2A with the T876A mutation having little effect on the free energy of
interaction in the BC domain, resulting in negligible change in amplitude during
crosslinking in this mutant due to little or no shift in carrier domain positioning towards
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the BC domain (Figure IV-4B). A reduction in the kinetic barrier to adoption of the
BCCP-CT interaction, the primary observed effect of this mutation in the absence of
ligands, is also shown to account for the increased kobs in QNT SaPC (Figure IV-1A). The
presence of ADP and phosphonoacetate is also shown to dramatically reduce the free
energy of the BCCP-BC interaction as well, matching the large increase of amplitude
change observed (Figure IV-4B). This drop in the free energy of interaction also results
in a much larger kinetic barrier to the adoption of the BCCP-CT interaction, matching the
observed drop in kobs in QNT SaPC in the presence of ADP and phosphonoacetate
(Figure IV-4A)
An alternate interpretation is possible with the T876A mutation resulting in an
increase in the free energy of the BCCP-CT interaction in the presence of ADP and
phosphonoacetate (Figure VI-2B). This would have the similar effect of shifting carrier
domain positioning towards the BC domain in the presence of these ligands, resulting in a
larger observed amplitude change during crosslinking. An increase in the kinetic barrier
to adoption of the BCCP-CT interaction in the presence of ADP and phosphonoacetate is
also shown. This would result in the decreased kobs observed in QNT SaPC in the
presence of ADP and phosphonoacetate (Figure IV-4A). A reduction in the kinetic barrier
to adoption of the BCCP-CT interaction is still necessary, as shown in Figure VI-2B, in
the absence of ligands to account for the increased kobs in QNT SaPC (Figure IV-1).
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Figure VI-2: Energy landscape diagram for QNT SaPC
A potential energy landscape is shown for the QNT SaPC mutant. The Gibbs free energy (G) is plotted
against the translocation progress of BCCP between the BC and CT domains. The kinetic barrier is
represented by a dashed black line. The wild-type reaction is represented in black while the QNT mutation
is represented in blue. The effect of the presence of ADP and phosphonoacetate (PPA) in the QN mutant on
this landscape is shown in red while in the QNT mutant it is shown in blue. A. The traditional interpretation
is shown with the mutation affecting the kinetic barrier in the absence of ligand. B. An alternate
interpretation is shown.
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Shifting energy landscapes in Q891C/N1102C/Y621A SaPC mutant. An
acknowledgement of the complexity of this system needs to be made in light of the odd
ITF signal behavior in this mutant. The data may be unable to be interpreted in the same
manner as the other mutants, given the starkly different ITF signal observed. The
alteration in ITF signal could be due to a different set of interactions between biotin and
tryptophans in QNY SaPC due to the Y621A mutation. The mutation may have caused a
change in observed fluorescence that was not due to an alteration in carrier domain
positional equilibrium. Another possibility for the difference in observed signal could be
due to an alteration in the orientation of biotin in this mutant. This could occur if we
consider that Y621 not only positions biotin in a specific location in the CT domain
active site, but most likely orients it in a specific plane for optimal interaction between
the aromatic ring of Y621 and the thiophene ring of biotin. This orientation of biotin may
influence interactions with tryptophans either inside the CT domain active site or Trp808,
located near the exo-binding site. However, if the interactions between biotin and
tryptophans in QNY SaPC remain similar and changes in the observed fluorescence
signal were due to changes in carrier domain positioning, the data will be interpreted in
the following paragraphs in a similar manner to the other SaPC mutations.
To interpret this data in a similar manner as the other mutations, a subtle
distinction needs to be made between the CT domain active site and exo-binding site.
Whereas the T876A mutation did not have a significant impact on carrier domain
positioning in the absence of ligands, the Y621A mutation was observed to, with a large
decrease in amplitude change compared to the QN SaPC background (Figure IV-1).
Generally, an increase in amplitude has been interpreted as a shift towards the BC
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domain while a decrease in amplitude has been interpreted as a shift towards an
intermolecular interaction for crosslinking. More precisely, the conformation trapped due
to crosslinking was chosen to be the conformation in which biotin is positioned in the
exo-binding site. Thus, I propose that the mutation of Y621A resulted in a large shift in
carrier domain positioning away from the CT domain active site. This shift would lead to
a higher population of carrier domains occupying to exo-binding site conformation,
among potential other conformations, including BCCP-BC interactions. The increased
population of the exo-binding site would lead to a higher initial ITF signal intensity.
When the crosslinker was introduced, a much smaller magnitude of the amplitude was
observed, consistent with a smaller shift in carrier domain equilibrium due to the large
initial re-equilibration due to the mutation (Figure IV-2B). The equilibrium may be such
that ITF is at or close to a maximum possible value and the introduction of the
crosslinker pulls the carrier domain equilibrium away from that maximum, resulting in a
decrease in ITF signal intensity during crosslinking (Figure IV-2B).
The QNY mutant was observed to have a higher kobs and a decreased amplitude
compared to the QN SaPC background (Figure IV-1).The presence of ADP and
phosphonoacetate during crosslinking resulted in a small decrease in kobs in the QNY
mutant and a decrease in observed amplitude compared to the QNY mutant in the
absence of ligands (Figure IV-3). However, it should be noted that this decrease in
observed amplitude actually results in a larger ITF signal intensity, due to the fact that the
signal is starting out with a negative amplitude. These concepts can be visualized in the
energy landscape diagram shown in Figures VI-5A,B. Figure VI-5A depicts the increase
in the free energy of the BCCP-CT interaction as a result of the Y621 mutation, which
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results in a carrier domain positioning shift towards the exo-binding site and a reduction
in the kinetic barrier for this equilibrium shift.
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Figure VI-3: Energy landscape diagram for QNY SaPC
A potential energy landscape is shown for the QNY SaPC mutant. The Gibbs free energy (G) is plotted
against the translocation progress of BCCP between the BC and CT domains. The kinetic barrier is
represented by a dashed black line. The wild-type reaction is represented in black while the mutation is
represented in red. A. The BCCP-Exo and BCCP-CT interactions are shown. B. The BCCP-BC and BCCPExo interactions are shown. The effect of the presence of ADP and phosphonoacetate (PPA) in the QN
mutant on this landscape is shown in red.
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Figure VI-3B illustrates the energy landscape between the BCCP-BC and BCCPExo interactions. The addition of ADP and phosphonoacetate results in a reduction in the
free energy of the BCCP-BC interaction. This would result in a shift in carrier domain
positioning towards the BC domain, increasing the fluorescence intensity observed in
QNY SaPC compared to that in the absence of ligands in the QNY SaPC mutant. A
smaller change in kobs in the presence of these ligands compared to QN background could
result from a simpler translocation pathway. The kinetic barrier to crosslinking in the
exo-binding site may be decreased due to the proposed instability of positioning at the
CT domain active site. If the carrier domain does not interact with the CT domain active
site while translocating from the BC domain to the exo-binding site, there is one less
kinetic barrier to overcome to adopt the final crosslinking conformation.
An alternate interpretation of the energy landscape is possible with the Y621A
mutation resulting in an increase in the BCCP-BC interaction free energy. As observed,
this would lower the kinetic barrier for the adoption of an intermolecular conformation,
resulting in a higher kobs in the Y621A mutant (Figure IV-1A). This would also shift
carrier domain positioning towards the CT domain and/or exo-binding site, resulting in a
decrease in observed amplitude when crosslinking in the absence of ligands (Figure IV1B). The presence of ADP and phosphonoacetate results in a small decrease in the free
energy of the BCCP-BC interaction as illustrated in Figure VI-4 and observed by an
increase in absolute ITF signal in Figure IV-5B.
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Figure VI-4: Alternate energy landscape diagram for QNY SaPC
A potential alternate energy landscape is shown for the QNY SaPC mutant. The Gibbs free energy (G) is
plotted against the translocation progress of BCCP between the BC and CT domains. The kinetic barrier is
represented by a dashed black line. The wild-type reaction is represented in black while the mutation is
represented in blue. The effect of the presence of ADP and phosphonoacetate (PPA) in the QN mutant on
this landscape is shown in red while in the QNY mutant it is shown in blue.

Experimentally testing these energy landscape models. The experiments
conducted in this study inform on the relative difference in free energies between the
interactions. Thus, the limitation in this approach is that absolute energies of the
interactions are unable to be measured. Further, the relative height of the kinetic barrier
moving from the BC domain to the CT domain is measured but the height of the kinetic
barrier moving towards the BC domain isn’t measured by this system. These limitations
are due to the conformation crosslinked, with the carrier domain positioned in the vicinity
of the CT domain. Carrier domains traveling from a position away from the CT domain,
such as those interacting with the BC domain must overcome the kinetic barrier to
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interact with the CT domain. In order to measure the relative height of the kinetic barrier
on the right side of these depictions, a system must be designed that crosslinks the carrier
domain when interacting with the BC domain. ITF experiments and analysis similar to
that presented in Chapters IV and V would be performed to obtain a thermodynamic and
kinetic analysis of the effect of mutations and the presence of ligands on the carrier
domain energy landscape. I predict that the ITF signal intensity would decrease in many
cases when crosslinking to the BC domain, since carrier domain positioning would be
drawn away from the tryptophans in the vicinity of the CT domain.
To further explore the relationship between the observed tryptophan fluorescence
signal as it relates to carrier domain positioning in Y621A SaPC, solution FRET could be
utilized as a way to sidestep any change in interactions between biotin and the CT
domain tryptophans compared to the QN background that may cause the signal to be
untrustworthy. With a FRET-compatible fluorophore introduced onto the carrier domain
and a matching FRET-compatible fluorophore placed in the CT domain, whether through
maleimide-based reactions or using non-natural amino acids and click chemistry, an
analysis of carrier domain positioning should be possible. Instead of receiving a high
tryptophan fluorescence signal upon crosslinking of the carrier domain or a shift in
positioning towards the CT domain, a higher FRET signal should be observed. A similar
analysis to that presented in these studies should be possible to reveal the effect of this
mutation on carrier domain positioning.
To distinguish whether a change in the free energy of interaction is occurring in
the BC or CT domain, dynamic light scattering could be used to measure thermodynamic
parameters of interacting proteins (Hanlon, et al., 2010). This technique has been used in
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other systems to study protein-protein interactions. However, given that the PC tetramer
stays intact during the translocation process and that this technique is generally used
more to study entire proteins during association and dissociation, a different technique
may be better suited to study this phenomenon. A technique that may be able to more
directly investigate these free energies of domain interactions is isothermal calorimetry.
This technique can measure the entropic and enthalpic contributions to the affinity
between two proteins and is likely the most applicable technique for directly investigating
alterations in the affinity between the carrier domain and BC or CT domains (ValazquezCampoy, et al., 2015). A number of controls must be investigated given the multitude of
interactions that exist in PC. For example, the protein with the carrier domain truncated
would serve as an important control to be able to account for any measured energy
changes due to ligand binding and small active-site conformational changes from the free
energy change of a carrier domain associating and dissociating with another domain.
Finally, microscale thermophoresis may offer an alternative technique to measure these
thermodynamic parameters. This technique follows changes in either intrinsic
fluorescence or signal changes due to the interaction of fluorophores across a range of
temperatures to allow the deduction of a number of thermodynamic quantities that would
ultimately allow the measurement of changes in Gibbs free energies of interacting
proteins (Jerabek-Willemsen, et al., 2014).

2.

Extending the Model to Other Multi-Domain Enzymes

The carrier domain of S. aureus PC was observed here to be governed by
conformational selection with the equilibrium positioning shifted by the presence/absence
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of ligands that alter interactions between BCCP-biotin and active-site residues. These
findings are consistent with the conformational flexibility observed in S. cerevisiae
acetyl-CoA carboxylase (Hunkeler, et al., 2016). While carrier domain conformational
changes haven’t been investigated in acetyl-CoA carboxylase to date, a large, noncatalytic central domain (CD) has been shown to exhibit great conformational flexibility
that allows two distant BC domains to come together and dimerize, forming a
catalytically-active conformation. A regulatory loop controls these conformational
dynamics, when phosphorylated, restricting the conformational flexibility in the CD and
preventing the BC domain dimerization necessary for catalysis. This is similar to the role
of acetyl-CoA in PC, where it has been observed to limit conformational flexibility of the
carrier domain (Westerhold, et al., 2017; Liu, et al., 2018). In the case of acetyl-CoA,
however, this confinement of conformational dynamics results in more efficient catalysis,
not the inability to form a catalytically-relevant conformation as is the case with
phosphorylation of the regulatory loop in acetyl-CoA carboxylase. Given the lack of
studies on carrier domain positioning in acetyl-CoA carboxylase, it seems reasonable to
expect its positioning to be governed by conformational selection, similar to PC. One
potential mechanism to favor/disfavor carrier domain positioning was recently
discovered. As introduced in Section I.3.1, a loop that sterically blocks carrier domain
binding is shifted out of the way when the BC domain dimerizes (Wei and Tong, 2015).
Future crystal structures with the carrier domain interacting with either active site would
aid in further determining how the positioning of the carrier domain of acetyl-CoA
carboxylase is regulated.
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The assembly line polyketide synthase, 6-deoxyerythronolide B synthase (DEBS),
is a composition of three polypeptides that in total contain six homologous, homodimeric
modules that catalyze the production of the macrocyclic core of erythromycin. As
described in the Introduction, this multi-domain enzyme uses an acyl-carrier protein to
shuttle the growing polyketide chain from the intramodular ketosynthase (KS) domain to
the downstream KS domain. A recent study has investigated how vectorial synthesis may
be coordinated to maintain proper reaction directionality during chain elongation (Lowry,
et al., 2016). A novel turnstile mechanism was discovered that prevents the KS domain
from premature acylation until the previous elongation and modification reactions
product have been removed from the intramolecular ACP domain. This model appears
consistent with conformational selection as well, with catalytic steps energetically
coupled without relying on a complex induced conformational change mechanism. This
energetic coupling of reaction steps is also similar to an observation made in SaPC in
which the two half-reactions are thermodynamically coupled in the presence of the
allosteric activator, acetyl-CoA (Westerhold, et al., 2017). Both of these mechanisms rely
on regulation of translocation of the carrier domain to efficiently couple the multi-step
reactions. In the case of PC, acetyl-CoA was observed to favor translocation of the carrier
domain (Figure V-8) with the effects of mutation to several active-site residues on carrier
domain translocation discussed above.
The bacterial sulfur oxidation pathway enzyme SoxB interacts with the carrier
protein SoxYZ, which carries Sox pathway intermediates. A recent study investigated the
interaction between these two proteins to better understand how carrier proteins transport
intermediates between enzymes in the Sox pathway (Grabarczyk, et al., 2015). It was
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observed that the carrier protein has 2 major points of interaction with the SoxB enzyme.
One point of contact is in the active site tunnel with multiple points of hydrogen bonding
between the carrier protein and SoxB. More tangential to my research is the formation of
a second point of contact outside of the active size. A mobile loop on the surface of SoxB
was observed to be stabilized when substrate-bound SoxYZ bound with SoxB. In the
substrate-free form, this mobile loop occupies a different conformation that clashes with
SoxYZ binding, favoring the release of SoxYZ after the reaction has completed. This
mechanism is similar to the CT domain mechanism of stabilizing biotin in the active-site
of PC in that when substrate is bound in the CT domain, Tyr621 adopts a conformation
favorable for carrier domain positioning at the CT domain active site.
Finally, gramicidin synthase I, a non-ribosomal peptide synthase, was recently
investigated to study the control of interactions between the catalytic and carrier domains
(Alfermann, et al., 2017). It was observed that this flexible enzyme exists in an
equilibrium of at least two conformations, with product inhibition, and in general the
presence of ligands, shifting the conformational equilibrium. A series of interactions
between active site residues, carrier domain residues and prosthetic groups, and ligands
were proposed to be responsible for these equilibrium shifts. These findings are
consistent with the work presented here regarding how the positioning of the carrier
domain of pyruvate carboxylase is governed. The authors have come to a very similar
conclusion in that the enzyme exists in a conformational equilibrium that is shifted by the
presence of ligands.
In summary, our understanding of how carrier domain positioning is regulated has
progressed dramatically in recent years. Mechanisms have been discovered in several
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enzyme systems that have revealed various types of interactions between carrier domains
and catalytic domains, pushing forward our understanding of the underlying biophysical
nature of how carrier domain translocation is governed for efficient catalysis. The studies
that I have performed in PC offer further evidence of conformational selection governing
carrier domain positioning and translocation while offering to further extend our
understanding of how interactions between active site residues and the prosthetic group
of carrier domains can shift equilibrium positioning.
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VII.

FUTURE DIRECTIONS

To explore trapping the carrier domain during translocation in a cleaner system,
the single mutant Q1118C needs to be investigated in the same manner as presented here.
A double mutant that would trap the carrier domain in the conformation in which biotin
extends into the active site, which was the goal of the D907C/Q1118C SaPC mutant,
should also be generated and investigated. These two systems would allow a higher
confidence of interpretation of not only the data regarding carrier domain translocation in
Chapter V, but also offer a comparison to the data presented in Chapter III and IV. For
instance, if carrier domain positioning if observed to have shifted towards the BC
domain, is it shifting away from every other state/conformation equally? Trapping the
carrier domain in more states would allow this more thorough explanation of carrier
domain dynamics. Throughout this current work, the positioning of the carrier domain at
the BC domain has been presumed when carrier domain positioning is shifted away from
the intermolecular CT domain in the presence of BC domain ligands. While this is a
reasonable assumption, this study would be further supported by the ability to trap the
carrier domain at the BC domain to more completely assess shifts in carrier domain
positioning. Similar to the crosslinking system introduced in this study, a pair of
cysteines would need to be introduced that would come within crosslinking range (<8 Å)
when the carrier domain is docked at the BC domain for the generation of this new
crosslinking system.
As Liu, et al. demonstrated, the carrier domain can interact with both the
intramolecular and intermolecular BC domains (Liu, et al., 2018). This presents a
problem in that assaying crosslinking by SDS-PAGE would only report on intermolecular
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crosslinking and be blind to intramolecular crosslinking. Thus, inactivation kinetics,
which measures the inactivation of the enzyme due to carrier domain crosslinking in
either form, would be more appropriate to use when assessing the total amount of
crosslinking. Alternatively, a co-expression of two different mutants would allow a fuller
assessment of only intermolecular crosslinking. One mutant would have a cysteine
introduced onto the BC domain while the other mutant would have a cysteine introduced
onto the carrier domain. This population would form a hybrid tetramer in vivo during coexpression (Liu, et al., 2018). Thus, the carrier domain on one polypeptide chain would
only be able to form crosslinks with the BC domain cysteine on a separate polypeptide
chain, trapping the intermolecular interaction. For either the system assessing both
intramolecular and intermolecular crosslinking or just intermolecular crosslinking, the
techniques described in this study would be applied to assess kinetic and thermodynamic
changes to carrier domain positioning as a result of mutations or the presence of ligands.
The use of solution FRET, as used to investigate conformational shifts in an
NRPS as described in the introduction, could be implemented in SaPC to study shifts in
carrier domain positioning due to mutations or the presence of ligands without the need
for crosslinking (Alfermann, et al., 2017). FRET-compatible fluorophores could be
covalently attached to the carrier domain and either the BC domain or CT domain for an
introductory set of studies. These fluorophores could be bound through the introduction
of cysteines in the desired locations for maleimide-based linking or through the use of
non-natural amino acids in the desired location and click chemistry-based fluorophore
linking. Given that 5 cysteines exist naturally in SaPC, the use of non-natural amino acids
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for fluorophore labeling would most likely yield the greatest chance of success as
undesired background labeling of the enzyme should be limited.
A crystal structure of Q891C/N1102C SaPC with the carrier domain crosslinked
would allow an analysis of the positioning of biotin in relation to the tryptophans located
in the CT domain. The attainment of such a crystal structure would be a possible next
step in determining the origin of changes in the observed tryptophan fluorescence signals
with the goal of better understanding the exact positioning of the carrier domain in
relation to the observed signal. Alternatively, these tryptophans could be individually
conservatively mutated to phenylalanines or histidines to determine their contributions to
the observed fluorescence signal. However, 2 of the 4 remaining tryptophans to be
studied are strictly conserved, which suggests that their mutation could result in an
unstable protein. The tryptophan mutated as part of the studies described in Chapter III is
also strictly conserved with mutation of that tryptophan resulted in an unstable protein. In
summary, I believe the obtainment of a crystal structure of crosslinked SaPC would be
the logical next step for the determination of the origin of the tryptophan fluorescence
signal.
Finally, carrier domain movement could be investigated to determine the effects
of ligands, including acetyl-CoA and L-aspartate, on carrier domain movement rates. For
example, in chapter III, L-aspartate wasn’t observed to alter carrier domain positioning
but exhibited an effect on the kinetic barrier to translocation. Perhaps the movement rate
of the carrier domain is slowed by L-aspartate, resulting in a reduction in catalytic rate.
Carrier domain movement could be determined either through single-molecule FRET
studies, fluorescence anisotropy, or RFQ-DEER (rapid freeze quench-double electron-
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electron resonance). While our lab does not currently have direct experience with these
techniques, they would represent a new frontier of research for not only the lab, but
studies of carrier domain motion in carrier domain enzyme systems. Initial studies of
carrier domain movement have been investigated with fluorescence anisotropy in
collaboration with Dr. Evgueni Kovriguine. However, it was determined that either a
much higher percentage of fluorophore labeling of SaPC was required or a much higher
concentration of protein was necessary, as the obtained fluorescence signals were
inconclusive. Thus, for many of the research pathways described here, an optimization of
the specific labeling of PC with various fluorophores is necessary to expand our
investigations of carrier domain positioning and movement.
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VIII.

APPENDIX A: PRIMERS FOR MUTAGENESIS OF SaPC

Table VIII-1 Forward Primers for SaPC Mutagenesis

Mutation
Q891C

N1102C

D907C
Q1118C
K1112Q
Y621A

T876A

E243A
V1062*
W808F

Sequence
5’-GGCACTTTATATGGTATGCAATGATCTTGATGAACAATC-3’
(forward)
5’-GATTGTTCATCAAGATCATTGCATACCATATAAAGTGCC-3’
(reverse)
5’-GTGAAACTGTGAAAGCTTGTCAGCCGTTGCTAATTAC-3’
(forward)
5’-GTAATTAGCAACGGCTGACAAGCTTTCACAGTTTCAC-3’
(reverse)
5’-GGCTATAAATTATGTTTCCCAGAATCAG-3’ (forward)
5’-CTGATTCTGGGAAACATAATTTATAGCC-3’ (reverse)
5’-GAAACAACAATTTGCGCACCATTTG-3’ (forward)
5’-CAAATGGTGCGCAAATTGTTGTTTC-3’ (reverse)
5’-CTGAAGCTATGCAAATGGAAACAAC-3’ (forward)
5’-GTTGTTTCCATTTGCATAGCTTCAG-3’ (reverse)
5’-GCTTCAAACGCAGTTGGTGCTAAAAACTATCCTGATAATG-3’
(forward)
5’-CATTATCAGGATAGTTTTTAGCACCAACTGCGTTTGAAGC-3’
(reverse)
5’-GGTGATATCGTAAAAGTAGCACCATCGTCTAAAGTAG-3’
(forward)
5’-CTACTTTAGACGATGGTGCTACTTTTACGATATCACC-3’
(reverse)
5’-CAAAAAGTTGTAGCAGTTGCACCATC-3’ (forward)
GATGGTGCAACTGCTACAACTTTTTG-3’ (reverse)
5’-GATGAAAATTAGCATACAAATGCG-3’ (forward)
5’-CGCATTTGTATGCTAATTTTCATC-3’ (reverse)
5’-GGAGTCACTTAGTCATTATTTCTCAACTGTACGTAC-3’
(forward)
5’-GTACGTACAGTTGAGAAATAATGACTAAGTGACTCC-3’
(reverse)

